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Abstract 
Alzheimer’s Disease (AD) is characterized by neurofibrillary tangles, senile plaques and 
neuronal loss. Although the mechanisms underlying Amyloid beta 42 (Aβ42) neurotoxicity 
have not been firmly established, it is proposed that the neuronal loss is elicited through 
associations with cell surface receptors. The cellular prion protein (PrP
c
) has been identified 
as an Aβ42 receptor and as a regulator of the amyloidogenic cleavage pathway. As Aβ42 
shares common binding partners with the 37kDa/67kDa laminin receptor (LRP/LR), 
including PrP
c
, we investigated whether these proteins interact and assessed the pathological 
significance of this association. LRP/LR was found to co-localize with Aβ on the cell surface. 
The occurrence of FRET suggested that an interaction between LRP/LR and Aβ indeed exists 
at the cell surface. Furthermore, pull down assays and Aβ-specific ELISAs demonstrated that 
LRP/LR forms a physical association with endogenously shed Aβ, thereby verifying the 
physiological relevance of this association. Antibody blockade by IgG1-iS18 and shRNA-
mediated downregulation of LRP/LR significantly enhanced cell viability and proliferation 
and decreased apoptosis in cells co-treated with Aβ42 when compared to cells incubated with 
Aβ42 alone. In addition, antibody blockade and shRNA-mediated downregulation of LRP/LR 
significantly impeded Aβ42 internalization. These results suggest that LRP/LR acts as an 
internalization receptor for Aβ42 and may thereby contribute to the cytotoxicity of the 
neuropeptide by facilitating intracellular Aβ42 accumulation and aggregation - which has 
consequences for cell proliferation and may promote apoptosis. These findings recommend 
anti-LRP/LR specific antibodies and shRNAs as potential therapeutic tools for Alzheimer’s 
Disease treatment.    
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 Chapter 1 
1.1 Introduction 
Alzheimer’s Disease (AD), also referred to as Morbus Alzheimer’s, Alzheimer’s Dementia 
and Alzheimer’s, is a multifactorial progressive neurodegenerative disease characterized 
clinically by the manifestation of dementia and histopathologically by neuronal 
degeneration
8
. The disease was first described by Alois Alzheimer in 1906 and has since 
become the most prevalent form of dementia (accounting for 60-80% of dementia cases) 
afflicting the elderly
9
.  
At present in excess of 35 million people globally
10
 and approximately 1 in 68 South 
Africans are afflicted with Alzheimer’s Disease. The incidence of AD increases exponentially 
with age, with people aged 65-69 exhibiting an incidence of 4.4%, whilst people over 90 
years of age display an incidence of 22%
11
. Furthermore, owing to global increases in life 
expectancies, the prevalence of AD is predicted to rise to 86 million people by 2050
12
.  
In addition, it is reported that the annual cost per patient with dementia (€ 20,000 in Europe 
in 2008) exceeds that for patients with cancer and cardiovascular disease
13
. In 2013 it was 
reported that $203 billion was spent in providing care for AD patients in the United States of 
America and this is predicted to increase to $1.2 trillion annually by 2050 (The Alzheimer’s 
Association, https://www.alz.org/). Thus, AD is not only a major social concern but also has 
grave economic implications. 
 
1.2. Symptomology 
AD related symptoms have been reported to occur in three stages. The initial symptoms, 
observable during the first stage of AD, include cognitive dysfunction, deficits in episodic 
memory, loss of visual-spatial skills
14
 and the deterioration of language skills. This cognitive 
decline is a result of neuronal degeneration, cell loss and finally atrophy in the brain regions 
associated with these functions, namely the limbic system, neocortical regions and the basal 
forebrain
15
. The second symptomatic stage is characterised by personality and behavioural 
disturbances including paranoia, confusion, hallucinations, aggression and loss of social 
appropriateness
16, 17
. Ultimately, AD patients exhibit progressive motoric disturbances, first 
in performing complex tasks and later in performing even basic tasks as well as exhibit loss 
1
in co-ordination
17, 18
. Disease progression, although variable in the chronology of symptom 
development and severity, is proposed to occur over a decade 
19
. 
 
It is noteworthy to highlight that that the neuropathological alterations associated with AD 
are present more than 20 years before the onset of symptoms
20
. 
 
 
1.3 Diagnosis 
A definitive diagnosis of AD is only attainable after a post-mortem biopsy, thereby allowing 
for the identification of the pathological hallmarks of AD - namely extracellular neuritic 
amyloid plaques and intracellular neurofibrillary tangles. Clinical diagnosis is currently 
performed employing a combination of neurological examinations, tests that assess mental 
status (including the Mini Mental State Examination (MMSE))
21
 and neuroimaging
14
 and is 
occasionally only reached by excluding other causes of dementia
8
. However, existing 
diagnostic criteria corresponds to advanced disease
13
, thereby making diagnosis during Mild 
Cognitive Impairment (MCI) and early stages of AD challenging
14
. MCI is an intermediate 
between normal and demented states and is often a beneficial label to define people at risk of 
developing AD
22
 (Figure 1.1). Patients with MCI are at triple the risk of developing AD 
compared to their normal counterparts
23
. However, it must be emphasized that patients with 
MCI may progress to other dementias, as opposed to just AD, including vascular, Lewy body 
and frontotemporal dementias
24
  (Figure 1.1). 
 
Clinical diagnostic criteria are outlined in several manuals including: the Diagnostic and 
Statistical Manual of Mental Disorders (4
th
 edition) (DSM-IV)(Americam Psychiatric 
Association), the International Statistical Classification of Diseases (10
th
 edition) (ICD-
10)(World Health Organisation) and the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA)
25
.  
 
Yet, as previously stated, pathology precedes symptoms by decades and as such earlier 
diagnosis and therapeutic intervention, in the aim of halting disease progression to AD, is 
highly desirable. This therefore highlights the need to identify reliable and robust biomarkers 
of early pathological changes.  
2
1.4 Biomarkers for Alzheimer’s Disease 
Biomarkers are biological measures of processes, either physiological or pathological in 
nature, that are employed to evaluate disease risk or prognosis. Although the value of 
diagnostic AD biomarkers cannot be stressed enough, biomarkers may additionally be 
indicative of the degree of neuroprotection, serve as tools for the detection and monitoring of 
the disease-modifying effects of AD therapeutics as well as serve as indicators of potential 
undesirable side effects
25
. Currently, neuroimaging techniques and cerebrospinal fluid (CSF) 
biomarkers are the best characterised and most accurate indicators of the ongoing 
pathophysiological processes in AD
26, 27
. Strides are currently being made with regards to the 
identification and validation of blood based AD biomarkers owing to the non-invasive and 
inexpensive procedures associated with sample collection.  
 
1.4.1. Neuroimaging 
Four such techniques are currently utilized. The first being magnetic resonance imaging 
(MRI) which reveals the degree of grey matter in the affected brain regions and is employed 
as a biomarker owing to its ability to ascertain the rate of AD-associated brain atrophy. Blood 
oxygen-dependent level (BOLD) functional MRI (fMRI) which assesses memory input and 
neuronal processing within different brain regions is the second technique. The third 
technique, magnetic resonance spectroscopy (MRS), allows for changes in biochemical 
compounds within the brain to be assessed- including glutamate, creatine, myoinisitol and N-
acetyl aspartate - metabolites deregulated during AD pathology. The final technique is the 
most widely used neuroimaging AD biomarker, namely positron emission tomography 
(PET), specifically those employing the Aβ-binding compound- Pittsburgh compound B (11C-
PIB) – a thioflavin analogue. These amyloid-PET scans provide visual information regarding 
Aβ plaque load25. 
   
1.4.2 CSF biomarkers 
Owing to the relative ease with which proteins may be transported between the brain and the 
CSF, CSF biomarkers most accurately reflect brain neurochemistry. The four validated and 
established CSF biomarkers are: Aβ40, Aβ42, total tau and phosphorylated tau (p-tau) levels
25
. 
The degree to which the levels of these biomarkers differ from those in cognitively normal 
people may be used as predictors of progression from MCI to AD. 
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The CSF levels of soluble Aβ42 and the Aβ42:Aβ40 ratio is decreased in AD, and it has been 
proposed that this may be due to sequestration of the peptide into amyloid plaques
28
 as well 
as enhanced cellular uptake and intraneuronal accumulation of Aβ42. Conversely, there is an 
increase in tau (an indicator of axonal damage not specific to AD) and p-tau levels in AD 
patients.  
 
Several other candidate CSF biomarkers, specifically those associated with amyloidogenic 
processing, the innate immune system, cholesterol metabolism and endosomal vesicle 
recycling 
29
, have been explored, however these have yet to be fully validated. These include: 
secreted isoforms of the amyloid precursor priotein (APP) and its cleavage products (sAPPα 
and sAPPβ), Aβ oligomers, Aβ degradation products, β-site APP-cleaving enzyme-1 (BACE-
1) activity and concentration
25
 as well as 24S-hydroxycholesterol, angiotensinogen, 
apolipoproteins, complement components, transthyretin, thioredoxin and vascular growth 
factor to name a few
22
. 
  
It must be noted that the combination of neuroimaging and CSF biomarkers provides 
enhanced sensitivity and specificity and is therefore more accurate than each modality 
alone
29
. 
 
1.4.3 Blood biomarkers 
Another source of biomarkers that has been the focus of mounting investigative efforts is 
blood owing to the ease, enhanced frequency and cost-effectiveness with which samples may 
be collected. Although a number of studies have been conducted in the aim of identifying 
plasma-based biomarker panels, these results are often controversial and not well replicated.  
This is particularly true when assessing plasma Aβ levels as the relationship between Aβ 
levels in the brain and plasma remains unclear. Proposed candidate plasma-biomarkers 
include: desmosterol, clusterin, chitinase 3-like 1 protein, matrix metalloproteinase 2
29, α1-
antitrypsin
14
 as well as inflammation related proteins such as interleukins (IL-6, IL-1β).  
Doecke et al., have identified a panel of over 20 biomarkers that are differently represented in 
the plasma of AD patients
12
. 
 
In addition to these proteomic and metabolomic candidates, circulating microRNAs 
(miRNAs) have also gained interest as plasma-derived biomarkers. Numerous miRNAs, 
4
including miR-137,-181c,-9 and-29a/b
30
 as well as a novel 7-miRNA signature
14
 have been 
identified and shown to successfully distinguish between non-demented and AD patients.  
 
However, all the aforementioned plasma-biomarkers need to be further corroborated in 
additional studies and their AD-predictive potential needs to be validated.     
 
As discussed previously, AD biomarkers are not only invaluable in diagnosis but also as tools 
for monitoring the therapeutic potential and side effects of AD drug candidates and may 
henceforth become central to drug screening and treatment decisions
25
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5 Alzheimer’s Disease Therapeutics 
Owing to the social and economic implications of AD, the development of not only effective 
AD therapeutics but also potentially preventative strategies is of major importance. 
 
There are two AD therapeutic categories namely symptomatic and disease modifying. 
Although there is as yet no cure for AD, five drugs have been approved by the U.S. Food and 
Drug Administration (FDA) for the treatment of the disease symptoms. These include four 
cholinesterase inhibitors (Donepezil, Galantamine, Rivastigmine and Tacrine- although the 
latter is rarely prescribed due to reported adverse liver effects) – which offer benefit by 
reducing the enzymatic degradation of the vital neurotransmitter acetylcholine. The other 
Figure 1.1| A hypothetical model of the clinical trajectory of Alzheimer’s Disease.  Mild cognitive 
impairment (MCI) precedes Alzheimer’s Disease but it must be emphasized that not all individuals 
with MCI will progress to Alzheimer’s Disease (Adopted from 1). 
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FDA approved treatment is Memantine, a N-methyl-D-aspartate (NMDA) receptor antagonist 
- as overstimulation of these receptors in AD contributes to neuronal cell death (The 
Alzheimer’s Association, https://www.alz.org/).  
 
Additional symptomatic treatments include non-steroidal anti-inflammatory drugs  (NSAIDs) 
and anti-depressants
31
.  
 
While most avaliable AD therapeutics are merely palliative in nature, both academic and 
pharmacological research efforts over the past few decades have concentrated on developing 
strategies to either prevent disease onset through the sequesteration of pathogic progenitors or 
slow disease progression
31
.   
 
The majority of these treatment strategies target the amyloid beta (Aβ) peptide, considered 
the primary aetiological agent in AD. These include agents that the modulate the activity of 
the enzymes involved in Aβ generation namely β- and ɣ- secretases inhibitors (such as 
thiazolidinediones and semagacestat, respectively)
32
 and α-secretase stimulators 
(EHT0202)
33
. However, as these enzymes have a multitude of physiological substrates (as 
shall be discussed below) their inhibition often results in adverse physiological effects. Thus 
there is a need to enhance the selectivity of such inhibitors/modulators for the amyloid 
precursor protein (APP) whilst not affecting the cleavage of other substrates before such 
strategies may be considered as AD therapeutics. Moreover, Aβ immunotherapy has received 
the most attention as potential AD therapeutics. This includes passive administration of 
antibodies directed against the neurotoxic peptide (such as Bapineuzumab and Solanezumab) 
and active immunisation (with the peptide itself) with the aim of inducing an endogenous 
polyclonal antibody response
20
. Aβ fibrillization inhibitors (i.e. metal chelators such as 
iodochlorohydroxyquin and cliquinol)
31
 have also been designed, with those preventing the 
formation of Aβ oligomers (such as scyllo-inositol) believed to have the greatest potential20.  
 
As most therapeutics targeting Aβ have failed during clinical trials, researchers are beginning 
to look at therapeutic targets beyond the neurotoxic peptide. This includes targeting tau 
through the use of tau phosphorylating kinase inhibitors (such as valproate), aggregation 
inhibitors (such as Methylthioninium), microtubule stabilizing agents (such as BMS241027) 
as well as passive and active immunotherapy
20
.  In addition, drugs targetting processes which 
are perturbed during AD, such as microglial-mediated inflammation, oxidative stress, cell 
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signalling, membrane dynamics, receptor activation and ion channel formation, are under 
investigation and may bode well in the search for effective disease modifying therapeutics
20
. 
 
  
1.6 Alzheimer’s Disease Epidemiology 
1.6.1 Genetic Epidemiology 
AD is classified into two categories based on the age of symptom onset, namely Early onset- 
AD (EOAD) and Late onset-AD (LOAD). 
Early onset-AD (EOAD), also referred to as Familial Alzheimer’s Disease (FAD), is an 
autosomal dominant disease characterized by an early (<65 years old) onset of disease 
symptoms
11
. EOAD accounts for merely 1-5% of all AD cases,  and generally results in more 
rapid disease progression. EOAD is the result of mutations in three genetic loci (genes) 
namely: APP on chromosome 21 and the presenilin (the enzymatically active subunit within 
the ɣ-secretase complex) encoding genes (PSEN1 and PSEN2) on chromosomes 14 and 1, 
respectively
34. These mutations result in either enhanced Aβ42 synthesis
35
 or reduced Aβ40 
generation
36
.  
 
LOAD, which accounts for >95% of all AD, is characterised by disease onset after 65 years 
of age.  There are numerous “susceptibility” genes associated with LOAD and the difference 
in disease risk frequency between monozygotic and di-zygotic twins have led to the 
suggestion that genetic epidemiology contributes substantially (60-80%) to LOAD
22
. The ε4 
allele of the apolipoprotein E (ApoE ε4), a cholesterol-binding glycoprotein, is the only 
unequivocally established genetic risk factor which predisposes the carrier to LOAD
37
. 
Numerous other candidate genes have been identified during genome-wide association 
studies as possible risk factors but most require additional studies to verify their reliability as 
susceptibility loci. Genes which have been repeatedly identified in independent studies 
include: SORL1 (sortilin-related receptor, an APP transporter protein),  CLU (apolipoprotein 
J, a lipid transporter protein), BIN1 (amphiphysin II, a protein involved in cellular trafficking, 
actin dynamics and clathrin-mediated endocytosis), PICALM (phosphotidylinositol-binding 
clathrin assembly protein, involved in clathrin-mediated endocytosis) and CR1 (complement 
receptor type I, involved in neuro-inflammation by clearing immune complexes comprising 
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the C3b and C4b factors). Other candidate genes have also been identified and most are 
involved in a handful of cellular processes such as APP processing (CASS4, ABCA7), tau 
pathology (CASS4, FERMT2) and immune responses (CD33, INPP5D,CD2AP, EPHA1, 
MEF2C, HLA-DRB5/DRB1 as well as the MS4A4A/MS4A4E/MS4A6E cluster)
22
. It is 
important to note that the majority of these studies have been conducted on Caucasian cohorts 
and these may not necessarily represent susceptibility genes across other ethnic groups. 
1.6.2 Environmental Epidemiology 
There are several environmental factors that have been implicated in increasing AD 
susceptibility.  
These include suffering from other health concerns, predominantly during mid-life, such as 
cerebrovascular disease (which contributes to brain damage, Aβ deposition and promotes tau 
hyperphosphorylation), hypertension (which has adverse effects on the blood-brain barrier 
(BBB))
22
, Type II diabetes (as insulin competitively inhibits Aβ degradation and thereby 
facilitates Aβ deposition and tau phosphorylation), adiposity (as it leads to hyperinsulinemia 
and the production of cytokines)
38
 and high cholesterol (influences the activity of APP 
cleaving enzymes and enhances Aβ deposition)39.  
Lifestyle factors also contribute to the likelihood of developing AD, with poor diet and 
inadequate physical activity being the primary risk factors. Excessive caloric intake and fat 
consumption directly contribute to oxidative stress which promotes AD pathology
40
. 
Consumption of diets high in fruits and vegetables (anti-oxidants and vitamins E and C) and 
mono- and polyunsaturated fats (fish and olive oil) are associated with reduced cognitive 
impairment by reducing the neuronal damage associated with reactive oxygen species (ROS) 
and inflammation
22
.  The mechanisms underlying the neuroprotective effects, namely reduced 
plaque formation
41
, of physical exercise are unclear but it has been proposed that exercise 
may enhance glucose utilization, promote cerebral blood flow and thereby facilitate oxygen 
extraction
22
. 
A history of traumatic brain injury (TBI) has also been linked to enhanced AD risk as such 
brain injury has been reported to promote APP overexpression and thereby result in elevated 
Aβ levels42. Furthermore, performing tasks that are cognitively stimulating has been shown to 
reduce the likelihood of developing dementia
22
.  
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As previously stated the neuropathological hallmarks of AD are extracellular neuritic 
plaques, intracellular neurofibrillary tangles, cerebrovascular amyloidosis as well as synaptic 
and neuronal loss, particularly in the basal forebrain and hippocampus, these being regions of 
higher-order cognitive function
43
. 
 
1.7 Neuropathology 
1.7.1. Neurofibrillary Tangles 
The neurofibrillary tangles (NFTs) (Figure 1.2 and Figure 1.3) are composed of 
hyperphosphorylated forms of the microtubule-associated protein tau.  
 
1.7.1.1 Tau 
Tau is the predominant (>80%) microtubule associated protein (MAP)
44
. This protein, 
encoded on chromosome 17q21
45
, exists in six isoforms 
46
 and is unusually hydrophilic for a 
cytosolic protein
47
 which thereby provides an explanation for its natively unfolded state. The 
physiological role of tau is to promote the assembly and maintain the stability of 
microtubules in neurons and other cells as well as protect against microtubule length 
fluctuations
47
. It is important to note that the microtubule binding and stabilising activity of 
tau is dependent on the degree of its phosphorylation
2
. Under normal physiological 
conditions, 2-3 moles of phosphate are bound per mole of tau protein
48
. 
  
1.7.1.2 Hyperphosphorylated Tau 
Within the AD diseased context, the degree of tau phosphorylation is thrice (3x) that of 
normal tau, thus 6-9moles of phosphate bind per mole of tau
48
. Three sites have been 
identified as distinguishers between non-diseased and AD patients and must be 
phosphorylated in order to induce aggregation, these are namely Thr231, Ser235 and Ser262
2
. 
Phosphorylation lowers the affinity of tau for microtubules resulting in their dissociation 
from microtubules. The microtubule binding site on tau coincides with the tau-tau interaction 
site, therefore dissociation of tau from microtubules consequently allows for tau 
aggregation
49
. Hyperphosphorylated tau consequently aggregates into paired helical filaments 
(PHFs) which in turn form the neurofibrillary tangles characteristic of AD
50
. It is noteworthy 
to add that heparan sulphate proteoglycans (HSPGs) facilitate efficient NFT formation
51
. 
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This enhanced phosphorylation during AD may be attributable to enhanced kinase and/or 
reduced phosphatase activity.  
 
The most studied tau protein kinase within the AD context is  glycogen synthase kinase- 3β 
(GSK-3β), which is stimulated by Aβ as well as other AD associated processes such as 
oxidative stress, endoplasmic reticulum stress and proteasomal dysfunction
44
. Other kinases 
which have been reported to regulate tau phosphorylation are: cyclin-dependent kinase 5 
(Cdk5), Protein Kinase A (PKA), calcium/calmodulin-dependent kinase II (CaMKII), serine 
kinases (Fyn, Src, Abl) and the kinases involved in the Mitogen Activated Protein Kinase 
(MAPK) signal cascade (ERK1/2 and JNK) (as discussed later in section 1.12.1) to name a 
few
2
 
47
 (Figure 1.2).  
 
Several serine/threonine protein phosphatases have been implicated in tau dephosphorylation, 
these include metal-dependent protein phosphatases (PP1, PP2A, PP2B, PP4-PP7) and 
phosphoprotein phosphatases (PP2C). PP2A is the most abundant (>70%) and effective tau 
phosphatase
52
. It is important to note that GSK-3β activation promotes the accumulation of 
protein tyrosine phosphatase 1B (PTP1B) which consequently phosphorylates and inactivates 
PP2A
44
. Furthermore, specific PP2A inhibitors, PHAP-I and PHAP-II, are upregulated in 
AD
53
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2| Tau phosphorylation. Graphical representation of the tau protein. The four repeat sequences which 
comporise the microtubule binding domain (MBD) are shown as well as sites of phosphorylation at serine (S) or 
threonine (T) residues. Those residues followed by Proline (P) are denoted as SP or TP, respectively. The kinases 
involved in tau phosphorylation at these varying sites are depicted and include: glycogen synthase kinase-3β 
(GSK-3β), cyclin-dependent kinase 5 (Cdk5), protein kinase A (PKA), calcium-calmodulin protein kinase 2 
(CaMKII), mitogen activated protein kinases (MAPK), microtubule affinity regulating kinase (MARK) and Akt 
and Fyn kinases (Adopted from 
7
). 
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The consequences of NFT formation, which primarily accumulate in the neuronal cell bodies  
and dendrites
54
 (Figure 1.3), includes cytoskeletal destabilization which consequently has 
adverse effects on cellular morphology and viability as well as disrupts microtubule dynamics 
and intracellular trafficking of organelles, functional proteins and neurotrophins
2
. In addition, 
the generation of toxic intracellular aggregates reduces proteosomal efficacy
55
. 
 
Although the tangle load is reported to correlate more closely with AD severity than the 
plaque level
56
, NFTs are additionally the central features of an assembly of 
neurodegenerative disorders termed “tauopathies”, which include: progressive supranuclear 
palsy, corticobasal degeneration, Pick’s disease54 and subacute sclerosing panencephalitis16. 
The NFTs are thus not exclusively associated with AD. Conversely, Aβ neuritic plaques, 
although present in healthy and diseased brains (patients suffering from AD as well as 
Dementia with Lewy bodies (DLB)), are not the principle pathological hallmark of any other 
disease. Moreover, tau gene-related mutations result in the development of frontotemporal 
dementia as opposed to AD
57
, whereas familial AD is the consequence of mutations 
triggering the excessive generation of Aβ42. 
 
Furthermore, Aβ42 accumulation has been reported to stimulate the initiation of molecular 
mechanisms underlying tau hyperphosphorylation. Aβ42 accomplishes this through kinase 
activation, especially GSK-3β (and consequently hinders PP2A activity) and Fyn kinase (via 
the cellular prion protein (PrP
c
)). In addition, Aβ induces apoptosis (to be discussed in detail 
in section 1.9.3 below) and the resultant proteolysis of tau by caspases promotes its 
aggregation
51
. It is noteworthy to add that recent reports have demonstrated that tau 
pathology is vital for the full extent of Aβ42 toxicity to develop
58
.  
 
Thus, it has been highlighted that Aβ, and more specifically Aβ42, as opposed to tau, is indeed 
the principal aetiological (disease causing) agent in AD.    
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Figure 1.3| Neurofibrillary tangles (NFTs) and Amyloid beta (Aβ) composed plaque in a section of the 
entorhinal cortex derived from an individual with severe Alzheimer’s Disease. Senile plaques, composed 
primarily of Aβ, are identified by arrow heads and the neurofibrillary tangles (NFTs), composed of 
hyperphosphorylated tau, are identified by arrows (Adopted from
59
). 
 
 
 
1.7.2. Amyloid Plaques 
The second neuropathological hallmark of AD, the extracellular senile/neuritic plaques, are 
largely composed of 8nm amyloid fibrils
60
. These fibrils in turn are composed of amyloid 
beta (Aβ) peptides (Figure 1.3), predominantly the 42 amino acid isoform (Aβ42), as it 
exhibits an augmented aggregation propensity
61
 owing to the presence of additional 
hydrophobic amino acid residues, namely isoleucine and alanine
62, 63
. Although the neuritic 
plaques were originally regarded as the destructive agents, current hypotheses posit Aβ 
oligomers (Aβo), as the neurotoxic agents instead64. Conversely, recent studies have 
suggested that neuritic plaques may in fact be neuroprotective as they are able to sequester 
the toxic soluble Aβ oligomers, thereby diminishing their neurotoxic effects60. Despite the 
fact that plaques themselves are not the neurotoxic species, they may contribute to AD 
neuropathology by adversely affecting dendrite spine formation and geometry
65
. 
Furthermore, Aβ plaques have been demonstrated to block inter-neuronal transport and 
significantly impair neocortical synaptic transmission, thereby reducing the ability of neurons 
to integrate and propagate information
66
. Senile plaques have also been reported to deregulate 
calcium(Ca
2+
) homeostasis which consequently results in structural and functional disruption 
of neuronal networks
67
. 
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It must be stated that amyloid plaque load correlates poorly with the degree of cognitive 
impairment whilst soluble non-fibrillar Aβ oligomers are better quantitative correlates.  
 
 
1.8  The molecular basis of Alzheimer’s Disease 
1.8.1. The Amyloid Precursor Protein (APP) 
1.8.1.1  APP Structure and Trafficking 
 
The amyloid precursor protein (APP) (Figure 1.4) is a type I transmembrane protein with a 
single transmembrane domain. It is encoded by a single gene on chromosome 21 and this 
thereby underlies the finding that individuals with Down Syndrome have a higher 
predisposition to develop AD
68
. APP, which is ubiquitously expressed but at higher levels in 
neurons, exists in three splice variants: APP695, APP751 and APP770
69
, the expression of 
the former is enhanced in neuronal tissues
70
. APP  may be divided into several functional 
domains namely (from N to C terminus): heparin and copper binding domains, an acidic 
domain, a Kunitz-type protease inhibitor (KPI) domain, Aβ region (which distinguishes APP 
from other APP-like protein APLP1 and APLP2) and the YENPTY motif which is central for 
clathrin-mediated endocytosis
71
(Figure 1.4). During its transport through the secretory 
pathway towards the plasma membrane, APP is post-translationally modified through N- and 
O- glycosylation, sialylation, phosphorylation and tyrosine sulphation
72
. Moreover, it has 
been suggested that only approximately 10% of APP indeed reaches the plasma membrane, 
the remaining APP localizes primarily in the Golgi apparatus and trans-Golgi network 
(TGN)
72
. 
 
At the cell surface, APP may either undergo proteolytic processing or may be internalized, 
delivered into endosomes and consequently either degraded in lysosomes or recycled to the 
cell surface
73
. 
  
1.8.1.2  Physiological role of APP and its cleavage products 
Several physiological roles have been ascribed to APP and its cleavage products (the 
generation of which will be discussed later in section 1.8.2).  
 
A role for APP in neuronal cell adhesion has been proposed and may be as a result of APP 
binding to multiple extracellular matrix components (such as laminin, collagen type I and 
13
heparin
71
  and cell surface adhesion proteins (such as neural cell adhesion molecules 
(NCAMs) and integrins)
71
 as well as the fact that APP molecules on neighbouring cells have 
been demonstrated to interact
74
. Furthermore, APP and its non-amyloidogenic cleavage 
product sAPPα (Figure 1.5) have been documented to  have trophic functions. APP, upon 
binding to extracellular proteoglycans, has been reported to induce neurite outgrowth
75, 76
 and 
promote neurogenesis through ERK phosphorylation
77
. 
 
sAPPα similarly serves multiple physiological roles - this peptide my stimulate neuronal 
proliferation
78
 and is required for normal brain development as well as to mediate long-term 
potentiation (LTP) and learning
79
. In addition, sAPPα is reportedly neuroprotective as it 
downregulates Cdk5 activity, thereby hindering tau hyperphosphorylation
80
 and has also been 
documented to antagonize neuronal death triggered by proteasomal stress
81
.    
 
Cleavage of APP by ɣ-secretase yields an APP intracellular domain (AICD), which has been 
demonstrated to translocate to the nucleus and form a complex with Fe65 and Tip60 (a 
chromatin remodelling factor)
82
. A role of this transcriptional complex in activating the 
expression of the cellular prion protein (PrP
c
) has been proposed
83
. However, the 
transcriptional activity and the downstream targets (supposedly GSK-3β, neprilysin, p53 and 
the epidermal growth factor receptor (EGFR)) of this complex have been areas of much 
controversy and require unambiguous confirmation
71
.  
 
APP may be metabolized via two pathways namely, a non-amyloidogenic pathway and an Aβ 
generating amyloidogenic pathway (Figure 1.5). Both pathways occur under normal 
physiological conditions in healthy individuals. It is rather the disproportionate favouring of 
the amyloidogenic cleavage or retardation in the rate at which Aβ is cleared that results in the 
development AD. 
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 Figure 1.4| Schematic representation of the Amyloid Precursor Protein (APP) and the enzymatic cleavage 
sites located within the amyloid beta (Aβ) sequence. The APP770 isoform is represented here. SP represents a 
17aa cell-surface N-terminal signal peptide. The protein contains an E1 domain comprising a heparin-binding 
domain (HBD) and a copper-binding domain (CuBD) as well as a 56aa Kunitz-type serine protease inhibitor 
domain (KPI), an E2 domain containing a second HBD and the Aβ region. There is a YENPTY intracellular C–
terminal signal motif. The 40-42aa Aβ sequence and the enzymatic cleavage sites of β-secretase, α-secretase and 
ɣ-secretase are depicted.TMD = transmembrane domain (Adapted from 84). 
 
1.8.2 APP Processing 
It is important to highlight that although APP is initially targeted to the plasma membrane via 
the secretory pathway, APP processing occurs at several subcellular sites. 
 
1.8.2.1 The non-amyloidogenic pathway 
This pathway involves APP proteolytic cleavage by alpha (α)-secretase between residues 
APP687 and APP688
85
, between Lys16 and Leu17 of the Aβ sequence, and thereby precludes 
Aβ shedding. The released amino terminal ectodomain fragment is termed sAPPα (Figure 
1.5). The remaining 83aa carboxyl terminal fragment (CTF83) is cleaved by gamma (ɣ)-
secretase generating a soluble 3kDa p3 fragment and a 57-59aa amyloid intracellular domain 
(AICD).  
 
1.8.2.1.1 α-secretase 
Although several members of the disintegrin and metalloprotease (ADAM) family have been 
demonstrated to function as α-secretase, including ADAM9, ADAM19 and ADAM 17 (also 
termed tumour-necrosis factor-α converting enzyme (TACE)), it has recently been reported 
that ADAM10 accounts for most α-secretase activity86. ADAM-10 exists as a pro-enzyme 
and is only activated upon association with the plasma membrane
87
 and thus non-
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amyloidogenic processing of APP predominantly occurs at the cell surface. Moreover, non-
amyloidogenic processing is the preferred pathway in non-neuronal cells but is not the 
predominant pathway in neuronal cells owing to their enhanced expression of β-secretase72.  
 
Numerous other proteins of physiological importance are similarly cleaved by α-secretase, 
including cadherins, other type I transmembrane proteins, Notch receptors and tumour 
necrosis factor α (TNFα)72. 
 
The activity of this enzyme may be modulated by calcium, Protein Kinase C (PKC)
87
 and 
cholesterol levels (α-secretase activity being promoted upon cholesterol depletion)88. 
 
1.8.2.2 The amyloidogenic pathway 
The amyloidogenic pathway is initiated by APP cleavage by beta (β)-secretase between 
residues APP671 and APP672
70
 generating sAPPβ (Figure 1.5). The resultant CTF99 is 
further cleaved by ɣ-secretase yielding a soluble 4kDa Aβ monomer and the AICD (Figure 
1.5). Cleavage by ɣ-secretase between APP712 and APP713 generates Aβ40 whilst cleavage 
at APP714 generates Aβ42
89
. 
 
In addition to Aβ, the sAPPβ cleavage fragment has recently been suggested to posses 
neurotoxic properties. It has been proposed that sAPPβ may be further cleaved into a 35kDa 
fragment denoted N-APP which may bind to death receptor 6 (DR6), resulting in caspase 
activation which consequently leads to axonal degeneration and neuronal death
90
.  
 
It must be emphasized that the amyloidogenic pathway is a normal physiological process and 
Aβ is therefore present in the cerebrospinal fluid (within the 3-8nM range91) and plasma 
(500pM
35
) of healthy individuals.  
 
1.8.2.2.1 β-secretase 
The aspartyl protease which catalyzes the rate limiting step in Aβ generation92, is termed the 
β-secretase or more specifically β-site APP cleaving enzyme-1 (BACE-1) and is encoded by 
a gene on chromosome 11. This enzyme is ubiquitously expressed, with highest levels 
present in the pancreas and brain. It is owing to the elevated levels of BACE-1 in neuronal 
tissue in comparison to that of α-secretase, that amyloidogenic APP processing is favoured in 
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neurons
72
. BACE-1 expression is further enhanced during times of environmental
93
 and 
cellular stress
92
. 
 
BACE-1 is transiently present on the cell surface, specifically in the lipid raft region, where it 
may catalyze the cleavage of APP, a process facilitated by glycosaminoglycans (GAGS)
94
. 
However, this enzyme is predominantly localized to the Golgi apparatus, trans-Golgi network 
(TGN) and endosomal compartments - which provide the ideal acidic environment for 
optimal enzymatic activity (pH4.5)
92
. Therefore, the majority of APP amyloidogenic 
processing occurs within the endosome/endocytic vesicles.   
 
Although BACE-1 is a central target for AD therapeutics, it must be borne in mind that 
BACE-1 does not exclusively cleave APP but is additionally involved in the proteolytic 
processing of other physiological substrates, such as platelet selectin glycoprotein ligand-I, 
interleukin-like receptor type II as many others
95
. The most important BACE-1 substrate 
reported to date is Neuregulin-1 (NRG1), the cleavage of which is central to signal 
transduction pathways involved in myelination
72
- which is central to synaptic transmission 
and memory consolidation.    
 
An explanation for the confinement of AD pathology to the brain is provided by the fact that 
both APP and BACE-1 are expressed at highest levels in neuronal cells.   
 
 
1.8.2.2.2 ɣ-secretase 
Gamma(ɣ)-secretase is also an aspartyl protease, consisting of 6-9 transmembrane domains96, 
97
 and is involved in the cleavage of the C-terminal fragments (CTF) derived after either α- or 
β- secretase cleavage. This cleavage occurs within the transmembrane regions of these 
proteins. ɣ-secretase is a complex consisting of four subunits, namely Nicastrin (Nct) (a 
substrate receptor), Anterior pharynx defective (APH) (which serves as a scaffold protein for 
complex assembly), Presenilin enhancer (PSEN-2) (which facilitates proteolysis) and a 
catalytic subunit termed presenilin (PS), either PS1 or PS2 (which catalyze substrate 
cleavage)
72
. The cleavage activity of ɣ-secretase differs from that described above in that this 
enzyme complex catalyzes a stepwise proteolysis of its substrates - meaning that the enzyme 
does not cleave at a single site only but rather catalyzes sequential cleavage at multiple sites, 
often 3 amino acids apart. Depending on the site of initial cleavage, ɣ-secretase may result in 
17
the formation of several Aβ isoforms (Aβ37-Aβ42). Enzymatically active ɣ-secretase is 
localized to the plasma membrane as well as the endosomal and lysosomal compartments
72
. 
 
This enzyme is of great physiological importance and is involved in the proteolysis of over 
60 substrates - thereby highlighting the significance of this complex
98
. One such substrate is 
Notch, the resultant cleavage by ɣ-secretase is central for Notch signalling - which is central 
in regulating cell fate and affects cellular proliferation, apoptosis and differentiation, all of 
which are processes vital to normal embryonic development and homeostasis during 
adulthood
99, 100
. ɣ-secretase has additionally been shown to cleave N- and E-cadherins, ErbB-
4 (neuregulin receptor), SREBPs (sterol regulatory element binding proteins) and it has been 
proposed that this enzymatic complex may play a role in protein turnover as well as in 
calcium homeostasis
98
. 
 
 
 
 
 
 
 
 
 
Figure 1.5| The proteolytic processing of the Amyloid Precursor Protein (APP) and its cleavage products. 
The non-amyloidogenic pathway (left) involves successive alpha(α)-secretase cleavage (after residue 687), 
releasing sAPPα and gamma (ɣ)-secretase cleaves the resultant 83aa C-terminal fragment CTF83 to generate p3 
and the amyloid intracellular domain (AICD). The amyloidogenic pathway (right) entails beta (β)-secretase or β-
site amyloid precursor protein-cleaving enzyme-1 (BACE-1) cleavage after residue 671, thereby releasing 
sAPPβ, and the subsequent CTF99 cleavage by ɣ-secretase resulting in Aβ shedding and intracellular AICD 
release. AICD translocates to the nucleus and stimulates transcription activation (Adopted from
7
). 
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1.8.3  Mutations in APP 
The following missense mutations in APP are known to cause AD either by augmenting Aβ42 
production, favouring β-secretase activity or thwarting α-secretase cleavage. Approximately 
40 APP missense mutations have been identified
101
. These are commonly named, with the 
mutated residues provided in brackets, as follows: Swedish (K670N, M671L), Flemish 
(A692G, E693Q), London (V717I, V717G), Indiana (V717F) and Florida (I716V), Dutch 
(E693Q)
96
, Iowa (D694N), Artic (E693G)
102
 to name a few.  
 
1.8.4 Presenilin Mutations 
More than 197 missense mutations have been identified in the PS1 gene and 25 missense 
mutations in the PS2 gene
101
 and these mutations promote ɣ-secretase cleavage that produces 
the longer 42aa Aβ isoform87. Only mutations in residues conserved between PS1 and PS2 
have been reported to result in a 1.5-3 fold increase in Aβ42 production and plaque load
16
 and 
are therefore linked to FAD/EOAD. An extensive list of such mutations is provided in the 
review by Cruts et al.,
101
.  
 
1.9 The Amyloid-beta (Aβ) peptide 
The Aβ peptide, which is generated as a result of the sequential proteolytic cleavage of its 
parental protein APP, is amphiphilic in nature with the first 28 aa residues being polar and the 
remaining residues being non-polar
103
 (Figure 1.4). Thus, at neutral pH the peptide exhibits 
great differences in polarity and thus exhibits a great aggregation propensity
104, 105
. Aβ was 
first isolated  by Glenner and Wong in 1984 and was shown exist not only as monomers 
(~4.4kDa) but also to associate into soluble SDS-stable dimers (~8kDa), trimers (~12kDa) 
and higher order oligomers (up to 20 monomers)
60, 106, 107
. It is  noteworthy to add that the Aβ 
region of APP, which is inserted into the membrane, is largely α-helical in conformation. It is 
only post cleavage and release, that Aβ acquires the β-sheet conformation required for 
aggregate formation
60
.  
 
1.9.1 The Physiological role of Aβ 
Although Aβ42 accumulation indisputably leads to the development of AD, it must be borne 
in mind that amyloidogenic processing is a normal physiological process and Aβ42 is present 
in the CSF and plasma of non-demented individuals throughout life
70, 108
. At physiological 
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concentrations (picomolar range, 1pM-1nM 
109) Aβ42 has recently been shown to play a 
central role in numerous processes. Aβ is vital for neuronal cell survival, cell growth, neurite 
outgrowth and axonal sprouting
108
 as well as differentiation (through binding to receptors for 
advanced glycation end products (RAGE)
110
. Furthermore, owing to its metal-binding affinity 
(specifically copper, zinc, aluminium and iron), Aβ42 has been proposed to protect against 
metal-induced oxidation
108. Aβ42 serves a very important role in regulating synaptic activity 
upon binding to cell surface receptors (NMDA and α7 nicotinic acetylcholine receptors 
(α7nAChR)) by impairing long term potentiation (LTP). This thereby prevents excessive 
synaptic activity which would lead to excessive glutamate release and neuronal cell death as a 
result of excitotoxicity
111
. In addition, Aβ42 has been reported to function in facilitating 
learning and regulating memory consolidation
112, 113
. The peptide has been suggested to do so 
by enhancing the production of acetylcholine
112
 and activating signal transduction pathways 
involved in memory formation, namely the phosphatidylinositol-3 kinase and MAP kinase 
cascades
113
.  
Owing to the diverse physiological functions of Aβ42, total eradication of the peptide may be 
detrimental to neuronal processes and perhaps should not be the aim of prophylactic and 
therapeutic approaches. Since it is the supraphysiological concentration (within the 
nanomolar range) of Aβ42 that results in pathogenesis, which is the consequence of an 
imbalance between Aβ42 production and clearance, therapeutic intervention should focus on 
these processes.         
 
1.9.2 Aβ-degrading proteases 
Under normal physiological conditions Aβ42 has a relatively short half-life of approximately 
1.7 h
114
. This therefore demonstrates that under physiological conditions Aβ42 is effectively 
and efficiently degraded. This degradation is mediated by a host of different proteases, 
collectively termed Aβ-degrading proteases (AβDP), each localized to a specific 
cellular/subcellular compartment. These enzymes display cooperativity with regards to 
eliminating Aβ42. These include: cathepsin B, matrix metalloproteases (MMP2, MMP9, 
MMP14), endothelin-converting enzymes (ECE1/2), angiotensin-converting enzyme (ACE), 
plasmin, the proteasome and BACE-1/2
115
. The enzymes identified to be of particular 
importance with regards to Aβ degradation are: neprilysin (NEP) and the insulin degrading 
enzyme (IDE).  
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NEP is the principal AβDP and accounts for 50% of Aβ degradation115. This Type-II, zinc-
metalloprotease which is predominantly expressed in neuronal ER and the Golgi apparatus, is 
able to degrade both Aβ monomers and some Aβ oligomers115. It is noteworthy to add that 
NEP phosphorylation is mediated by the MAPKinase signal transduction pathway and results 
in reduced NEP activity and enhanced Aβ levels, whilst dephosphorylation, as mediated by 
protein phosphatase 1 (PP-1), restores NEP functionality
116
. Both MAP kinases and PP-1 are 
involved in the 37kDa/67kDa LRP/LR associated signalling pathways (as discussed in 
section 1.11.1.1 below).  
IDE, also a zinc-metalloprotease, similarly degrades monomeric Aβ. This enzyme is present 
in the cytosol, ER, endosomes, lysosomes, peroxisomes and is also secreted into the 
extracellular space
115
.  
It must be highlighted that a cell’s Aβ degradation capacity is generally reached during 
normal metabolism
115, and therefore these systems are unable to match the elevated Aβ 
production levels characterised by AD. Excessive Aβ levels may additionally serve as AβDP 
inhibitors, thereby augmenting the cell’s Aβ degrading deficiency in AD. Furthermore, 
elevations in oxidative stress, which accompany aging, are detrimental to AβDP activity117. 
Moreover, cerebral Aβ levels may be reduced by transport of this peptide across the blood 
brain barrier (BBB) by certain proteins, such as the low-density lipoprotein receptor-related 
protein 1 (LRP1)
118
.      
 
1.9.3  Effects of Toxic Aβ oligomers 
Interactions between Aβ42 (usually oligomeric Aβ42) and cell surface receptors have been 
reported to induce oxidative damage by stimulating the generation of reactive oxygen species 
(ROS), namely superoxide and hydrogen peroxide
119
. This consequently results in protein 
degradation and lipid (i.e. myelin) peroxidation thereby slowing the rate of signal 
transmission which in turn hampers the consolidation of new information, retrieval of 
memories and motor functions
120. Additionally Aβ42-receptor interactions may induce cell 
death pathways and thereby mediate neurotoxicity. Moreover, the interaction of Aβ42 with 
metabotrophic glutamate-5 receptors (mGluR5)
121
 
94
 and N-methyl-D-aspartate receptors 
(NMDA)
122
 
94
disrupts calcium (Ca
2+
) ion homeostasis resulting in excitotoxicity, synaptic 
dysfunction and neuronal death
123
(Figure 1.6). Aβ42 interactions with cell surface receptors 
have also been demonstrated to result in aberrant signal transduction cascades with 
21
consequent adverse effects on normal cellular processes – this will be discussed with regards 
to the cellular prion protein (PrP
c
) in section 1.10.2.2 below. 
 
The toxicity of Aβ42 oligomers (Aβo) is not solely as a result of its cell surface associations, 
but is additionally attributable to intracellular Aβ42 accumulation. Aβ42 internalization, which 
is dependent on proteins located within the lipid raft region, allows for intracellular Aβ42 
accumulation which has been reported to have numerous deleterious functions including 
disruption of the ubiquitin-proteosomal system
124
,  promoting misfolding and aggregation of 
other functional cytosolic proteins as well as leading to organelle dysfunction including that 
of endocytic vesicles
125
, the endoplasmic reticulum
126
 and particularly that of the 
mitochondria
127
. Intracellular Aβ42 has been reported to insert into mitochondrial membranes 
and be present within the mitochondrial matrix, distorting mitochondrial structure and leading 
to mitochondrial dysfunction which consequently leads to energetic dysfunctions and the 
overproduction of reactive oxygen species (ROS)
128
. It is important to note that this serves as 
a positive feedback loop since oxidative stress promotes amyloidogenic APP processing
129
. 
The cytotoxicity of the Aβ42 peptide is proposed to reside between 25-35aa
130
. 
 
A protein that is celebrated within the AD research community with regards to mediating 
Aβ42 toxicity at the cell surface as well as through stimulating Aβ42 internalization is the 
cellular prion protein (PrP
c
) - this will be discussed in detail section 1.10.2.2 below. 
 
The Aβ42-protein interactions, as aforementioned, may further serve as the basis for AD 
related neuronal loss as they may result in either aberrant signal transduction, perturbation of 
Ca
2+ 
homeostasis
131
 (Figure 1.6) and/or the induction of oxidative stress
132
. 
 
 
1.9.3.1 Neuronal cell loss 
The peptide may activate a multitude of cell death modalities, the most significant being 
apoptosis and necrosis.  
Apoptosis is the predominant cell death pathway reported in AD related neuronal loss
131
. 
Apoptosis is an active (requires energy), highly regulated physiological process (initiated by 
either the extrinsic/death receptor, intrinsic/mitochondrial  or granzyme/perforin pathways) 
central to the maintenance of cellular homeostasis
133
, but when deregulated has pathological 
implications. The importance of apoptosis in AD pathogenesis is evidenced by elevated 
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levels of pro-apoptotic proteins p53, Bax and caspase 3
134
  in diseased brains as well as the 
fact that Aβ42-interactions with p75NTR, FAS, TNFR1, RAGE and APP not only induce 
reactive oxygen species (ROS) synthesis but also result in upregulated expression of pro-
apoptotic genes and enhanced mitochondrial permeability
6
. 
However, studies have also demonstrated that necrotic pathways as opposed to apoptosis may 
underlie Aβ42 neurotoxicity
130,135
. Necrosis is a passive non-programmed, cell death 
mechanism resulting from severe cellular injury/insults or extreme environmental alterations. 
This may either be a consequence of cross-talk between the death signalling pathways, such 
that the interactions discussed above serve as atypical necrotic signals or as a result of the 
membrane perforating properties of Aβ42
136
 (Figure 1.6). The latter may result in Ca
2+
 influx 
and cause the cytosolic Ca
2+ 
concentrations to rise to necrosis-inducing levels (in excess of 
1µM)
137
. Furthermore, the resultant increased Ca
2+
 concentration may activate calpains 
(cysteine proteases) which in turn mediate lysosome rupture and the consequent release of 
non-specific proteases termed cathepsins which are involved in cellular destruction
138
. 
Thus, as has been highlighted above, the Aβ42 peptide mediates its neurotoxicity through 
interactions not only with the plasma membrane but more notably through its associations 
with cellular proteins and receptors.  
 
1.9.3.2 Aβ interactions and their pathological implications 
Owing to their amphipatic nature, the hydrophobic C-terminus of Aβ42 oligomers may be 
incorporated into lipid raft regions of the plasma membrane
139,136
 (Figure 1.6) and/or 
nucleosomal, lysosomal membranes as well as those of the Golgi apparatus and endoplasmic 
reticulum
140
. The consequence hereof is disruption of membrane structure, function and 
fluidity which consequently has secondary implications for the functionality of membrane 
bound proteins and receptors
140
 and as well as results in the formation of Ca
2+
 permeable 
channels
141
 (Figure 1.6). This Ca
2+
 influx may disrupt synaptic plasticity, enhance 
mitochondrial permeability as well as activate both calpains and caspases - all of which 
contribute to cell damage and possibly death
135
. 
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A multitude of cell surface proteins present on neuronal and glial cells exhibit Aβ42 binding 
affinities (Table 1.1). Whilst associations between Aβ42 and some of these proteins are 
deemed neuroprotective, the majority are toxic
140
. It is noteworthy to emphasize that similar 
to the 37kDa/67kDa LRP/LR, the majority of these receptors ( p75NTR, CLAC-P/ColXXV, 
RAGE, SEC-R and integrins)  are transmembrane receptors
140,6
. 
 
Several of these receptors have additionally been implicated in Aβ42 internalization processes 
including, α-7 nicotinic acetylcholine receptor (α7nAChR)142, neurotrophin receptor p75 
(p75NTR)
143
 N-methyl-D-aspartate receptors (NMDAR), metabotrophic glutamate-5 receptor 
(mGluR5)
144
 and LRP1
145
. It must be emphasized that the ability of the majority of these 
receptors (NMDAR,mGluR5 and LRP1) to induce internalization is dependent on their 
association with PrP
c
.  
 
Conversely, certain Aβ-protein associations may be neuroprotective in nature - one such 
interaction is that between Aβ and laminin. Laminin, an 850kDa glycoprotein tri-peptide 
composed of disulfide-bonded chains: α (5 isoforms, 200-400kDa); β (220kda) and ɣ 
(210kDa)
146
, is a key component of the basal membrane. Laminin is central in maintaining 
the structure of the extracellular matrix (ECM) as well as in promoting neurite outgrowth, 
Figure 1.6| Deregulation of calcium (Ca
2+) homeostasis by Aβ. Aβ oligomers (Aβo) may augment 
intracellular Ca
2+
 levels by either: thinning the plasma membrane (PM) and thereby lowering the dielectric 
barrier of the PM and enhancing its ion conductivity; through insertion into the PM and the formation of Ca
2+
 
permeable pores or through interactions with Ca
2+
 transporter ion-channels  (Adopted from 
3
). 
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cell adhesion and the formation of synapses 
147-149
. The Aβ binding site (IKAV) is located on 
the α-chain150 and an high affinity interaction between these proteins (Kd= 2.7x10nM) 
151
 has 
been reported to promote neurite outgrowth
152
 and inhibit fibrillogenesis
151
. 
 
Table 1.1: Membrane associated proteins to which amyloid beta may bind 
6
 
Amyloid Precursor Protein (APP) 
N-methyl-D-aspartate receptor (NMDA-R) 
α-7 Nicotinic Acetylcholine receptor (α7nAChR) 
P75 Neurotrophin receptor (P75NTR) 
Integrins (especially α5β1) 
Receptor for advanced glycosylation end products (RAGE) 
Insulin receptor 
Formyl peptide receptor-like-1 (FPRL1) 
Scavenger receptors – class A,B,BI 
Heparan Sulfate Proteoglycans (HSPGs) 
 
An additional interaction of pathological significance, which has been alluded to previously,  
is that between Aβ and PrPc. 
 
1.10 The Cellular Prion Protein (PrP
c
) – a central factor in Alzheimer’s 
Disease 
1.10.1 Structure and physiological role of PrP
c
  
The cellular prion protein (PrP
c
) is a ubiquitously expressed 250aa protein encoded by the 
PRNP gene located on chromosome 20. PrP
c
 is most highly expressed in tissues of the central 
nervous system including neurons, glia and cells of the spinal cord
153
. Post synthesis in the 
ER, PrP
c
 is subjected to numerous post-translational modifications, whilst on its way through 
the secretory system to the cell surface: the N-terminal 22aa signal sequence is cleaved, two 
sites (Asn-181 and Asn-197) are glycosylated through the addition of N-linked 
oligosaccharide chains, a single disulfide bond is formed and post removal of the C-terminal 
hydrophobic peptide, a glycosyl-phosphatidylinositol (GPI) anchor is attached to the 
protein
153
. The resultant 208-209aa, which is predominantly α-helical in conformation, is 
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subsequently anchored to the plasma membrane and may occur in non- , mono- or 
diglycosylated forms
154
.  
It is also imperative to note that PrP
c
 is cleaved between residues 111 and 112 to yield two 
neuroprotective fragments, namely the N-terminal fragment (N1) and the C-terminal 
fragment (C1) 
153, 155, 156
. This cleavage is performed by ADAM10, the predominant α-
secretase involved in non-amyloidogenic processing of APP (discussed above in section 
1.8.2.1.1 above)
157
. It has been reported that N1 may block the neurotoxicity of Aβ oligomers 
(Aβo) – however, the neuroprotective effects thereof in the AD context are contentious owing 
to elevated amyloidogenic processing within the AD brain. The C1 fragment has been 
suggested to prevent the formation and accumulation of the infectious prion protein (PrP
Sc
) - 
the aetiological agent of prion disorders (to be discussed in section 1.10.2.1 below)
157
.   
PrP
c 
is constitutively cycled between the plasma membrane and endocytic compartments
158
 
via clathrin coated pits. However, as these proteins lack a transmembrane domain, this 
process requires an association between PrP
c
 and a transmembrane receptor. An alternative 
mechanism, namely caveolae mediated internalization, has been suggested to further 
contribute to PrP
c
 internalization (Figure 1.7). The rate of PrP
c
 internalization is relatively 
rapid, with complete recycling reported to occur within 60min
158
. This process of 
internalization is of importance not only with regards to the physiological functions of the 
protein but also in mediating pathogenic processes involved in prion disorders (Figure 1.7) 
and Alzheimer’s Disease (to be discussed in section 1.10.2.1 and 1.10.2.2 below).  
The most well established physiological role of PrP
c
 is that of a copper-binding protein 
(conferred by its octarepeat region). PrP
c
 is central to mediating the uptake of copper ions (an 
essential trace metal which serves as a cofactor for many enzymes and is vital for central 
nervous system development and is therefore most abundant in the brain
159, 160
) from the 
extracellular milieu. Since free Cu
2+
 promotes ROS production, PrP
c
 occupies a central 
protective role against oxidative stress
154
. Several other physiological functions have been 
conferred to PrP
c 
including ECM adhesion, mediating signalling pathways and in the 
formation and generation of synapses
161
. Although PrP-null mice are viable and do not 
display developmental or anatomical abnormalities (which suggests that the role of PrP
c
 may 
be redundant with that of other proteins), these animals do display alterations in sleep 
patterns, learning and memory deficits
158
 as well as neurodegeneration under oxidative stress 
conditions.   
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It must be emphasized however that many of these functions 
162-164
 are dependent on 
interactions between the PrP
c
 and numerous (> 70) proteins including ApoE, APP, HSPGs, 
RAGE, p75NTR, Aβ6, 164 and the 37kDa/67kDa laminin receptor (LRP/LR)165. These include 
roles in synaptic transmission, neuronal and specifically hippocampal morphology, cognition 
and circadian rhythmns as well as in cellular adhesion, signal transduction, metal (copper) 
binding and in the maintenance of oxidative stress homeostasis
166
. 
1.10.2 Pathological roles of PrP
c 
1.10.2.1 PrP
c
 in the development of Prion Disorders  
PrP
c
 is imperative to the development of a group of fatal neurodegenerative diseases aptly 
named prion disorders (PD) also referred to as transmissible spongiform encephalopathies 
(TSEs)
5, 6, 167, 168
. These diseases affect humans (Kuru, Creutzfeldt-Jakob (CJD), Gerstmann-
Straussler syndrome (GSS) and fatal familial insomnia (FFI)) as well as animals namely 
Scrapie in sheep, Bovine spongiform encephalopathy (BSE) in cattle and Chronic Wasting 
Disease (CWD) in ungulates
6, 167
.  
Prion disorders are unique in that they may be infectious, familial or sporadic in nature. The 
ease of transmissibility (both intra- and inter species) of the infectious agent  in these diseases 
is of particular concern owing to the ramifications these diseases have on both live stock and 
population health. The causative agent of TSEs
167
 is a purely proteinaceous, nucleic-acid free 
particle called the infectious prion protein and generally designated as PrP
Sc
. PrP
Sc
 is 
generated as a result a conversion of the α-helical structure of PrPc to a predominantly β-sheet 
structure
154
. Furthermore, differential proteolytic degradation of the isoforms illustrates that 
the tertiary structure of cellular and infectious PrP differ as well
169
. Following infection with 
PrP
Sc
 or a mutation-linked or spontaneous conversion of PrP
c
 to PrP
Sc
, PrP
Sc
 binds to and 
stimulates the conversion of endogenous PrP
c
 to PrP
Sc
 particles. This is said to occur both at 
the cell surface and within the endocytic compartments during internalization
170
 (Figure 1.7). 
PrP
c
 is vital to this pathogenesis and PrP-null mice are resistant to developing prion disorders.  
The resultant intraneuronal accumulation of PrP
Sc
 as well as a possible loss of physiologically 
functional PrP
c
 have been proposed to underlie the observed neurodegeneration
154
. 
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The non-integrin 37kDa/67kDa laminin receptor (LRP/LR) has been identified as a cellular 
receptor for both PrP
c165
 and PrP
Sc171
 and is central to prion protein internalization 
processes
165
. 
1.10.2.2 The influence of PrP
c
  on Alzheimer’s Disease 
A vital role for PrP
c
 in AD is undeniable. The role of PrP
c
 was first linked to the 
amyloidogenic pathway, where it was proposed that PrP
c
 inhibits the activity of BACE-1
172
, 
thereby inhibiting Aβ production. In line with this it was later proposed that a negative 
feedback loop exists between PrP
c
 and the amyloidogenic processing of APP. Here, the 
authors revealed that the AICD, upon formation of a transcriptional complex with Tip60 and 
Fe65 (discussed in section 1.8.1.2 above), regulates the transcription of p53 which 
subsequently promotes expression of PRNP. Thus, PrP
c
 inhibition of BACE-1 consequently 
results in reduced PrP
c
 expression
83, 173
 (Figure 1.8).  
 
Figure 1.7| Prion protein trafficking as well as the sites of PrP
c
 conversion and PrP
Sc
 formation. The cellular prion 
protein (PrP
c
) is synthesized in the ER and is transported via the Golgi apparatus to the cell surface, where it is 
anchored to the lipid raft region via a GPI anchor. PrP
c
 may be internalized by clathrin or cavoelin- dependent 
pathways. It is at the cell surface that the infectious prion protein (PrP
Sc
) binds to and is internalized in association with 
PrP
c
. PrP
Sc
 may seed the conversion of α-helical PrPc into PrPSc at both the cell surface as well as within the endo-
lysosomal system. The resultant PrP
Sc
 may form intracellular aggregates or may alternatively be recycled to the cell 
surface, thereby allowing for the infectious processes to persist. Inhibition of PrP
c
 transport to the cell membrane as 
well as internalization processes decreases PrP
Sc
 formation (Adopted from 
4
). 
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Lauren et al.
174
 revealed that PrP
c
 serves as a high affinity Aβ42 receptor and specifically 
binds via the PrP23-27 and PrP95-110 binding sites (thus primarily through the N-terminus) 
to Aβ oligomers (denoted as Aβo) (not monomers nor fibrils)175. It is now a universal belief 
that the most important role of PrP
c
 in AD is as a consequence of its Aβ42 binding affinity. 
This finding has been replicated multiple times and this interaction, specifically between Aβ42 
oligomers (Aβo) (not monomers or fibrils) and PrPc, is indisputable through the data 
regarding the biological effects of this association are largely controversial. However, recent 
elegant studies have demonstrated that PrP
c
 is indeed central to mediating the toxicity of Aβo.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It has recently been suggested that PrP
c
 is essential for Aβ oligomer (Aβo) induced neuronal 
loss, loss of long term potentiation and synaptic toxicity
176
. As cell surface PrP
c 
is considered 
a mediator of pro-apoptotic signalling
177
, it may be proposed that PrP
c
 may mediate pro-
apoptotic signalling upon interaction with Aβ oligomers (Aβo). Furthermore, PrPc has been 
shown to be central in mediating Aβ42 induced neurotoxic signal transduction cascades. Upon 
Figure 1.8| Feedback loop for the prion protein (PrP
c
)-mediated regulation of β-scretase activity. The 
amyloid intracellular domain (AICD) amyloidogenic APP cleavage product, indirectly upregulates prion protein 
(PrP
c
) expression through p53 gene activation. PrP
c
 consequently hampers beta (β)-secretase (BACE-1) activity 
thereby reducing APP amyloidogenic processing and Aβ synthesis. Binding of Aβ to PrPc prevents the protein 
from inhibiting β-secretase activity, compromising the regulatory control exerted on the amyloidogenic process 
and potentially increasing toxic Aβ levels (Adopted from6). 
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binding to Aβo, PrPc has been reported to activate the Src kinase, Fyn178. Fyn Kinase 
activation subsequently leads not only to tau hyperphosphorylation
179
 (Figure 1.9) but also to 
a significant increase in phosphorylated NR2B (a subunit of the NMDA receptor) therefore 
overactivating cell surface NMDA receptors which subsequently leads to excitotoxicity and 
finally dendritic spine loss and neuronal cell death 
157
. However, as previously stated, owing 
to its GPI anchored character, PrP
c
 likely relies on its transmembrane receptors to mediate 
these signal transduction cascades
174
. Proteins/receptors which have recently been implicated 
in this regard include LRP1
145
and caveolin-1, whilst others such as integrins and non-integrin 
receptors, which have the necessary structural characteristics, have been put forwards as 
possible candidates to mediate the PrP
c
-Fyn activation
2
. Thus, it is probable that PrP
c
 
signalling to Fyn may indeed occur through multiple PrP
c
 receptors.   
 
Novel roles for PrP
c
 within the AD context have also been proposed. A recent report suggests 
that PrP
c, in association with its receptor LRP1, is central in mediating the transcytosis of Aβ 
across the blood brain barrier (BBB)
180
. PrP
c
 has similarly been implicated in mediating the 
internalization/uptake of Aβo thereby allowing for the intracellular accumulation of Aβo and 
the resultant toxic effects thereof (as previously discussed in section 1.9.3 above).  
 
It may further be suggested that the binding of Aβ42 oligomers to PrP
c
 may hinder PrP
c
 
regulation of β-secretase through steric inhibition and/or through PrPc endocytosis 
augmentation and thereby thwart the neuroprotective PrP
c
-β-secretase interaction173. 
 
It is important to note that the GPI anchor of PrP
c 
is considered vital for PrP
c
-mediated 
toxicity
177
, thereby revealing that it is the cell surface location and the processes therewith 
associated, such as triggering signal transduction cascades and endocytosis, that are central to 
pathogenesis and not the binding of Aβ by PrPc alone. 
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A highly conserved receptor of both physiological and pathological significance, which 
similarly binds to the Aβ interactors laminin and PrPc, is the 37kDa/67kDa laminin receptor 
(LRP/LR). The possible role and importance of this receptor in AD has yet to be examined. 
 
1.11 The 37kDa/67kDa Laminin Receptor (LRP/LR) 
1.11.1 Structure and Function of the 37kDa/67kDa LRP/LR 
The 37kDa/67kDa LRP/LR, also referred to as the 37kDa laminin binding protein 
(37LBP)
181
, laminin receptor (LamR)
182
, laminin-binding protein precursor p40 (LBP-p40) 
183
and the ribosomal protein SA (RPSA)
184
 is a multifunctional, multiform and multilocus 
protein (Figure 1.10). The RPSA gene, located on chromosome 3p21.3, is comprised of seven 
exons, six of which correspond to the coding sequence
185, 186
. However, the sequence does not 
encode a signal peptide that targets the protein to the nucleus nor the cell membrane
185, 186
- 
however, the protein is located within both these subcellular compartments.  
 
The 295aa, type II receptor protein has a theoretical molecular mass of 32.854 kDa
187
 but has 
been detected via western blotting at apparent molecular masses of both 37kDa and 67kDa
187, 
188
. Although both isoforms of the protein are encoded by the same gene sequence, the 
mechanism through which the 37kDa LRP forms the 67kDa LR is elusive.  The receptor is 
acylated by 3 fatty acids at Ser2 namely: palmitate, stearate and oleate
189
 and the formation of 
the 67kDa isoform is prevented with acylation inhibition. Various isoforms of LRP/LR, 
Figure 1.9| Graphical representation of the proposed model of Aβ-PrPc induced Fyn activation. Upon binding of 
Aβ oligomers to the cellular prion protein (PrPc), Fyn kinase is activated and this results in the hyperphosphorylation of 
tau. The consequence hereof is the subsequent microtubule dissociation and aggregation of tau into neurofibrillarly 
tangles (NFTs) (Adopted from 
2
). 
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corresponding to different maturation states (44kDa,60/67kDa and 220kDa) all of which 
retain PrP
c
 binding affinities, have been identified in the murine brain
190
.    
 
This protein is divided into two domains, namely an intracellular N-terminal domain (1-
209aa), which contains a palindromic LMWWML sequence which has been conserved in all 
metazoans
188
 and an extracellular C-terminal domain (210-295aa), which is highly conserved 
amongst vertebrates
187, 188
 (Figure 1.10). The amino acid sequence of this receptor is 98% 
identical in all mammals, thereby implying that the receptor occupies a central physiological 
role. The N-terminus of LRP/LR displays an overall positive charge and the C-terminus, an 
overall negative charge - thereby accounting for the nature of the ligands able to bind to each 
domain
188
. Furthermore, the N-terminus has been reported to fold according to a three-state 
mechanism whilst the C-terminus was shown to be intrinsically disordered 
187, 188
and the two 
termini have been documented to weakly interact
187, 188
.  Although the a crystal structure of 
the 37kDa LRP has been solved at a resolution of 2.15 Å
191
, this structure contains residues 
1-220 only. Thus, the exact structure of the C-terminus is largely unknown. It must be noted 
that LRP/LR is post-translationally modified by phosphorylation at multiple sites, the most 
critical being Tyrosine 139
192
. The phosphorylation status of the 37kDa/67kDa LRP/LR is 
regulated in part by TGF-β inhibited membrane associated protein (TIMAP) and protein 
phosphatase-1 (PP-1)
193
, both of which interact with the intracellular N-terminus of the 
protein. It must be noted that TIMAP phosphorylation may be induced by GSK-3β 194and 
LRP/LR phosphorylation as a consequence of its association with TIMAP may be involved in 
filopodia formation
193
.  
 
The consequence of the alterable phosphorylation status of LRP/LR requires further 
investigation but it may be suggested that this feature may be of particular significance with 
regards to the signal transduction pathways triggered by the protein.  
 
LRP/LR is functional within multiple cellular locations, a characteristic largely attributable to 
its structural plasticity. The 37kDa/67kDa LRP/LR is located within the cholesterol-rich lipid 
raft domains of the plasma membrane, in the cytoplasm as well as in the nucleus
5, 168
.   
 
Within the nucleus, LRP/LR has been identified in association with DNA and histones H2A, 
H2B and H4
195
, and has been suggested to play a role in the maintenance of nuclear 
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structures. Furthermore, the protein has been associated with the pre-ribosome in the 
nucleolus
196
.  
 
In the cytosol LRP/LR has been implicated in the maturation and assembly of the ribosome 
(through its associations with 18s rRNA and the S21 ribosomal protein)
197
. Furthermore, as 
LRP/LR is homologous to the  ribosomal protein p40, it is not unexpected that LRP/LR 
forms an association with 40S ribosomal subunit and is therefore implicated in translational 
processes. In addition, LRP/LR has been reported to play a role in rRNA processing 
196, 198
. 
Moreover, LRP/LR has been shown to associate with cytoskeletal proteins including actin 
and α-tubulin, a major component of microtubules (to which tau similarly binds as discussed 
in above)
199
.   
 
At the cell surface, this protein serves as a multifunctional receptor exhibiting binding sites 
for an array of substrates (Figure 1.10) including: elastin and laminin-1
185, 200, 201
, heparin and 
heparan sulphate proteoglycans (HSPGs)
5
; viruses including Sindbis
202
, Dengue
203
, 
Venezuelan equine encephalitis (VEE) and Adeno-associated virus subtypes 2, 3, 8 and 9
5, 168
 
as well as the cellular (PrP
c
)
165
 (Figure 1.10) and infectious (PrP
Sc
) prion proteins
171
. Many 
of the binding sites for different ligands overlap, namely 161-180aa (termed the peptide G 
region) has been reported to serve as a binding site for both laminin-1 and heparin, whilst the 
region 205-229 may bind laminin-1 in addition to PrP
c 5, 204
. 
 
As has been previously stated, LRP/LR serves as a non-integrin high affinity laminin 
receptor, exhibiting a dissociation constant (Kd) of 5.8nM
205
. Furthermore, LRP/LR may 
associate with other laminin binding receptors (integrins) at the cell surface
206
. The 
conformation of laminin-1 is altered upon binding to the peptide G region (containing the 
palindromic sequence) of LRP/LR.  This association has been implicated in the induction of 
several signal transduction cascades and thereby largely underlies the receptor’s 
physiological roles in cellular proliferation, growth, differentiation
5
, migration
207
 and the 
remodelling of the extracellular matrix
208
 through the induction of urokinase-type 
plasminogen activator (uPA) and matrix metalloproteinase 9 (MMP-9)
209
 activity.  
 
Cell surface associated LRP/LR also serves as a receptor for midkine (MK)
210
, a growth 
factor which promotes gene expression as well as cellular growth, survival and migration
211
. 
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1.11.1.1 37kDa/67kDa LRP/LR and Cellular Signalling 
It is proposed that the 37kDa/67kDa LRP/LR occupies a central role in mediating the vital 
physiological cellular processes listed above largely as a result of its the binding to laminin-1, 
and the subsequent induction of the Mitogen Activated Protein Kinase (MAPK) signal 
transduction pathway. The 37kDa/67kDa LRP/LR has been shown to regulate expression 
levels of MKP1 and PAC1, MAPK phosphatases
212
,which consequently dephosphorylate and 
deactivate ERK, p38 and JNK.  
 
Interestingly, it has recently been reported that the LRP/LR-laminin-1 interaction, via MAPK 
signal transduction cascades, increases the phosphorylation status of c-Myc and thereby 
induces the expression of the Fas ligand (FasL)
213
. 
   
Moreover, the expression of the 37kDa/67kDa LRP/LR may in turn be regulated by the ERK 
and JNK MAPK signal transduction cascades, upon stimulation of these cascades by hypoxia. 
LRP/LR has an hypoxia response element 16bp upstream from the translational start site 
which is responsive to the hypoxia-inducible factor-1 (HIF-1), a transcription factor activated 
by a hypoxic micro-environment
209
 through the ERK and JNK pathways. This is of particular 
relevance to cancer biology as hypoxia promotes tumour metastasis.  
 
 
Figure 1.10| Schematic representation of the functional domains of the 37kDa/67kDa Laminin Receptor.  This 
receptor is 295aa in length. Residues LRP86-101 represent the transmembrane domain. The receptor features three 
ligand-binding domains, including a PrP
c
 and laminin-1 binding domain (LRP161-180); a laminin-1and heparin binding 
domain (LRP160-180 and LRP205-229) and an IgG-antibody binding domain (LRP272-280) (Adopted from 
5
). 
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It has additionally been suggested that the 37kDa/67kDa LRP/LR-laminin-1 association may 
regulate the activity dual specific phosphatases
212
, intracellular levels of Ca
2+ 214
 and 
calmodulin kinase II
215
.  
 
1.11.2 Pathological roles of the 37kDa/67kDa LRP/LR 
 
1.11.2.1 The role of the 37kDa/67kDa LRP/LR in Cancer 
Cancer is broadly described as the deregulation of normal cellular homeostasis resulting in 
uncontrolled cell proliferation. In 2012 there were an estimated 14.1 million new cancer cases 
globally (WCRF) and 8.2 million cancer-related deaths (GLOBOCAN, 2012), thus making 
cancer the 7
th
 leading cause of death globally in 2012 (WHO). 
 
The 37kDa/67kDa LRP/LR has been shown to be overexpressed in numerous cancer types 
including glioma, bile duct carcinoma, cystic carcinoma, urothelial tumours
209
, colon, 
colorectal, breast 
216
, uterine, cervical, ovarian, gastric, laryngeal, oesophageal
216
, liver
217
, 
lung
218
, prostate
219
, acute myeloid leukaemia
220
 to name a few.  
 
The mechanism underlying the overexpression of LRP/LR in cancer is not firmly established 
as no gene amplification has been reported
221
. However, numerous factors have been 
demonstrated to regulate the expression of receptor. The 37kDa/67kDa LRP/LR –  ECM 
associations have been suggested to result in upregulation of expression
222
. The regulatory 
effects of cytokines and inflammatory agents remains controversial as despite originally 
being reported to upregulate protein expression
223
, later evidence revealed that Tumour 
necrosis factor alpha (TNF-α) and  Interferon-gamma (IFN-ɣ) downregulate LRP/LR 
expression
224
. In addition, the tumour suppressor p53 has been proposed to regulate LRP/LR 
expression levels. The RPSA gene exhibits an enhancer element in intron-1 to which the 
transcription factor, AP-2, has been shown to bind. p53 has been shown to negatively 
regulate LRP/LR expression through the formation of a complex with AP-2 which 
consequently prevents its binding and finally results in the repression of RPSA
221
. As p53 is 
mutated and thereby functionally reduced in many cancers, this may accordingly provide an 
elegant explanation of the overexpression of LRP/LR in numerous cancer types. Furthermore, 
it must be noted that oxidative stress and Aβ peptides have been  shown to conformationally 
alter p53 and thereby impair the activity of this transcription factor
225
.   
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The level of LRP/LR expression has been shown to correlate directly with the invasive and 
metastatic potential of numerous neoplastic cells and is hence considered a marker for 
metastatic aggressiveness
226
. High LRP/LR expression levels are therefore a poor prognostic 
indicator in patients with solid tumours
227
.   
   
1.11.2.1.1 Uncontrolled Cellular Proliferation 
The overriding characteristic of neoplastic cells is their unlimited proliferative potential. The 
mechanisms underlying the transformation of normal cells into tumorigenic cells, which are 
able to undergo uncontrolled proliferation, are broadly divided into six categories
228
, namely: 
self-sufficiency in growth signals, resistance to cell cycle arrest signals, evasion of apoptosis, 
limitless replicative potential due to enhanced telomerase activity, the ability to induce 
angiogenesis as well as the ability to undergo invasion and metastasis.  
 
The 37kDa/67kDa LRP/LR has been implicated in most of the aforementioned processes, and 
its roles in contributing to uncontrolled cellular proliferation have been well-established, 
some which are discussed below. 
 
Overexpression of the 37kDa/67kDa LRP/LR is reportedly associated with an upregulation in 
the expression of cyclins A, B ,C as well as cyclin-dependant kinases (Cdk) 1 and 2, thereby 
allowing for cell cycle progression and irrepressible cellular proliferation and growth
229
. 
 
Furthermore, although the induction of FasL expression by LRP/LR through c-Myc, (as 
discussed above in section 1.11.1.1 above) may physiologically be involved in triggering 
apoptosis, it must be borne in mind that mutations in the Fas receptor (FasR), which are 
involved in both tumour development and progression both in vitro and in vivo
230
, may 
negate this effect. Furthermore, LRP/LR induced phosphorylation activates and stabilizes c-
Myc through this signalling pathway, which may thereby contribute to the neoplastic 
condition as c-Myc is involved in uncontrolled cellular proliferation
213
. 
  
LRP/LR has also been implicated in mediating uncontrolled proliferation in leukaemia cells. 
It has been reported that the receptor binds to and stimulates signal transduction cascades 
mediated through the granulocyte-macrophage colony stimulation factor (GM-CSF) receptor 
(GM-CSFR), which subsequently results in enhanced phosphorylation of the STAT5 
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transcription factor and ultimately stimulates proliferation (through self sufficient growth 
signals) and enhances resistance towards apoptosis
227
.  
 
The prominent role that this receptor occupies in mediating cell survival in cancer is 
emphasized by the fact that RNA interference (RNAi)-mediated downregulation of LRP/LR 
has been reported to induce apoptosis in neoplastic cells (liver, lung and cervical cancer 
respectively 
183, 231
) while non-tumorigenic cells remain viable
232
.  
 
1.11.2.1.1.1 Exploitation of LRP/LR to target uncontrollable neoplastic proliferation 
 
The overexpression of LRP/LR may conversely be exploited to mediate cancer-selective 
apoptosis. This is particularly true as a consequence of the binding between cell surface 
37kDa/67kDa LRP/LR and the green tea polyphenol epigallocatechin-3-gallate (EGCG)  
(Kd= 0.4µM)
229
. This polyphenol has been ascribed anti-carcinogenic, anti-allergic and anti-
inflammatory roles. This green tea component has been linked to reduced cancer risk as it has 
been shown to reduce neoplastic cell proliferation as well as to induce the apoptosis of 
tumorigenic cells without adversely affecting their non-tumorigenic counterparts. Both of 
these protective effects have been shown to be mediated through the 37kDa/67kDa LRP/LR. 
 
EGCG binding to LRP/LR triggers a signal transduction pathway that consequently results in 
the enhanced expression of the eukaryotic translation elongation factor 1A (eEF1A)
233
. This 
results in the dephosphorylation of myosin phosphatase-targeting subunit-1 (MYPT1) at 
threonine-696, thereby promoting the activation of myosin phosphate and finally the 
dephosphorylation of the myosin regulatory light chain (MRLC) at threonine-18/serine-19. 
The consequence hereof is cytoskeletal disruption through actin rearrangement, and growth 
inhibition
233
. This pathway thereby underlies the tumour growth inhibitory effects of EGCG. 
These inhibitory effects are achieved with 1µM of EGCG, a concentration  attainable by 
drinking two to three cups of green tea
234
. 
 
The pro-apoptotic mechanisms underlying the EGCG-LRP/LR association are varied. One 
study has suggested that EGCG binding to the receptor results in the activation of Akt and 
endothelial nitric oxide synthase (eNOS) signal transduction cascades. This would thereby 
induce nitric oxide (NO) production and enhance cyclic guanosine monophosphate (cGMP) 
levels
229
, both of which would result in the growth arrest and induction of apoptosis in 
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tumorigenic cells
235
. This EGCG-LRP/LR association has also been suggested to contribute 
to caspase activation and the collapse of the mitochondrial transmembrane potential - both 
prerequisites for cellular apoptosis. Another study has proposed that the pro-apoptotic effects 
of EGCG may be as a result of lipid raft disruption and removal of LRP/LR from these 
regions, thereby preventing receptor mediated activation of signalling cascades implicated in 
uncontrolled proliferation and evasion of apoptosis
236
.  
 
1.11.2.1.2 The role of the 37kDa/67kDa LRP/LR in Metastasis and Angiogenesis 
Metastasis, the dissemination of cancerous cells from a primary tumour to distal sites, causes 
approximately 90% of cancer deaths
237
 owing to the difficulty in preventing metastasis once 
it has initiated as well as targeting multiple sites for treatment. Metastasis involves the 
adhesion of cancerous cells to the basal membrane, the subsequent degradation of the basal 
lamina by proteolytic enzymes which allows for tumour cell entry into either the blood or 
lymphatic systems and finally extravasation (again requiring adhesion and basal lamina 
degradation) by the neoplastic cells at a secondary site. 
 
Tumour angiogenesis, the formation of new blood vessels to support tumour formation at a 
distal site through the supply of oxygen and nutrients, involves a similar process. 
Angiogenesis  involves endothelial cell activation and enzyme-mediated proteolysis of the 
surrounding extracellular matrix or basal lamina
238
. Furthermore, the activated proteases 
subsequently release pro-angiogenic factors/peptides which stimulate endothelial cell 
migration towards the angiogenic signal as well as promote proliferation and differentiation 
into tubular  structures (vessels)
238, 239
. Angiogenesis is vital for successful tumour metastasis, 
tumour progression and growth
240
.   
 
The 37kDa/67kDa LRP/LR has been shown to be instrumental in mediating both processes, 
and as previously stated, overexpression of this receptor correlates very well with the 
adhesive, invasive and thereby metastatic potential of numerous cancer cell types
216, 217
 
241
. 
The laminin-1 glycoprotein is a major constituent of the basal lamina and thus LRP/LR is 
required for cellular adhesion to the basal lamina. Furthermore, the interaction between 
LRP/LR and laminin-1 has been reported to induce the activity of ECM degrading enzymes, 
particularly matrix metalloproteases (MMPs) and type-IV collagenase
208, 242
. Additional ECM 
degrading enzymes, with activities enhanced by the LRP/LR–laminin-1 association, include: 
membrane-type I matrix metalloproteinase, MMP-2, cathepsin-L and stromelysin 3
226
. 
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Furthermore, as described above, environmental factor such as hypoxia may induce tumour 
metastasis and may do so through the 37kDa/67kDa LRP/LR. Hypoxia results in ERK/JNK 
activation of HIF-1 which upreguates LRP/LR expression and consequently enhances the 
production of downstream molecules such as the matrix degrading enzymes urokinase-type 
plasminogen activator (uPA) and MMP-2
209
. It must be noted that hypoxia is also a particular 
concern in neurodegenerative disorders and has been shown to promote and contribute to 
Alzheimer’s Disease. HIF-1 has also been shown to mediate AD neurodegeneration243, 244.  
 
The importance of this receptor in mediating these pathogenic processes is highlighted by the  
observation that, blockade the LRP/LR-laminin-1 association through the use of anti-LRP/LR 
specific antibodies as well as downregulation of the receptor, significantly decreases the 
adhesive and invasive potential of numerous cancer types
216,217,241,245-247
 as well as completely 
abolishes angiogenic tube formation
248
.  
 
1.11.2.2 The role of the 37kDa/67kDa LRP/LR in Viral and Bacterial Infections 
The 37kDa/67kDa LRP/LR serves as a cell surface receptor for many pathological agents. 
The receptor binds numerous viruses, including: Adeno-associated virus (AAV) (serotypes 
2,3,8 and 9)
249
, Dengue viruse (serotypes 1,2 and 3) 
250
, Sindbis virus 
202
, Venezuelan equine 
encephalitis virus (VEE)
251
, tick-borne encephalitis (TBE)
252
and the West Nile Virus 
253
.  
 
Furthermore, LRP/LR (C-terminus, specifically the region 263-282aa) serves as a receptor 
for bacterial adhesion to the blood brain barrier (BBB)
254
. As LRP/LR is highly expressed on 
the surface of human brain microvascular endothelial cells (BMECs)
255
, cells of which the 
BBB is composed, the receptor is exploited by numerous bacteria for enhanced adhesion to 
the BBB. These include Streptococcus pneumoniae, Neisseria meningitides and Haemophilus 
influenza
256
. Upon binding to the BBB, LRP/LR facilitates the uptake of these bacteria
254
. 
Thus the 37kDa/67kDa LRP/LR is essential to BBB crossing and the bacterial meningitis 
which ensues as a consequence of these cerebral bacterial infections. In addition, LRP/LR has 
been reported to serve as a cell surface receptor for the cytotoxic necrotizing factor 1 (CNF1), 
a toxin of the Escherichia coli K1 strain
255
.  
 
 It has therefore been revealed that the 37kDa/67kDa LRP/LR is central in mediating 
microbial pathogenesis and is particularly important in establishing infections of the central 
nervous system (CNS).  
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 1.11.2.3 The role of the 37kDa/67kDa LRP/LR in Prion disorders 
 
As has been previously, stated the 37kDa/67kDa LRP/LR has been shown to serve as a high 
affinity receptor for both cellular and infectious prion protein isoforms, PrP
c 165, 204
 and PrP
Sc
 
171, 257
 respectively. It is important to note that heparin sulphate proteoglycans (HSPGs) serve 
as co-receptors, facilitating the LRP/LR-PrP
c
 association
204
. Most importantly, the receptor is 
central to mediating the internalization of both isoforms
165, 257, 258
 
168, 259
. As the conversion of 
PrP
c
 to PrP
Sc
 is proposed to occur both at the cell surface as well as within endocytic 
vesicles
4,260,261
 (Figure 1.7), and intracellular accumulation of the aggregated isoform 
underlies neuronal death, the fact that the 37kDa/67kDa LRP/LR is involved in the uptake 
mechanism
257
 suggests that it is central in mediating the progression and pathogenesis of 
prion disorders. This has been confirmed by the fact that targeting the receptor, through the 
use of antibodies and decoy mutants, significantly hampers PrP
Sc
 propagation both in vitro
171, 
262
 and in vivo
260, 261
.   
Recent reports have demonstrated that LRP/LR is vital for alimentary PrP
Sc
 uptake
263
 across 
different species (between livestock species as well as between livestock and humans). This 
finding possess a great threat to agriculture as well as the possibility of developing zoonotic 
diseases, and thus understanding the role of LRP/LR in prion pathogenesis and targeting this 
association has become ever more critical.  
The importance of the 37kDa/67kDa LRP/LR in prion disorders has been verified by the 
observation that therapeutics targeting the receptor or impedance of the LRP/LR-PrP
c
 cell 
surface association significantly reduced PrP
Sc
 accumulation in vitro
171, 262
 as well prolonged 
the preclinical (before symptom onset) phase in vivo
260, 261
. Such strategies included the use 
of an LRP/LR decoy mutant (102-295aa, thereby lacking a transmembrane domain required 
for cell surface anchorage)
262
 as well as use of siRNA mediated downregulation of 
LRP/LR
264
, heparin mimetics
171
 and pentosane polysulfates (which interfere with the cell 
surface pathogenic association, thereby hindering PrP endocytosis)
168
 as well as antibodies 
directed against LRP/LR.   
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1.12 Mitogen Activated Protein Kinase (MAPK) signal transduction 
pathway 
1.12.1 The Role of MAPK in neurons 
Mitogen Activated Protein Kinases (MAPK) are a family of serine/threonine kinases that, 
through successive phosphorylation events, modulate the activity of numerous substrates 
(including transcription factors and cytoskeletal proteins
265
). The MAPK cascade plays a 
central role in physiological processes including: gene expression, cellular proliferation, 
differentiation and apoptosis as well as mitosis, migration and metabolism
265
.  
The MAPK cascade has three mammalian subgroups. These include the extracellular signal-
regulated kinases (ERKs), which are responsive to growth factors and mitogens and 
ultimately induce cellular proliferation, survival and differentiation 
212
 and inhibits 
apoptosis
213
. In contrast, the other two MAPK subgroups: c-Jun NH2-terminal protein kinase 
(JNK)/stress-activated protein kinase and p38 MAPK, are responsive to inflammation and 
cellular stress (be it chemical or environmental)
212
, with one of the resultant outcomes being 
the induction of apoptosis
266
. 
The MAPKinase signalling pathway is of particular importance in neuronal cells (as is 
evidenced by the abundance of ERK1and ERK2 in the central nervous system (CNS))
266
. In 
neuronal cells, neurotransmitters or neurotrophic factors stimulate either G-protein coupled 
receptors or ion-gated channels, triggering an increase in the intracellular Ca
2+
 concentration 
which ultimately activates MAPK signalling cascades.  
MAPK signalling cascades are of immense physiological significance and are implicated not 
only in neuronal survival but also in neuronal differentiation, neurite branching and neuronal 
plasticity
266
. Furthermore, these signalling pathways may be involved in: the synaptic 
potentiation of hippocampal neuron and synaptic transmission as a result of their ability to 
not only phosphorylate microtubule associated proteins (MAP2) but also modulate gene 
expression and influence protein synthesis
266
. With particular relevance to Alzheimer’s 
Disease, MAPK has been implicated in tau protein phosphorylation (NFTs are a consequence 
thereof)
266
. In addition, cross-talk between the ERK and JNK/p38 signalling pathways is  
crucial to the regulation of apoptosis and more specifically neurodegeneration and synaptic 
loss
266
 and it may therefore be proposed that aberrant MAPK signalling, as arises in AD, may 
result in augmented neuronal loss.   
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1.12.2 MAPK in Alzheimer’s Disease 
All three aforementioned mammalian MAPK subgroups are differentially activated during 
the course of the Alzheimer’s Disease 267. According to reports by Zhu et al.,267, non-
demented patients lacking AD-associated pathology exhibit either ERK or JNK activation 
whilst the activation of both ERK and JNK was observed in patients displaying pathological 
features but not yet demonstrating dementia. However, in patients suffering from mild to 
severe Alzheimer’s Disease, all three pathways (ERK, JNK and p38) were activated267. 
 
Augmented JNK signalling activity has been implicated in the phosphorylation of tau and the 
consequent fibrillization thereof 
268
. In addition, this pathway has been implicated in Aβ-
induced cytotoxicity as inhibition hereof significantly hindered apoptosis induced by Aβ268, 
269
. JNK, more specifically JNK3, has been implicated in the mitochondrial release of 
cytochrome c and Smac/Diablo
265
, and is thereby considered pro-apoptotic and has been 
associated with hippocampal neuronal death.  
 
The p38 MAPK pathway occupies a central role in AD pathogenesis and is implicated in 
neuroinflammation, excitotoxicity, reduced synaptic plasticity, tau hyperphosphorylation
270
 
and apoptosis (through increased expression of Bax proteins)
265
.   
 
ERK activation, although classically associated with cell survival, has been reported to be 
increased in neurons treated with Aβ peptides269, 271.  ERK signalling has been shown to play 
a pro-apoptotic role, in a caspase-independent manner, in the event that the external stimulus 
is plasma membrane damage
265
- which is a consequence of Aβ insertion into the plasma 
membrane. 
 
It must be stated that altered phosphatase activity cannot be excluded as a contributor to the 
MAPK signalling modulation (ERK, JNK and p38 levels and activities) observed in AD
267
.  
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1.13 Therapeutics targeting the 37kDa/67kDa LRP/LR 
The 37kDa/67kDa LRP/LR is overexpressed in numerous cancer cell types and has been 
shown to play a central role in the enhanced adhesive and invasive potential (key features of 
metastasis) of tumourigenic cells 
261, 5, 168, 241
. In addition, as the receptor exhibits binding 
affinities for both PrP
c
 and the infectious PrP
Sc 
isoforms, LRP/LR may be implicated in either 
direct or indirect PrP
Sc
 uptake and consequently the establishment of prion disorders
168
.  
Furthermore, LRP/LR has also been considered a significant mediator in numerous viral and 
bacterial diseases. As a result of the wide array of pathological processes in which LRP/LR is 
involved, a multitude of therapeutic approaches for the modulation of the receptor have been 
developed. The most notable being, heparan mimetics; an LRP decoy mutants (lacking the 
transmembrane domain); RNA-interference strategies, including small-interfering RNAs 
(siRNA) for the down-regulation of the receptor and anti-LRP/LR specific antibodies 
168
.  
 
1. 14 Implications of the 37kDa/67kDa LRP/LR in Alzheimer’s Disease 
The 37kDa/67kDa LRP/LR localizes to lipid raft domains of the plasma membrane and 
HSPGs have been suggested to mediate the receptor’s binding interactions5, 168. As previously 
stated, Aβ42 oligomers interact with a multitude of cell surface proteins/receptors (Table 1.1) 
and HSPGs and may additionally be directly incorporated into the lipid raft domains of the 
plasma membrane. Furthermore, the 37kDa/67kDa LRP/LR binds laminin-1 (to which Aβ42 
oligomers similarly bind), as well as PrP
c (a protein to which Aβ42 oligomers bind with high 
affinity). 
 
Therefore, Aβ42 and LRP/LR share a similar cellular location and multiple common binding 
partners. Furthermore, the pathological agents of TSEs and AD share structural similarities 
and the resultant neurodegenerative diseases exhibit mechanistic commonalities
6
. A result 
hereof, a relationship between Aβ42 and the 37kDa/67kDa LRP/LR seems to be possible. 
Moreover, a binding interaction between these proteins, be it direct or indirect, seems 
plausible and thus the possibility of such an interaction and the influence thereof on Aβ42-
mediated cell loss warranted investigation. 
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CHAPTER 2 
2.1 Hypothesis 
The 37kDa/67kDa laminin receptor (LRP/LR) forms an association with amyloid-beta (the 
42aa isoform) (Aβ42) peptides and the receptor thereby influences Aβ42 pathogenesis.   
2.2 Objectives 
The objective of this study is (i) to definitively determine whether an interaction between 
LRP/LR and Aβ42 exists (ii) to explore the role of LRP/LR in Aβ42-mediated neuronal loss 
and (iii) to investigate the mechanism underlying the role of LRP/LR in Aβ42 pathogenesis.  
2.3Aims 
2.3.1 To probe the cell surface distribution and possible co-localization of Aβ42 and LRP/LR 
on both non-neuronal and neuronal cells by immunofluorescence and confocal microscopy.  
2.3.2 To employ Fӧrsters resonance energy transfer (FRET) for further sensitive and reliable 
examination of an interaction between LRP/LR and Aβ42 on the cell surface . 
2.3.3 To employ pull down assays, western blotting and Aβ-specific ELISAs to ascertain 
whether a physiologically relevant physical association occurs between LRP/LR and Aβ.  
2.3.4 To examine the role of LRP/LR in Aβ42-mediated cytotoxicity by 3-(4,5-
Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT)  cell viability assays.  
2.3.5 To ascertain whether cell death processes (apoptosis or necrosis) and/or modulation of 
cellular proliferation are responsible for the observed variations in cell viability by Annexin-
V-FITC/7-AAD assays as well as 5-bromo-2'-deoxyuridine (BrdU) (proliferation) assays.  
2.3.6  To investigate whether LRP/LR is implicated in Aβ42 internalization by flow cytometry 
and confocal microscopy.  
2.3.7 To establish whether LRP/LR occupies a central role in Aβ42 pathogenesis (objectives 
2.3.4-2.3.6) by employing short hairpin RNA (shRNA) directed against LRP/LR mRNA to 
achieve LRP/LR downregulation. 
 
 
44
CHAPTER 3  
Peer-reviewed Review Article 
I have contributed to the generation of a single review article during the course of this PhD. 
The manuscript was prepared in collaboration with other members of the S.F.T Weiss 
Research Group in the School of Molecular and Cell Biology (MCB) at the University of the 
Witwatersrand and reported on the proceedings of the Global Alzheimer Research Summit 
held in Madrid, Spain in 2011.    
The review article to which I contributed during the course of this PhD is entitled: 
3.1 Global Alzheimer Research Summit: Basic and clinical research: Present and future 
Alzheimer research. 
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3.1 Global Alzheimer Research Summit: Basic and clinical research: 
Present and future Alzheimer research 
Authors:  D. Gonsalves* , K. Jovanovic* , B. Da Costa Dias and Weiss S.F. 
Journal:   Prion, 6(1):7-10 
 
Year of Publication: 2012 
Brief Overview of Article: 
This meeting report briefly summarizes the central points of discussion raised during the 
Global Alzheimer’s Summit held in Madrid, Spain in  2011. This article reports on recent 
advances, novel outlooks and the status of clinical trials within the broad field of Basic and 
Clinical Alzheimer’s Disease Research. In addition to the conventional areas of investigative 
research, namely the molecular mechanism giving rise to Aβ and genetic risk factors, novel 
areas of interest were highlighted namely, the importance of oxidative stress, mitochondrial 
abnormalities, disruption of intracellular transport, lifestyle risk factors (such as hypertension 
and hypercholesterolemia) and pathogenic associations which result in neurodegeneration 
through aberrant cell signalling cascades (Reelin). Furthermore, the need to identify reliable 
biomarkers not only for disease diagnosis but also for monitoring the efficacy of treatment 
strategies was highlighted and the enhanced sensitivity of using both CSF and imaging 
biomarkers was discussed. Data regarding the progress of therapeutics undergoing clinical 
trials were presented and the opinion that a single AD therapeutic will not be effective in 
treating Alzheimer’s Disease, and that rather a multitude of drugs targeting different 
processes is necessary, was held by most delegates.  
 
 
Contribution:  I contributed to the writing and editing of this review article. 
 
*These authors contributed equally to this work. 
 
46
© 2012 Landes Bioscience.
Do not distribute.
www.landesbioscience.com Prion 7
Prion 6:1, 7-10; January/February/March 2012; © 2012 Landes Bioscience
MEETING REPORT MEETING REPORT
Introduction
Alzheimer disease (AD) is the most prevalent form of dementia 
globally, affecting an excess of 36 million people, of which 7 mil-
lion are found in Europe alone. Ten percent of individuals over 
60 years of age and 50% of those over 85 years are afflicted with 
the disease.1 To date, there is no cure for this disease and there are 
few effective palliative therapies available. Research is thus criti-
cal for the further understanding of the molecular basis of AD 
and the development of therapeutic interventions.
The Global Alzheimer Research Summit was held on the 
September 22–23, 2011 at the Palacio de Congresos de Madrid 
in Madrid, Spain. The conference was organized by the Queen 
Sofia Foundation and the Pasqual Maragall Foundation. The 
aim of this conference was to bring together leading experts in 
the field of AD and provide a comprehensive overview of the 
molecular mechanisms and genetics underlying this disease with 
the intent of providing a clear direction for future research into 
early diagnosis and therapeutic interventions.
The conference was divided into two sections: Health 
and Social Care Research (Learning to Live Better with 
Alzheimer Disease) and Basic and Clinical Research 
*Correspondence to: Stefan F.T. Weiss; Email: stefan.weiss@wits.ac.za
Submitted: 11/11/11; Revised: 11/21/11; Accepted: 11/23/11
http://dx.doi.org/10.4161/pri.6.1.18854
We report here on the proceedings of the Global Alzheimer 
Summit that took place September 22–23, 2011 in Madrid, 
Spain. As Alzheimer disease (AD) is the leading cause of 
neurodegeneration in elderly individuals and, as yet, has no 
effective therapeutic option, it continues to stimulate global 
research interests. At the conference, leaders in the field of 
AD research provided insights into current developments 
in various areas of research, namely molecular mechanisms, 
genetics, novel aspects of AD research and translational 
research. Emphasis was also placed on the importance of 
biomarkers in the diagnosis of AD and development of current 
therapeutic strategies.
Global Alzheimer Research Summit
Basic and clinical research 
Present and future Alzheimer research
Danielle Gonsalves,† Katarina Jovanovic,† Bianca Da Costa Dias and Stefan F. T. Weiss*
School of Molecular and Cell Biology; University of the Witwatersrand; Johannesburg, Republic of South Africa (RSA)
†These authors contributed equally to this work.
Keywords: Alzheimer disease, amyloid beta, tau, β-secretase, γ-secretase, neurodegeneration, clinical trials, biomarkers, 
therapeutics, diagnosis
(Present and Future of Alzheimer Research), the latter of which 
will be the focus of this meeting report. There were five main areas 
of focus examined in this conference, namely molecular mecha-
nisms, genetics, biomarkers, diagnosis and therapeutic advances, 
translational research and novel aspects of basic research in AD.
Molecular Mechanisms
The causative agent of AD is thought to be the 4 kDa neurotoxic 
amyloid β (Aβ) peptide. The proposed mechanism by which 
Aβ is generated involves the sequential proteolytic cleavage of 
the Amyloid Precursor Protein (APP) by β-secretase and the 
γ-secretase complex.2-4 Sangram Sisodia (University of Chicago) 
opened the conference with an elucidating overview on the func-
tion of presenilin (PS), the catalytic subunit of the γ-secretase 
complex, in health and disease. He presented findings aimed at 
describing the γ-secretase complex and its function, as well as 
the importance of PS in autophagy. The differentiation and pro-
liferation of neuronal progenitor cells was shown to be impaired 
in Familial AD (FAD)—linked PS1 variants suggesting a link 
between PS1 and neurogenesis.
Christian Haass (Ludwig-Maximilians University Munich) 
emphasized the unique role of the GxGD motif with regards to 
PS1 activity, drawing a parallel between this catalytic subunit and 
intramembrane cleaving aspartyl proteases. He further illustrated 
functional commonalities between the two in terms of their 
sequential substrate cleaving activities and the autoactivation 
which is a result thereof. γ-secretase modulation, as opposed to 
inhibition, was suggested as a means to prevent unwanted modi-
fications of the essential Notch signaling pathway. First genera-
tion γ-secretase modulators (GSMs) have failed to prove effective 
in clinical trials, but second generation GSMs have been shown 
to reduce Aβ
42
 production in cases exhibiting PS1 and PS2 muta-
tions. Moreover, genome-wide RNA interference (RNAi) screen-
ing is being employed to identify endogenous GSMs.
Neurofibrillary tangles (NFTs) are one of the major patho-
logical hallmarks of AD. The main constituent of these NFTs 
are paired helical filaments (PHF), which are assembled from 
the hyperphosphorylated microtubule associated protein, tau.5 
Virginia Lee (University of Pennsylvania) hypothesized that the 
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underlie the cause of AD. The APOE ε4 allele is considered to 
be the risk factor most commonly associated with LOAD and 
increases risk in a dose-dependent manner, while the APOE ε2 
allele reduces the risk for AD. Goate also described the use of 
cerebro-spinal fluid (CSF) biomarkers, i.e., CSF Aβ and tau, as 
endophenotypes for genes which may influence the expression 
levels of these CSF proteins. These analyses revealed that risk 
factors associated with AD correlate to CSF Aβ levels, while 
CSF tau levels corresponded to the rate of disease progression as 
opposed to risk.
In a plenary talk given by Kenneth Kosik (University of 
California), entitled “Stalking an Alzheimer’s gene in the 
Colombian countryside,” an interesting case was presented 
about a number of Colombian families residing in the state of 
Antioquia. These families, which include over 5,000 individu-
als, have been identified as carriers of one of the deadly muta-
tions associated with early onset AD. This group of individuals 
presents an interesting opportunity for researchers and clinicians, 
through the use of genetic testing, to predict who will be afflicted 
with the disease and the possible age of onset. This scenario is 
ideal for Alzheimer “trialists” who believe that treatment of pre-
symptomatic AD will prove most beneficial in delaying the age 
of onset—past the expected mean of 47 years of age, which is the 
case in this Colombian population.
Biomarkers, Diagnosis and Therapeutic Advances
Bruno Dubois (University of Paris) provided insight into new 
diagnostic criteria as proposed by the International Working 
Group for New Research Criteria for the Diagnosis of AD 
in 2007, moving away from the original criteria outlined by 
the National Institute of Neurological and Communicative 
Disorders and Stroke-Alzheimer Disease and Related Disorders 
Association (NINCDS-ADRDA) in 1984. According to these 
new criteria, a clinician can make a clinical diagnosis of AD 
based on one major clinical criterion (e.g., episodic memory 
test with cued recall measures) and the presence of one or more 
biomarkers. This new classification system allows for the early 
diagnosis of AD at the prodromal stage. In terms of biomark-
ers, structural alterations, such as atrophy of the medial temporal 
lobe, can be assessed by Magnetic Resonance Imaging (MRI), 
while biological changes can be recorded by CSF analyses of tau 
and Aβ. Functional or molecular changes can be examined using 
neuro-imaging patterns or amyloid ligand retention on Positron 
Emission Tomography (PET) such as the Pittsburgh compound 
B (PiB-PET).
Dale Schenk (Elan Pharmaceuticals and Janssen Alzheimer 
Immunotherapy, LLC) and Jeffery Cummings (University of 
California) both highlighted the use of biomarkers, such as low 
CSF Aβ
42
 and elevated CSF tau levels, as possible endpoints for 
clinical trials. The observed reduction in CSF Aβ
42
 levels or an 
increase in PiB staining could be used as an indicator for demen-
tia later in life, while a decrease in CSF tau levels correlates well 
with treatment efficacy. The use of such biomarkers in Phase II 
clinical trials can effectively increase the accuracy of reported 
therapeutic benefits using a smaller sample size, while reducing 
amount of normal tau available for microtubule stabilization 
would therefore be reduced and axonal transport compromised, 
leading to the neurodegeneration associated with AD. Lee focused 
her talk on targeting tau as a therapeutic tool for the treatment 
of AD, specifically focusing on Paclitaxel and Epothilone D. 
Animal trials employing Epothilone D have indicated its poten-
tial use in treating AD and other tauopathies.
Jesus Avila (Universidad de Autonoma de Madrid) discussed 
the role of glycogen synthase kinase 3 (GSK3), the enzyme 
responsible for the hyperphosphorylation of tau, in the impair-
ment of neurogenesis and memory loss associated with AD. Avila 
suggested that the depletion of dentate gyrus (DG) stem cells 
within the hippocampus could be a cause for the inhibition of 
memory and learning associated with AD. The elevated Aβ levels 
observed in AD are thought to possibly promote the activation of 
GSK3. Adult neurogenesis was impaired in transgenic mice over-
expressing GSK3 at the DG, and this correlated with a decrease 
in DG volume and hindered memory. Avila further illustrated 
that these memory impairments could be reversed so long as neu-
ronal stem cells were present at the DG. It is therefore speculated 
that this could be a possible molecular mechanism underlying 
episodic memory loss as is noted in AD patients.
In the keynote lecture presented by the esteemed Dennis 
Selkoe (Harvard Medical School), the pathological effects of 
neuronal derived Aβ oligomers (as opposed to synthetic Aβ 
assemblies) were highlighted. Soluble Aβ oligomers, at nano-
molar concentrations, were shown to not only inhibit long-term 
potentiation (LTP) but also induce long-term synaptic depres-
sion (LTD) while decreasing dendritic spine density in the hippo-
campus of normal rodent models. The administration of anti-Aβ 
antibodies directed against the N-terminus of Aβ prevented the 
aforementioned effects on LTP and LTD. Since the amyloid 
plaque cores themselves did not influence LTP or LTD, it was 
concluded that the soluble Aβ dimers and other low oligomeric 
number (low-n) Aβ species are the synaptotoxic species. Selkoe 
also discussed the ongoing phase III clinical trials of the anti-Aβ 
vaccine, Bapineuzumab.
Genetics
The apolipoprotein E (APOE) allele was the first major risk fac-
tor identified for the sporadic form of AD. However, despite our 
advances in the understanding of the genetics underlying this 
disease, over 50% of AD cases have no known genetic risk factors 
or components. Alison Goate (Washington University School of 
Medicine) and Sandra Barral (Columbia University) elaborated 
on their findings from several genome-wide association studies 
(GWAS) aimed at discovering novel risk factors by comparing 
AD cases to non-demented elderly controls. Nine novel risk 
factors (CLU, PICALM, CR1, BIN1, MS4A4A cluster, ABCA7, 
CD2AP, CD33 and EPHA1) were identified, which increase the 
risk for late onset Alzheimer disease (LOAD) by 10–15%. These 
novel risk factors are believed to play roles in a number of cellular 
pathways including lipid metabolism, the immune system and 
endocytosis. Barral further elaborated on the risk factors associ-
ated with LOAD, hypothesizing that multiple common variants 
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LY2811376, was recently generated using a fragment based chem-
istry strategy. LY2811376 was shown to significantly lower Aβ 
production in animal models, an effect which persists in humans. 
LY2811376 development was however terminated due to toxicol-
ogy findings in preclinical studies. Citron’s studies proved that 
BACE1 inhibition is a plausible therapeutic approach for the 
treatment of AD.
Translational Research
Oxidative and mitochondrial abnormalities were discussed in 
detail by George Perry (University of Texas at San Antonio). 
Impairments in mitochondrial function, fission and fusion events 
develop in the early stages of AD. A decrease in the expression 
levels as well as altered distribution of fission/fusion proteins 
DLP1, OPA1, Mfn1 and Mfn2C were reported in AD neurons, 
while a significant increase in Fis1 was noted. Moreover, APP and 
Aβ were found to be responsible for these changes in expression 
levels. The result thereof is a reduction in mitochondrial density, 
which consequently manifests as a decrease in spine numbers. 
Various structural changes are also evident in AD vulnerable 
neurons and include a reduction in the number and increase in 
the average size of mitochondria. However, it should be noted 
that the mitochondrial changes in AD are not solely from nor 
demonstrated to be the result of Aβ/APP alone as a similar effect 
of oxidative stress independent of Aβ is seen.
Lennart Mucke (Gladstone Institute of Neurological Diseases 
and University of California) discussed the key role of tau in Aβ 
induced changes in neuronal and cognitive function as well as 
intracellular transport. A reduction in tau effectively prevents 
neuronal dysfunction induced by Aβ oligomers in transgenic 
mouse models. Furthermore Aβ, tau and Fyn (a src family 
kinase) were found to function co-dependently. The receptor 
tyrosine kinase EphB2 is targeted for proteosomal degradation 
upon interacting with Aβ oligomers; this in turn affects NMDA-
type glutamate receptors and ultimately results in synaptic defi-
cits and memory and learning impairments.
Novel Aspects of Basic Research in AD
Eduardo Soriano (University of Barcelona) elucidated the 
intriguing link between Reelin (an extracellular matrix protein 
which functions in neuronal development) and AD. Reelin was 
shown to be an important protein in the brain controlling adult 
neurogenisis, glutamatergic neurotransmission and structural 
and functional properties of dendritic spines. This protein was 
found to regulate tau phosphorylation through GSK3 activity. 
Moreover, Reelin was shown not only to delay the accumulation 
of Aβ plaques but also to sequester the pathogenic oligomeric Aβ 
species within these plaques, preventing cognitive impairment. 
The Reelin-Aβ association disrupts the Reelin signaling cascade 
thus impairing the essential neuroprotective function of Reelin 
in the brain and leading to neurodegeneration.
The importance of side-chain oxidized oxysterol in AD 
pathogenesis was discussed by Angel Cedazo-Minguez 
(Karolinska Institutet Alzheimer Disease Research Center). It 
the potential risk of entering into Phase III trials. As a repre-
sentative of Elan Pharmaceuticals, South San Fransisco, Schenk 
also briefly spoke about Bapineuzumab and the ongoing Phase 
III trials.
Kaj Blennow (University of Gothenberg) further highlighted 
the use of biomarkers for monitoring the pathophysiological 
mechanisms central to AD. He reported on numerous studies 
that suggest that CSF biomarkers, including total tau reflect-
ing neuronal degeneration, Aβ
42
 reflecting plaque pathology 
and phosphorylated tau reflecting tau phosphorylation state and 
tangle pathology, have clinical use in the accurate diagnosis of 
prodromal AD. Blennow further elaborated on many of the same 
themes raised by Shenk and Cummings, suggesting the use of 
biomarkers in clinical trials to enhance patient selection for the 
trials and possibly increase the likelihood of identifying any sig-
nificant clinical effects of the drugs in question. He further raised 
attention to the use of the shorter Aβ isoforms, namely Aβ
1–15
 
and Aβ
1–16
 for the monitoring of γ-secretase inhibitor treatment, 
a biomarker found to be more sensitive compared with CSF Aβ
42
 
for monitoring this particular treatment option.
Mony de Leon (New York University School of Medicine) 
emphasized the combined use of both imaging and biomarkers in 
the pre-symptomatic diagnosis and identification of new mech-
anisms of AD. His team discovered two emergent AD related 
mechanisms: first, higher amyloid plaque load in the brain and 
reduced glucose metabolism was noted in pre-symptomatic 
patients whose mothers had a positive AD diagnosis and, sec-
ond, higher plasma Aβ
40
 levels were correlated with alterations 
in CO
2
-linked hippocampal vasoreactivity. These findings sug-
gest inherited maternal mutations in mitochondrial DNA could 
contribute to an increased AD risk and provide a vascular mecha-
nism for the basis of Aβ-induced neurodegeneration.
Khalid Iqbal (New York State Institute for Basic Research in 
Developmental Disabilities) focused on the multifactoral nature 
of AD, suggesting that an inability to accurately identify various 
subgroups of AD and the assignment of these groups to specific 
clinical trials has hampered the development of effective AD 
therapies. It is his belief that the treatment of AD should not 
only target the inhibition of neurodegeneration but also stimulate 
neurogenesis and neuronal plasticity, and suggests that a careful 
balance between these two factors is necessary to reverse the cog-
nitive damage inflicted by AD.
Bengt Winblad (Karolinska Institutet Alzheimer Disease 
Research Center) believes that we have achieved a partial degree 
of success in terms of the development of palliative therapies for 
the treatment of AD, but emphasizes a need for disease modi-
fying drugs. He highlighted the ongoing clinical trials, many 
of which are based on the amyloid hypothesis of AD, but also 
acknowledged that a single therapy for AD is improbable. 
Winblad agreed with Iqbal in that multiple drugs targeting vari-
ous pathways of AD will be needed to effectively manage this 
disease.
Although many clinical trials for BACE1 inhibitors have 
failed thus far, Martin Citron (Eli Lilly and Company) provided 
evidence for the fact that “BACE1 is druggable.” The first orally 
available non-peptidic BACE1 (β-secretase) inhibitor, namely 
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has come a long way; however, many hurdles still remain. The 
continuing development of biomarkers and their use for not only 
the preclinical diagnosis of AD but also as endpoints for clini-
cal trials will continue to change the face of AD research. It is 
now a reality that AD can be diagnosed in the prodromal stages. 
Numerous ongoing clinical trials offer hope to the millions of 
those afflicted by this devastating disease. The continued efforts 
of leading researchers in the field have offered a promising future 
for AD and its sufferers.
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was hypothesized that these oxysterol compounds were not by-
products in cholesterol metabolism but rather play an important 
pathological role in the development of AD. Further he provided 
evidence linking hypercholesterolemia and hypertension to AD 
via disturbances in cholesterol metabolism and the overactiva-
tion of the brain rennin-angiotensin system ultimately resulting 
in disruptions in long-term potentiation (LTP).
Javier DeFelipe (Universidad Politecnica de Madrid) focused 
his talk on the dendritic spine alterations associated with AD. 
DeFelipe’s group used powerful micro-anatomical tools to inves-
tigate the effects of tau aggregation on dendritic spines. It was 
found that non-aggregated pre-tangle tau proteins did not alter 
pyramidal neuron dendrites, as opposed to aggregated forms, 
which result in dendritic atrophy and spinal loss.
The Future of AD Research
Since Alois Alzheimer first described the disease in 1907,6 our 
understanding of AD and its underlying molecular mechanisms 
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CHAPTER 4  
Research Articles 
During the course of this PhD, the results obtained in fulfilment of the aforementioned  aims 
and the resultant novel findings were compiled into two separate scientific articles for 
publication in international peer-reviewed journals.  
The first article, which revealed for the first time that the 37kDa/67kDa LRP/LR may occupy 
a central role in Aβ42 mediated pathogenesis and thereby uncovered an as yet unidentified 
association between the two proteins, was published in the Scientific Reports Journal. The 
second article, which expanded on the results of the first paper and further provided a 
mechanism underlying the role of LRP/LR in Aβ42 pathogenesis, has recently also been 
published in the Scientific Reports Journal.  
 
Therefore, the scientific articles prepared in fulfilment of the requirements for a PhD degree 
are: 
4.1 Anti-LRP/LR specific antibody IgG1-iS18 and knock-down of LRP/LR by shRNAs 
rescue cells from Aβ42 induced cytotoxicity.  
 
4.2 The 37kDa/67kDa Laminin Receptor acts as a receptor for Aβ42 internalization.  
 
In addition, I have contributed (experimental planning, data analysis, writing and editing) to 
the generation, submission and publication of numerous other manuscripts throughout the 
course of my PhD. Some of these articles were within the context of neurodegenerative 
disorders whilst others were concerned with the role of LRP/LR in cancer metastasis and 
angiogenesis.  
 
These articles, arranged according to relevance to data obtained during my PhD, are: 
4.3 The 37kDa/67kDa LRP/LR plays a central role in Aβ-PrPc mediated cytotoxicity in 
Alzheimer’s Disease. 
4.4 Anti-LRP/LR specific antibodies and shRNAs impede amyloid beta shedding in Alzheimer’s 
Disease.  
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4.5 High resolution imaging study of interactions between the 37kDa/67kDa Laminin Receptor 
and APP, -secretase and -secretase in Alzheimer’s disease. 
4.6 Prion Interactions with the 37kDa/67kDa Laminin Receptor on Enterocytes as a cellular 
model for intestinal uptake of prions.  
4.7 Inhibition of angiogenesis by antibodies directed against the 37kDa/67kDa laminin receptor 
in vitro.  
4.8 Anti-LRP/LR specific antibody IgG1-iS18 impedes adhesion and invasion of liver cancer 
cells.  
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4.1  Anti-LRP/LR specific antibody IgG1-iS18 and knock-down of LRP/LR 
by shRNAs rescue cells from Aβ42 induced cytotoxicity 
Authors:  B. Da Costa Dias, K. Jovanovic, D. Gonsalves, K. Moodley, U. Reusch,                      
S. Knackmuss, C. Penny, M. Weinberg, M. Little and S.F.T. Weiss. 
Journal:   Scientific Reports 3, 2702; DOI:10.1038/srep02702 
 
Year of Publication: 2013 
Brief Overview of Article: 
This original research article was the first to examine the possibility of an association 
between the 37kDa/67kDa LRP/LR and Aβ and was the first to report that this association 
indeed exists and has cell biological effects. It was demonstrated that the 37kDa/67kDa co-
localized with Aβ42 on the cell surface of both human embryonic kidney (HEK293) and 
murine neuroblastoma (N2a) cells. Furthermore, a physical association between the receptor 
and synthetic Aβ42 was detected by FLAG
®
 co-immunoprecipitation. Antibody blockade as 
well as shRNA-mediated downregulation of LRP/LR was shown to significantly enhance 
cellular viability and proliferation across all cell lines investigated - HEK293, N2a and 
human neuroblastoma (SH-SY5Y) cells. This led authors to propose that the cell biological 
effects of this association may contribute to Aβ42-pathogenesis and LRP/LR may thereby 
mediate Aβ42-induced cytotoxicity. This article recommended, for the first time, the use of 
tools targeted against the 37kDa/67kDa LRP/LR (such as specific antibodies and RNAi) as 
therapeutic tools for the treatment of Alzheimer’s Disease, particularly with regards to 
treating the neuronal loss characteristic of the disease.  
 
Contribution:  I planned and conducted the experiments, analysed the data, wrote and edited 
this original research article. 
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Anti-LRP/LR specific antibody IgG1-iS18
and knock-down of LRP/LR by shRNAs
rescue cells from Ab42 induced
cytotoxicity
Bianca Da Costa Dias1, Katarina Jovanovic1, Danielle Gonsalves1, Kiashanee Moodley1, Uwe Reusch2,
Stefan Knackmuss2, Clement Penny3, Marc S. Weinberg4, Melvyn Little2 & Stefan F. T. Weiss1
1School of Molecular and Cell Biology, University of the Witwatersrand, Private Bag 3, Wits 2050, Johannesburg, Republic of South
Africa, 2Affimed Therapeutics AG, Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany, 3Department of
Internal Medicine, University of the Witwatersrand, 7 York Rd, Johannesburg, 2193 Parktown, Republic of South Africa, 4Antiviral
Gene Therapy Research Unit (AGTRU), Department of Molecular Medicine & Haematology, School of Pathology, University of the
Witwatersrand, Private Bag 3, Wits 2050, Johannesburg, Republic of South Africa.
Alzheimer’s disease (AD) is characterized by neurofibrillary tangles, senile plaques and neuronal loss.
Amyloid beta (Ab) is proposed to elicit neuronal loss through cell surface receptors. As Ab shares common
binding partners with the 37 kDa/67 kDa laminin receptor (LRP/LR), we investigated whether these
proteins interact and the pathological significance of this association. An LRP/LR-Ab42 interaction was
assessed by immunofluorescence microscopy and pull down assays. The cell biological effects were
investigated by 3-(4,5-Dimethylthaizol-2-yl)-2,5-diphenyltetrazolium bromide and Bromodeoxyuridine
assays. LRP/LR and Ab42 co-localised on the cell surface and formed immobilized complexes suggesting an
interaction. Antibody blockade by IgG1-iS18 and shRNAmediated down regulation of LRP/LR significantly
enhanced cell viability and proliferation in cells co-treated withAb42 when compared to cells incubated with
Ab42 only. Results suggest that LRP/LR is implicated in Ab42 mediated cytotoxicity and that anti-LRP/LR
specific antibodies and shRNAs may serve as potential therapeutic tools for AD.
N
eurodegenerative diseases represent the fourth major cause of global mortality after ischaemic heart
disease, cerebrovascular disease and trachea, bronchus and lung cancers. Alzheimer’s Disease (AD) is the
predominant progressive dementing neurodegenerative disorder afflicting the elderly1 and is character-
ized by ‘‘positive’’ and ‘‘negative’’ lesions including amyloid beta plaques, neurofibrillary tangles and neuronal,
neuropil and synaptic loss respectively2,3. Many of the neuronal perturbations in AD are attributable to and
probably induced by the amyloid beta (Ab) peptide2. The Ab fragment is derived from the transmembrane region
of the Amyloid Precursor Protein (APP). Although Ab is a normal physiological peptide, elevated concentrations
of the peptide, which consequently results in the onslaught of AD, are generated either through the misappro-
priate favouring of the amyloidogenic processing of APP or a decline in Ab clearance or degradation4. The
amyloid plaques are predominantly composed of the Ab42 isoform which has a higher aggregation propensity5
and neural toxicity6 than the 40 amino acid isoform (Ab40) which predominates in non-diseased brains. However,
the prevailing sentiment is that the plaques themselves are not the pathological agents but rather contribute to
neural dysfunction through the distortion of neuronal morphology (within a 50 mm radius7,8) and by hampering
neurotransmission9. Rather, it is the soluble Ab oligomers which are deemed neurotoxic.
The proposed mechanisms whereby Ab has been reported to impair neuronal function are numerous. A
common thread in Ab induced cytotoxicity and neuronal dysfunction is the requirement for an interaction
between the neurotoxic peptide and cellular components, of greatest importance are the lipid membranes and
cellular receptors10.
Owing to the hydrophobic nature of the peptide, Abmay readily associate with and be subsequently incorpo-
rated into plasma11,12, nucleosomal and lysosomal membranes. This may result in membrane structure distortion
and the formation of ion-permissible (of particular concern is Ca21) channels, the resultant ion influxmay induce
cytotoxicity13,14.
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Several of the factors thought to contribute to AD, namely oxid-
ative stress, protein degradation, lipid oxidation and slowed signal
transmission may be attributed to Ab interaction with cell surface
receptors15–17. These include, but are not limited to, N-methyl-D-
aspartate receptors (NMDAR), integrins (particularly a5b1), insulin
receptors, a-7 nicotinic acetylcholine receptors (a7nAChR), the
receptor for advanced glycation end products (RAGE), Ephrin-type
B2 receptor (EphB2) and the cellular prion protein (PrPc)1,10. Abmay
thwart NMAR activation and the resultant induction of long term
potentiation (LTP) by desensitizing the receptor to synaptic glutam-
ate10,18 or by prompting receptor internalization10. This in turn results
in aberrant signaling cascades and ultimately results in synaptic dys-
function and neuronal death.
Although the association between Ab and PrPc has been one of
mounting interest over the past decade, its biological influence
remains to be definitively characterized. It has been suggested that
PrPc plays a role in mediating the devastating effects of Ab oligomers
particularly neuronal and synaptic toxicity and LTP impedance19 as
well as stimulating pro-apoptotic signal transduction cascades20. On
the contrary a neuroprotective role for PrPc has been proposed as the
protein was reported to hinder b-secretase cleavage of APP21.
A receptor of noted physiological importance which binds to PrPc
and is implicated in PrPc internalization is the 37 kDa/67 kDa lami-
nin receptor (LRP/LR)22. This multifunctional protein is located in
multiple cellular compartments namely the nucleus, cytosol and
within the lipid raft domains of the plasma membrane23,24. LRP/LR
exhibits binding affinities for a multitude of cellular components
including: extracellular matrix (ECM) molecules, laminin-1 being
of greatest physiological relevance with regard to cellular adhesion,
survival and migration as well as cytoskeletal, ribosomal and histone
proteins and PrPc 23,24. LRP/LR is also of pathological importance as
the receptor has been shown to be central in prion protein uptake,
propagation and progression of prion disorders25–27. Furthermore,
LRP/LR plays a central role in metastatic cancer and antibodies
targeting the receptor have been reported to significantly impede
adhesion and invasion of numerous cancer types, namely fibrosar-
coma28, lung, cervical, colon, prostate29, breast and oesophageal can-
cer30 as well as inhibit in vitro angiogenesis31.
As Ab toxicity has been posited to be mediated through its asso-
ciation with the lipid raft region of the plasma membrane and its
interactions with plasma membrane anchored proteins, and LRP/LR
shares mutual binding partners with Ab (laminin32 and PrPc), we
aimed to examine whether LRP/LR and Ab interact on the cell sur-
face and to investigate whether LRP/LR plays a central role in Ab
induced cytotoxicity.
Results
LRP/LR co-localises with Ab on the cell surface. Indirect immuno-
fluorescence is regularly employed to provide a preliminarily indica-
tion of potential interactions at the cell surface33,34. Here too this
methodology was employed to investigate whether endogenous
LRP/LR and Ab are located in close proximity on the cell surface,
which would thereby indicate that an association between these
proteins is conceivable. Co-localization of LRP/LR and Ab was
observed on the surface of non-permeabilized HEK293 and N2a
cells (Fig. 1c and Fig. 1o, respectively). 2D cytofluorograms
represent both green and red fluorescence and the resultant yellow
diagonal (Fig. 1d and Fig. 1p) reveals that the fluorescence from both
proteins is jointly distributed. These images, in addition to the highly
positive Pearson’s correlation coefficient (Table 1), verify that LRP/
LR and Ab co-localize on the cell surface. LRP/LR did not co-localize
with the Very Late Antigen 6 (VLA6), a laminin binding integrin,
(Fig. 1g and Fig. 1s). This was indicated by the 2D-cytofluorogram
(Fig. 1h and Fig. 1t) as well as the very low Pearson’s correlation
coefficient (Table 1).VLA6 thereby served as the negative control25.
Therefore, owing to the cell surface proximity of LRP/LR and Ab, an
association between these proteins is feasible.
Interaction of Ab with LRP/LR. Although co-localisation studies
between LRP/LR and Ab proved the proximity of the proteins on the
cell surface, this finding merely indicates that an interaction between
these proteins is feasible. Therefore a pull down assay was performed
to investigate definitively whether a stable interaction exists.
Recombinantly expressed LRP::FLAG was immobilized on the
anti-FLAGH M2 agarose beads, as highlighted by the red arrow
(Fig. 2a and 2e) as it is present in the eluted sample. The identity
of the band was further authenticated by immunoblotting (Fig. 2b).
Co-incubation of anti-FLAGHM2beads with LRP::FLAG containing
cell lysate to which 100 ng/ml of synthetic Ab42 was applied resulted
in the immobilization of both proteins. The presence of Ab42 in the
eluted sample (Fig. 2a) was confirmed by equivalent polypeptide
position in Fig. 2a lane 6 containing pure, synthetic Ab42 (2 mg).
The presence of both proteins in eluted samples (Fig. 2a - lane 5)
implies that an association exists. The relevant controls are shown in
Fig. 2c–f.
IgG1-iS18 rescues cells fromAbmediated cytotoxicity.AMTT cell
viability assay was employed to assess the cytotoxicity of synthetic
amyloid beta (Ab42) at various concentrations on HEK293FT, N2a
and SHSY5Y cells (Fig. 3 a–c). Exogenous application of 200 nM and
500 nM Ab42 significantly reduced cell viability in HEK293 cells
(Fig. 3a). Co-incubation of cells with 50 mg/ml anti-LRP/LR
specific antibody IgG1-iS18 and 500 nM Ab42 significantly
enhanced cell viability (Fig. 3a). Similar results, albeit at different
Ab42 concentrations were observed for SH-SY5Y (Fig. 3b) and
N2A (Fig. 3c) cells. The decrease in cell viability observed in N2a
cells (Fig. 3c) was shown to be as a result of hampered cellular
proliferation (Fig. 3d). Protocatechuic acid (PCA) an apoptosis
inducing agent was employed, at a concentration of 8 mM, as the
positive control. Antibody, IgG1-iS18, treatment alone in the absence
of Ab does not significantly enhance cellular viability in all themodel
cell lines employed (Fig. S1), thereby negating the possibility that
IgG1-iS18 non-specifically enhances cellular viability.
To confirm that LRP/LR plays a role in Ab toxicity, and that the
IgG1-iS18 effects observed are not owing to the possible lack of
antibody specificity, RNA interference technology and more specif-
ically short hairpin RNAs (shRNAs) were employed to down regulate
LRP/LR.When compared to the shRNAscr control, shRNA1.1 trans-
fection resulted in a 20.52% reduction in LRP/LR expression, whilst
shRNA7.6 transfection produced a significant 67.46% reduction in
LRP/LR expression levels (Fig. 4a and 4b). LRP/LR down regulation
(mediated by the aforementioned shRNAs), in the presence of vary-
ing concentrations of exogenously administered Ab42, resulted in a
significant enhancement in cell viability (Fig. 4c) and cellular prolif-
eration (Fig. 4d). These results are analogous to those obtained
employing IgG1-iS18. No significant difference amongst untreated,
mock transfected and shRNAscr transfected cells HEK293 cells was
observed with regards to both cellular viability (Fig. S2a) and prolif-
eration (Fig. S2b).
Discussion
LRP/LR and Ab were demonstrated to share close cell surface prox-
imity by indirect immunofluorescence microscopy (Fig. 1c and
Fig. 1o) and these results were considered as a primary indication
of a potential interaction between these proteins on the cell surface.
However, supplementary systems are commonly required to verify
the interaction proposed by immunofluorescence data.
In an attempt to confirm the proposed interaction between LRP/
LR and the neurotoxic Ab42 peptide, as revealed by co-localization
results, pull down assays were performed. The presence of both
proteins in the eluted sample suggests that an association between
www.nature.com/scientificreports
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LRP and Ab42 exists. However, the exclusivity of this interaction
could not be verified owing to the presence of contaminant bands
present within the eluted sample lane (Fig. 2a, lane 5). These poly-
peptides may represent numerous LRP ligands, possibly including
laminin, PrPc, actin, tubulin35, heparin sulphate proteoglycans as well
as ribosomal and histone components. The control shall be briefly
discussed. Anti-FLAGHM2 agarose beads were subjected to incuba-
tion in the presence of lysis buffer (Fig. 2c) as well as cell-lysates
Table 1 | Pearson’s Correlation Co-efficient for LRP/LR, Ab and
VLA6 cell surface co-localization
HEK293 N2a
LRP/LR 1 Ab 0.926 0.969
LRP/LR 1 VLA6 0.30 0.12
Figure 1 | Cell surface co-localisation between LRP/LR with Ab. (a) Endogenous cell surface LRP/LR and Ab onHEK293 (upper panel) and N2a (lower
panel) cells were indirectly immunolabelled. Abwas indirectly detected using anti-b-amyloid (22–35) (Sigma) and anti-rabbit Alexafluor 633 antibodies
(Fig. 1a, m). LRP/LR was detected employing anti-IgG1-iS18 (human) and anti-human-FITC (Cell lab) antibodies (Fig. 1b, f and Fig. 1n, r). Merged
images (Fig. 1c, o) and 2D-cytofluorograms (Fig. 1d, p) (acquired using CellSens Software) verified the co-localization. The negative control, Very Late
Antigen 6 (VLA6) was detected employing anti-VLA6 and anti-rabbit Alexaflour 633 antibodies (Fig. 1e, q). The merged images (Fig. 1g, s) and
2D-cytofluorograms (Fig. 1h, t) demonstrated that VLA6 and LRP/LR do not co-localize on the cell surface. Secondary antibody controls are shown in
Fig. 1i-l and Fig. 1u-x. Fluorescence was detected and resultant images acquired using the Olympus IX71 Immunofluorescence Microscope and Analysis
Get It Research Software. Scale bars are 10 mm.
www.nature.com/scientificreports
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lacking recombinant LRP::FLAG expression (Fig. 2d). Furthermore,
cell lysates in which LRP::FLAG was recombinantly expressed were
analysed and column immobilization was confirmed (Fig. 2E). In
addition, this control served to demonstrate the number of cellular
components which were able to bind to LRP::FLAG (Fig. 2e). Fig. 2f,
served to assess whether the ‘‘sticky’’ nature of Ab42 allowed it to bind
to the affinity column in the absence of the tagged protein. Upon
analysis of 10 mg of synthetic Ab42, the peptide was present in the
unbound soluble fraction (Fig. 2f, lane 2) thereby illustrating that the
presence of Ab42 in the eluted sample of the Fig. 2a, lane 5, was owing
to an immobilizing interaction with LRP.
As an interaction between LRP/LR andAb42 has been proposed an
investigation into the influence of such an interaction on AD patho-
genesis, specifically cellular survival, was justifiable. Significant
reductions in cellular viability across all three cell lines were observed
at varying concentrations of exogenously administered synthetic
Ab42 (Fig. 3a–c). More notably, upon co-incubation of cells with
the Ab42 peptide and anti-LRP/LR specific antibody IgG1-iS18, a
significant enhancement in cell viability was observed (Fig. 3a–c).
These results were further confirmed by shRNA mediated down
regulation of LRP/LR (Fig. 4c), thereby demonstrating that the cell
rescuing abilities of IgG1-iS18 are not owing to a lack of antibody
specificity. Thus, it may be suggested that LRP/LRmay be implicated
in Ab mediated cytotoxicity and the association between these
proteins may be pathological in nature. It is plausible that this asso-
ciation may be pathological in nature as PrPc has been reported to be
important in mediating the synapotoxic effects of Ab19 and the neu-
roprotective role of PrPc may be inhibited upon its binding to Ab.
Thus both PrPc and its cell surface receptor LRP/LR25 may be impli-
cated in mediating this pathological role.
Furthermore, to assess whether the impediment of cellular
proliferation contributed to reduced cell viability (Fig. 3a–c), the
proliferative potential of N2a cells incubated with varying Ab42 con-
centrations was evaluated. Cellular proliferation was similarly ham-
pered in the presence of Ab42 and IgG1-iS18 (Fig. 3d) rescued cells
from this effect. This result was further corroborated by enhance-
ment in cellular proliferation observed when Abwas administered to
cells in which LRP/LR was down regulated by shRNAs (Fig. 4d).
Therefore, it may be proposed that the LRP/LR-Ab42 interaction
may possibly result in aberrant proliferative cell signaling pathways.
Under physiological conditions, LRP/LR promotes cellular survival,
reported through the activation of the Mitogen activated protein
(MAP) kinase signal transduction pathway36. It is plausible that an
interaction between LRP/LR and Ab42 may foil the receptor
mediated initiation of proliferative pathways.
In conclusion, it has been demonstrated that an LRP/LR-Ab42
interaction occurred on the cell surface and antibody blockade of
LRP/LR by IgG1-iS18 or shRNA mediated down regulation of LRP/
Figure 2 | LRP/LR as a potential Ab-interacting protein. Pull down assays were employed using FLAGH Immunoprecipitation kit (Sigma Aldrich), to
investigate the proteins detectable in unbound samples (lane 2), wash steps (lanes 3 and 4) and eluted samples (Fig. 2a–e: lane 5 and Fig. 2f : lane 6) and
2 mg of synthetic Ab42 (positive control) (Fig. 2a: lane 6 and Fig. 2f: lane 7). (a) Cell lysates containing recombinantly expressed LRP/LR::FLAG were co-
incubated with exogenous Ab. (b) Immunoblot employed to validate the position of LRP::FLAG (,38 kDa). Figures represent anti-FLAGHM2 beads
incubated with (c) lysis buffer, (d) non-transfected HE293 cell lysates, (e) HEK293 cell lysates of cells transfected with pCIneo::FLAG as well as (f) pure
synthetic Ab42 in the absence of cell lysate. Samples were resolved on 16%Tris-tricine SDS PAGE gels and stained with Coomassie Brilliant Blue. Blue and
red arrows are indicative of Ab42 and LRP::FLAG respectively.
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LR rescued cells from Ab42 induced cytotoxicity and impedance of
proliferation. These results suggest that LRP/LR may contribute
to Ab42 mediated pathogenesis in AD and that anti-LRP/LR specific
antibodies and shRNAs directed against the receptor mRNA
may show promise in the quest for effective AD disease-modulating
therapeutics.
Methods
Immunofluorescence Microscopy. HEK239FT and N2a cells were seeded onto
microscope coverslips and incubated until a confluency of 50–70% was attained. The
cells were subsequently fixed with 4% Paraformaldehyde (10 minutes, room
temperature), rinsed thrice with 1xPBS and blocked in 0.5%PBS-BSA (5–10minutes).
Post blocking, coverslips were additionally washed in PBS and placed such that the
cell-free side came into contact with themicroscope slide. 100 ml of primary antibody
solution (diluted in 0.05%PBS-BSA) containing 15150 IgG1-iS18 (human), 15150
anti-VLA6 or 15100 anti-b-amyloid (22–35) (rabbit (Sigma) was administered to the
cells. Post an overnight incubation at 4uC in moist containers, coverslips were again
washed thrice in 0.5% PBS-BSA and placed on clean slides. A 100 ml volume of a
secondary antibody solution containing15300 goat anti-human FITC (Cell Lab) and
15300 goat anti-rabbit IgG conjugated to Alexa FluorH 633 (Invitrogen) were
administered to cells and incubated for an hour in the dark. Post incubation,
coverslips were washed twice in 0.5% PBS-BSA and once in PBS and mounted onto
clean microscope slides using 50 ml Fluoromount (Sigma Aldrich). The Olympus
IX71 Immunofluorescence Microscope and Analysis Get It Research Software were
employed to detect fluorescence and acquire images, respectively. Images were
analysed and 2D cytofluorograms were constructed using Cell Sens Software.
Pull down assay.HEK293 cells were transfected via calcium phosphate methodology
with a pCIneo-LRP::FLAG plasmid for 72 hours at 37uC, 5% CO2. Pull down
experimental samples were composed of 200 ml of HEK293 whole cell lysates in
which LRP::FLAG was recombinantly expressed and 10–20 ml of synthetic Ab42
(Sigma-Aldrich) was exogenously administered. Assays were performed using
FLAGH Immunopercipitation Kit (Sigma-Aldrich) according to manufacturer’s
instructions. Samples were subsequently electrophorectically analysed and gels were
stained with Coomassie Blue. LRP::FLAG was detected via immunoblotting using
murine anti-FLAG antibody (154000) (Sigma-Aldrich) and goat anti-mouse HRP
(1510 000) (Beckman Coulter).
3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide (MTT) cell
viability assay.HEK293, N2a and SH-SY5Y cells were seeded in a 96 well plate as to
attain 50–70% confluency within 24 hours and incubated in a 5% CO2 humidified
atmosphere at 37uC. Post incubation, synthetic neurotoxic Amyloid beta (Ab)
peptide (Sigma Aldrich) was administered to the cells in varying concentrations
(100 nM, 200 nM and 500 nM respectively) to determine the affect thereof on cell
viability. In addition, untreated controls (cells incubated inDMEM) aswell as positive
controls (cells incubated with 8 mM protocatechuic acid(PCA)-an apoptosis
inducing agent) were included. Furthermore, cells were additionally co-incubated
with Ab (at the concentrations listed above) as well as either 50 mg/ml IgG1-iS18
antibody or 50 mg/ml IgG1-HD37 antibody (Affimed Therapeutics). Treated cells
were incubated (37uC, 5% C02) for 48 hours, following which 20 ml of 1 mg/ml MTT
was added to each well and the cells subsequently incubated (37uC, 5%CO2) for 2
hours. After incubation, culture media was aspirated and 180 ml of DMSO added to
each well to lyse the cells and dissolve the formazan crystals formed within the cells.
The absorbance was recorded at 570 nm using an ELISA microtiter plate reader and
the percentage survival of the cells, relative to the non-treated controls, calculated.
Three separate experiments were performed, each in triplicate.
Bromodeoxyuridine (BrdU) proliferation assay. HEK293, N2a and SH-SY5Y cells
were seeded in a 96 well plate as to attain 50–70% confluency within 24 hours and
incubated in a 5% CO2 humidified atmosphere at 37uC. Post incubation, synthetic
neurotoxic Amyloid beta (Ab) peptide (Sigma Aldrich) was administered to the cells
in varying concentrations (100 nM, 200 nM and 500 nM respectively) in the
presence or absence of IgG1-iS18 or IgG1-HD37. Proliferative potential of treated
cells was assessed as per manufacturer’s instructions for BrdU Proliferation Assay Kit
(CalbiochemH). Three separate experiments were performed, each in triplicate.
Production of shRNA directed against LRP/LR mRNA. shRNAs were designed to
be expressed from the H1 RNA Pol III Promoter. shRNA1.1 was designed to be
homologous to murine sequences reported in previous studies and shRNA7.6 was
designed using The RNAi Consortium. The expression cassettes comprised of a full
H1 RNA Pol III promoter sequence, a poly T termination signal and the guide strand
on the 39 arm. The shRNA expression cassettes were generated using nested PCR in
Figure 3 | Cell rescuing effects of anti-LRP/LR antibody IgG1-iS18. (a) Cellular viability of HEK293 cells, as determined by (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) (1 mg/ml) assay, post exogenous treatment with synthetic Ab42 and upon co-incubation with anti-LRP/LR
IgG1-iS18 or IgG1-HD37 (negative control). The cell viability was assessed 48 h post treatment and the no antibody control was set to 100%. SH-SY5Y (b)
and N2a cells (c) were exposed to similar treatments. (d) Cellular proliferation of N2a cells as determined by colorimetric 5-bromo-29-deoxyuridine
(BrdU) non-isotopic immunoassay (CalbiochemH), allowing 4 h for BrdU incorporation into cultured cells. Error bars represent sd. **p , 0.01;
Student’s t-test.
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Figure 4 | shRNA-mediated downregulation of LRP/LR and the effects thereof. (a) HEK293FT cells were transfected with shRNAscr, shRNA1.1 and
shRNA7.6 using the TransITH-LT1 Transfection reagent. 72 h post transfection total LRP/LR levels were assessed by Western blotting. b-actin was
employed as a loading control. Gels have been cropped for clarity and conciseness purposes and have been run under the same experimental conditions.
(b) Bar graph depicting percentage LRP/LR down regulation was generated by quantifying the Western blot band intensities of three independent
experiments employingQuantityOne 4.6 Software. To assess the role of LRP/LR inAb, toxicity 24 h post transfection, varying concentrations of synthetic
Ab was exogenously administered to cells. 72 h post transfection (48 h post Ab incubation) cellular viability was assessed by MTT assay (c) and cellular
proliferation was assessed by BrdU assay (d) Error bars represent sd. ***p , 0.001; **p , 0.01; *p , 0.05 Student’s t-test.
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which the H1 RNA Pol III promoter served as the template. The forward primer was
complementary to that of the H1 RNA Pol III promoter and the shRNA sequences
were incorporated into the reverse primers. The resultant PCR products, which coded
for the shRNA expression constructs were subsequently cloned into the pTZ57R/T
vector (Fermentas).An shRNA that does not target any gene, herein termed
scrambled shRNA (shRNAscr), served as the negative control. The LRP/LR target
sequence as well as the structure of shRNA1.1 and shRNA7.6 are described in
Jovanovic et al., (2013)37.
Cellular transfection with shRNA directed against LRP/LR mRNA. The
TransITH–LT1 Transfection reagent (Mirus) was employed to transfect LRP/LR
shRNA 1 and 7 into HEK293 cells as per the manufacturer’s instructions.
Western blotting. Post 72 h transfection of HEK293 cells with shRNAs, cells were
lysed and total LRP/LR levels were determined byWestern blotting employing IgG1-
iS18 (1510 000) and goat anti-human horseradish peroxidase (HRP) (1510 000) (Cell
Lab) antibodies, respectively. Western blot band intensities were quantified using
Quantity One 4.6 Software.
Assessing cell viability and proliferation post cellular transfection with shRNA.
Synthetic Ab42, at varying concentrations, was exogenously administered to
transfected cells, 24 h post transfection. Thereafter cells were incubated in the
presence of Ab for an additional 48 h prior to analysis by MTT and BrdU assay
respectively.
Statistical evaluation. Student’s t-tests were used to analyse the data and obtain p
values. All statistical evaluations were performed using GraphPad Prism (version
5.03) software.
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Brief Overview of Article: 
This original research article expanded on the findings of the first report and revealed a 
probable mechanism underlying the role of the 37kDa/67kDa LRP/LR in Aβ42 pathogenesis. 
Owing to the low resolution of confocal microscopy employed for our preliminary co-
localization studies, Fӧrsters resonance energy transfer (FRET) was employed to assess 
protein interactions. The detection of FRET upon immunolabelling of both proteins of 
interest demonstrated that LRP/LR and Aβ42 interact on the cell surface. Furthermore, the 
physiological relevance of this association was verified by performing FLAG
®
 co-
immunoprecipitation studies with conditioned media (into which Aβ was endogenously 
shed). In addition to the cellular effects observed during the first study, it was revealed that 
the LRP/LR-Aβ42 association resulted in the induction of apoptosis, which was significantly 
deterred upon blockade of this association with anti-LRP/LR specific antibodies. Finally, this 
study demonstrated that LRP/LR is central in mediating Aβ42 internalization, as both 
antibody blockade and shRNA-mediated downregulation of the receptor significantly 
impeded Aβ42 uptake. These results therefore demonstrated that the LRP/LR-Aβ42 association 
is of physiological relevance. Moreover, it was revealed for the first time that the 
37kDa/67kDa LRP/LR may serve as an internalization receptor for Aβ42. This may thereby 
underlie the receptor’s role in Aβ42-induced pathogenesis. Through facilitation of Aβ42 
uptake, the receptor may promote intracellular Aβ42 accumulation and the adverse cellular 
effects (induction of apoptosis and inhibition of proliferation) which are consequences 
thereof. These results further confirmed the potential of tools directed against LRP/LR as 
promising Alzheimer’s Disease therapeutics. 
Contribution:  I planned and conducted the experiments, analysed the data, wrote and edited 
this original research article. 
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The 37kDa/67kDa Laminin Receptor
acts as a receptor for Ab42
internalization
Bianca Da Costa Dias1, Katarina Jovanovic1, Danielle Gonsalves1, Kiashanee Moodley1, Uwe Reusch2,
Stefan Knackmuss2, Marc S. Weinberg3, Melvyn Little2 & Stefan F. T. Weiss1
1School of Molecular and Cell Biology, University of the Witwatersrand, Private Bag 3, Wits 2050, Johannesburg, Republic of South
Africa, 2Affimed Therapeutics AG, Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany, 3Antiviral Gene
Therapy Research Unit (AGTRU), Department of Molecular Medicine & Haematology, School of Pathology, University of the
Witwatersrand, Private Bag 3, Wits 2050, Johannesburg, Republic of South Africa.
Neuronal loss is amajor neuropathological hallmark of Alzheimer’s disease (AD). The associations between
soluble Ab oligomers and cellular components cause this neurotoxicity. The 37 kDa/67 kDa laminin
receptor (LRP/LR) has recently been implicated inAb pathogenesis. In this study themechanismunderlying
the pathological role of LRP/LR was elucidated. Fo¨rsters Resonance Energy Transfer (FRET) revealed that
LRP/LR and Ab form a biologically relevant interaction. The ability of LRP/LR to form stable associations
with endogenously shed Ab was confirmed by pull down assays and Ab-ELISAs. Antibody blockade of this
association significantly lowered Ab42 induced apoptosis. Furthermore, antibody blockade and shRNA
mediated downregulation of LRP/LR significantly hampered Ab42 internalization. These results suggest
that LRP/LR is a receptor for Ab42 internalization, mediating its endocytosis and contributing to the
cytotoxicity of the neuropeptide by facilitating intra-cellular Ab42 accumulation. These findings
recommend anti-LRP/LR specific antibodies and shRNAs as potential therapeutic tools for AD treatment.
A
lzheimer’s Disease (AD), primarily identified by Austrian physician Alois Alzheimer in 19061, is a
progressive neurological disorder characterised by extracellular neuritic plaques and intracellular neu-
rofibrillary tangles (caused by aberrant misfolding and aggregation of amyloid beta peptides (Ab) and the
hyperphosphorylated tau protein), cerebrovascular amyloidosis as well as synaptic and neuronal loss. These
neuropathological features are particularly evident in the basal forebrain and hippocampus, as these are the
regions of higher-order cognitive function2,3. It is predicted that in 2050, approximately 1 in 85 people will be
afflicted by the disease4 owing to the global increase in aged populations due to enhanced life expectancies.
The transmembrane amyloid precursor protein (APP) is the parental protein from which Ab is generated
through sequential cleavage by b-secretase and c-secretase. This cleavage may occur at the plasma membrane or
within endosomes5. The resultant Ab may consequently be shed into the extracellular space, be exocytosed or
accumulate intracellularly.
Although extracellular neuritic plaques are a pathological hallmark of AD, the soluble intracellular oligomeric
assemblies of Ab, particularly the aggregation-prone Ab42 isoform, are largely considered the aetiological agents
of this disease. They precede andmay contribute to tau hyperphosphorylation and have been reported to directly
cause synaptic and neuronal loss as well as vascular degeneration of the brain6. Moreover Ab exerts its toxicity
intracellularly6 and the senile plaques themselves have been proposed to serve a neuroprotective role as Ab sinks
which sequester the toxic soluble intracellular oligomers- the peripheral sink hypothesis7.
Although amyriad ofmolecular mechanisms reportedly contribute to Ab42mediated neuropathology, the lack
of effective therapeutics suggests that central role players in disease initiation and progression have yet to be
identified. Until all the intricate pathological networks underlying AD are uncovered, effective therapeutic
strategies may remain elusive. Thus, understanding the cellular trafficking as well as the associations between
Ab and cellular components (particularly cell surface receptors) are imperative to understanding its
neurotoxicity.
A protein of immense interest with regards to Ab pathogenesis is the cellular prion protein (PrPc). PrPc is
considered neuroprotective under normal physiological conditions, through the maintenance of oxidative stress
homeostasis and inhibition of b-secretase cleavage of APP8. In contrast, the overwhelming majority of recent
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reports have demonstrated that within the AD context, PrPc acquires
a pathological role. Upon binding to Ab oligomers (which it is able to
do with high affinity, kD 5 0.4 3 1029M9,10) PrPc has been shown to
mediate neurotoxic signals through Fyn kinase11,12, impair synaptic
plasticity, inhibit long term potentiation and contribute to intracel-
lular accumulation of Ab by mediating the internalization of Ab
oligomers13. However, owing to the glycosylphosphatidylinositol
(GPI)-anchored nature of this protein14, it is largely dependent on
its receptors to mediate the aforementioned functions. One such
receptor, which exhibits a high binding affinity (kD 5 1 3 1027 M)
for PrPc, is the 37 kDa/67 kDa laminin receptor (LRP/LR) (also
known as LamR, RPSA and p40)15. This multifunctional receptor
is implicated in numerous physiological roles including translation,
maintenance of cytoskeletal structure16, cell survival, differentiation,
proliferation and migration17,18. LRP/LR is also involved in the
development of numerous pathological states, including cancer18,19
and tumour angiogenesis20, prion disorders and both viral21–24 and
bacterial infections (of particular interest being bacterial meningitis
as the receptor mediates translocation across the blood brain
barrier)25.
As LRP/LR serves as a PrPc receptor we aimed to investigate
whether LRP/LR is implicated in Ab pathogenesis. Antibody block-
ade and shRNA mediated downregulation of LRP/LR was shown to
significantly enhance the viability and proliferative potential of cells
treated with Ab4226. In this study we aimed to further probe the
mechanism underlying the role of LRP/LR in mediating Ab
pathogenesis.
Results
Fo¨rsters resonance energy transfer between cell surface LRP/LR
andAb. Fo¨rsters resonance energy transfer (FRET) is one of themost
sensitive techniques employed to assess protein interactions in
cellular systems. The non-radiative energy transfer from a donor
to an acceptor will only occur if the fluorochromes are within 1–
10 nm from each other. A cytometry-based FRET assay was
employed to investigate whether LRP/LR and Ab interact on the
surface of HEK293 cells. The highly sensitive27,28 PE/APC FRET
pair (donor and acceptor, respectively) was employed to immuno-
label the proteins of interest on non-permeabilised cells. As PE is
maximally excited by the 488 nm argon laser and emits maximally at
575 nm it may be detected with the FL2 filter set of the Accuri C6
(BD Biosciences),whilst APC, excited by the 650 neon/helium laser
and exhibiting maximal emission at 660 nm, is readily detectable
with the FL4 filter set (Fig. S1). Successful labelling of the proteins
of interest (LRP/LR, PrPc, CAT andAb) was confirmed (Fig. S2). The
presence of FRET between the proteins of interest was evaluated
employing the FL3 filter set. Within this channel, excitation is
achieved with the 488 nm argon laser and emission of 660 nm is
detected. The APC antibody is not excited and does not exhibit
fluorescence within this channel. This therefore accounts for the
overlay between unlabelled cells; cells labelled solely with the APC
secondary antibody as well as cells in which PrPc, CAT and Ab were
immunolabelled with APC (Fig. 1a,c,e). However, upon the close
proximity of the PE-coupled secondary antibody, APC may be
indirectly excited via FRET, and this may result in the enhanced
fluorescence emission of the acceptor in FL3 (Fig. S1). It is owing
to this that FL3 is considered the optimal channel for FRET detection
between the PE/APC pair.
The efficacy of this flow cytometry based FRET assay was inves-
tigated employing PrPc, a cell surface protein to which LRP/LR binds
with very affinity15 (positive control) and chloramphenicol acetyl
transferase (CAT), a bacterial protein to which LRP/LR has been
shown to not bind26 (negative control). Upon co-labelling of cells
with PrPc-APC with LRP/LR-PE, the fluorescence of APC was
enhanced, as was observed by the rightward shift of the APC his-
togram along the FL3 fluorescence intensity axis (Fig. 1b).
Conversely co-labelling of CAT-APC with LRP/LR-PE had no effect
on the emission of APC, as was evident by the overlay between the
two histograms (Fig. 1d). The augmentation of APC fluorescence
intensity upon co-labelling of cells with Ab-APC and LRP/LR-PE
(Fig. 1f), therefore suggests that FRET occurred between these
proteins.
LRP/LR interacts with shed Ab. To confirm that LRP and Ab form
stable associations, pull down assays were conducted. Although
similar experimental procedures have been previously reported26,
these were conducted employing exogenously administered
synthetic Ab42 peptide. Those reported here employed conditioned
cell culture media (supernatant) from HEK293 cells into which Ab
was shed, thereby investigating the presence of this association
within a physiological context. The averaged total concentration of
Ab present in the conditioned media was approximately 37.6 pg/ml,
results which are consistent with the concentration of Ab detected by
others in the supernatant of HEK293 cells29. The efficacy of this assay
was confirmed by the presence of both the BAP-fusion protein
(,49 kDa) and LRP::FLAG (,38 kDa) in the eluted samples,
which indicates that these proteins were successfully immobilized
by the Anti-FLAGH M2 beads (,17 kDa) (Fig. 2a, lane 4). The
presence of CAT (,26 kDa) in the unbound sample (Fig. 2a, lane
1), reveals that this protein was not immobilised by LRP::FLAG and
further confirms that CAT does not interact with LRP. Evaluation of
the degree of Ab present in each pull down assay fraction required
sensitive detection employing an Ab- specific ELISA assay. Upon co-
incubation of conditioned media with LRP::FLAG containing cell
lysate, it was observed that Ab was successfully immobilized by
LRP:FLAG, as there was a significant increase (27%) (p 5 0.0433)
in the Ab levels in the eluate sample when compared to that present
in wash 3 (Fig. 2b). To account for possible binding of Ab to other
proteins within the cell lysate or non-specific binding to the Anti-
FLAGH M2 beads, the degree of Ab in the eluates of samples
containing conditioned media co-incubated with NT lysates or
conditioned media alone, were compared to LRP::FLAG contain-
ing samples (Fig. 2c). There was a significant increase in the
amount of Ab bound to the column in the presence of LRP::FLAG
when compared to that in NT lysates (34%) (p 5 0.039611287) and
conditionedmedia alone (19%) (p5 0.04788224). It is noteworthy to
add that the degree of Ab present in the eluate was not significantly
different to that in wash 3 in both NT lysate (Fig. S3a) and
conditioned media only samples (Fig. S3b). It must be noted that
the ELISA employed to quantify the concentration of Ab is unable to
distinguish between the Ab40 and Ab42 isoforms.
Cellular incubation with Ab42 induces apoptosis. An Annexin-V-
7AAD assay was employed to assess the cellular effects of synthetic
Ab42 on HEK293 cells. The exogenous application of 200 nM and
500 nM Ab42 did not produce cytotoxic effects after 24 h (Fig. 3a)
but did result in a progressive induction of apoptosis after 48 h.
Apoptosis induction was concentration dependent with the degree
of apoptosis detected after 72 h being approximately 30% greater in
the 500 nM treatment when compared to the 200 nM treatment
(Fig. 3a).8 mM PCA, an apoptosis inducing agent, was employed
as a positive control and was similarly assessed over 72 h. The
time-dependent induction of apoptosis was confirmed by the
nuclear morphological changes observed in cells treated with
500 nM Ab42 (Fig. 3b). At 24 h, most nuclei appeared normally
stained but 48 h post-treatment, the first stage of chromatin
condensation, namely chromatin condensation around the nuclear
periphery, was observed. Post 72 h treatment, apoptotic bodies were
detectable (Fig. 3b).
IgG1-iS18 rescues cells from Ab induced apoptosis. The degree of
cell death (comprising early and late apoptosis as well as necrosis)
induced upon cellular treatment with 200 nM and 500 nM
www.nature.com/scientificreports
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exogenous synthetic Ab42 for 72 h was assessed by Annexin-V-
7AAD assay. Upon assessment, cellular incubation with 200 nM
Ab42 resulted in 53.6% cell death, whilst treatment with 500 nM
Ab42 resulted in 78.84% cell death (Fig. 4). In both treatments,
apoptosis accounted for .85% of the detectable cell death. Co-
incubation of the cells with 50 mg/ml IgG1-iS18 (anti-LRP/LR
specific antibody) significantly reduced the extent of cell death
induced by Ab42 at both concentrations by 45.35% (p , 0.001)
and 57.39% (p , 0.001), respectively whilst the anti-CAT antibody
(negative control) had no effect on cell death processes (Fig. 4).
Protocatechuic acid (PCA), an apoptosis inducing agent, was
employed as the positive control. Antibody treatment with IgG1-
iS18 alone does not significantly reduce cell death when compared
to the untreated control (Fig. 4).
Ab42 internalization. The degree of cell surface Ab42 served as a
measure of the degree of receptor-mediated internalization - with
lower cell surface Ab42 levels being indicative of enhanced interna-
lization, whilst higher levels reveal reduced internalization or
recycling. Cellular incubation of control cells at 4uC prior to and
after exogenous Ab42 administration was performed to limit
internalization as receptor-mediated internalization is halted under
these conditions. Thus, the cell surface levels of Ab42 in the no
internalization control (1 h, 4uC) was set to 100%. The progressive
decrease in cell surface Ab42 may therefore be interpreted as a
consequence of receptor-mediated internalization of the exogenous
Ab42. Although internalization (12.05%) was observed after 5 min,
the extent of Ab42 internalization was at its highest and most evident
after 15 min (66.9%) after which the level of cell surface Ab42
remained relatively constant for a further 15 min and then
increased (Fig. 5a). The significant 11.36% increase (p , 0.001) in
cell surface Ab42 at 1 h when compared to 30 min may be indicative
of Ab42 recycling to the cell surface (and ultimately exocytosis) by the
cell. The internalization of the exogenously administered Ab42 was
Figure 1 | Flow cytometric analysis of Fo¨rsters Resonance Energy Transfer (FRET) between cell surface LRP/LR and Ab. The fluorescence intensity
histogramof the unlabelled non-permeabilisedHEK293 cells (black histogram, a,c,e) was superimposed with that of cells labelled with the APC secondary
antibody only (brown histogram, a,c,e) as well as with cells in which the proteins of interest (PrPc, CAT and Ab42) were labelled with APC (a,c,e
respectively). Co-labelling of LRP/LR-PE and PrPc-APC (positive control) (pink histogram, b). Co-labelling of LRP/LR-PE and CAT-APC (negative
control) (green histogram, d). Co-labelling of LRP/LR-PE and Ab-APC (red histogram, f). Each panel is a representative image. Three biological
replicates, each performed in triplicate, were conducted.
www.nature.com/scientificreports
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further confirmed by confocal microscopy. Cells were previously
transfected with pCFP-mem such that the plasma membrane could
be readily identified. At 5 min, it is evident that most of the Ab42 is
located at the cell surface whilst at 15 min and more markedly at
30 min, the degree of Ab42 labelling within the cell lumen is
unmistakably enhanced. As 100 nM Ab42 is considered to be
below the detection limit for intracellular immunostaining6, micros-
copic visualization was only attained upon cellular treatment with
500 nM, to ensure dependable results were obtained. It is noteworthy
to add that very high cell densities negatively affect ligand binding
efficiencies and thus 70% densities were considered optimal for
successful internalization. Furthermore, cell signalling and receptor-
mediated internalization events were synchronized as a result of
serum starvation prior to experimentation30.
LRP/LR is a central mediator of Ab42 internalization. The degree
of cell surface Ab42 served as a measure of the degree of receptor-
mediated internalization. Cells were either subjected to antibody
treatment (Fig. 6a) or RNA intereference technology in which
LRP/LR was downregulated by shRNA7.6 (Fig. 6b)29. All relevant
controls were similarly incubated at 4uC, prior and post exogen-
ously 500 nM Ab42 administration as this halts receptor-mediated
internalization processes30. The cell surface levels of Ab42 in the
untreated no internalization control (1 h, 4uC) was set to 100% in
both experimental sets (Fig. 6a & 6b). Upon, co-incubation of cells
with 50 mg/ml IgG1-iS18 (anti-LRP/LR specific antibody), a
significant enhancement in cell surface Ab42 was observed across
all incubation periods when compared to untreated controls at
corresponding time points (Fig. 6a). This therefore demonstrates
Figure 2 | FLAGH Immunoprecipitation Assays demonstrate LRP/LR-Ab association.HEK293 cell lysates, non transfected as well as lysates containing
recombinant LRP::FLAG to which either recombinant CAT lysates (negative control), BAP-Fusion protein (positive control) or conditioned tissue
culture media containing Ab was added, were subjected to pull down assays. Samples were analysed by Immunoblotting (a) Lane 1, unbound sample
(flow through); lane 2, first wash step (W1); lane 3, third wash step (W3) and lane 4, eluate samples. b-actin served as the loading control. Fraction sample
of pull down assays containing conditioned media were assessed by Ab-ELISA (b & c). The Ab levels per fractions of the LRP::FLAG pull down were
detected by Ab ELSA (b).The Ab levels present in eluate of: LRP::FLAG lysate & conditioned media sample; NT lysate & conditioned media and
conditioned media alone are depicted (c). Gels have been cropped for clarity and conciseness purposes and we all run under the same experimental
conditions. Data shown are representative (mean 6 s.e.m.) of three biological replicates, each performed in triplicate. *p, 0.05, **p, 0.01; Student’s
t-test.
www.nature.com/scientificreports
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that antibody blockade of LRP/LR resulted in more cell surface-
associated Ab42 across all time points (in comparison to untreated
controls) and this therefore suggests that Ab42 internalization is
hampered as a result of LRP/LR antibody blockade. Cells similarly
treated with the anti-CAT antibody displayed Ab42 internalization
processes analogous to those of untreated controls (Fig. 6a).
Furthermore, antibody treatment alone, in the absence of Ab42, did
not significantly alter internalization processes.
To confirm that LRP/LR is indeed implicated in Ab42 internaliza-
tion, and the effects observed during IgG1-iS18 treatment were not
owing to steric effects of the antibody on surrounding proteins, LRP/
LR was downregulated employing short hairpin RNAs (shRNAs).
When compared to the shRNA scrambled (shRNA scr) controls (at
corresponding incubation points), LRP/LR downregulation as
mediated by shRNA7.6, significantly enhanced the degree of cell
surface Ab42 and therefore impeded internalization (Fig. 6b). The
transfection methodology itself did not adversely affect the interna-
lization processes, as the difference in cell surface Ab42 levels was not
significantly different between control, mock transfected and
shRNAscr samples across all incubation periods (Fig. 6b).
Flow cyometric analysis confirmed that shRNA7.6 resulted in a
significant 55.4% decrease (p 5 0.008) in cell surface LRP/LR levels
when compared to the shRNA scr (Fig. 6c). This was evidenced as a
shift towards a lower fluorescence intensity when the fluorescence
Figure 3 | Ab42 treatment induces apoptosis. The induction of cell death in HEK293 cells treated with 200 nM or 500 nM Ab42 for different incubation
periods, was assessed by Annexin-V-7AAD assay (a). The induction of apoptosis was further confirmed by assessing the nuclearmorphology at 24 h, 48 h
and 72 h post-treatment with 500 nM Ab42 (b). Arrows depict chromatin condensation against the nuclear periphery, arrow heads depict apoptotic
bodies. Figures shown are representative images. Three biological replicates, each performed in triplicate, were conducted per experiment.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 5556 | DOI: 10.1038/srep05556 5
67
intensity histograms of both treatments are overlayed (Fig. S4a). The
LRP/LR fluorescence intensity histograms of control, mock and
shRNA scr controls overlayed perfectly (Fig. S4b) and the median
fluorescence intensities (MFI) of these treatments were not signifi-
cantly different to that of the untreated control (set to 100%) (Fig.
S4c). These results confirm that the transfection methodology did
not alter cell surface LRP/LR expression levels. To assess whether
LRP/LR downregulationmay influence cell surface PrPc levels, which
would confound the observed results, the cell surface expression of
PrPc was evaluated. Flow cytometric analysis of shRNA transfected
cells revealed that LRP/LR downregulation had no significant effect
on cell surface PrPc levels (Fig. 6d). Similarly the PrPc fluorescence
intensity histograms of control, mock and shRNA scr controls over-
layed perfectly (Fig. S4d) and theMFIs of these treatments were again
not significantly different (Fig. S4e). Thus, PrPc cell surface express-
ion levels were not affected by the transfection methodology.
Discussion
Ensuring that LRP/LR and Ab42 interact naturally preceded investi-
gations regarding the mechanism underlying the receptor’s role in
AD pathogenesis. We have previously demonstrated that LRP/LR
and Ab co-localize on the surface of HEK293 and N2a cells26, results
which suggested that a potential interaction may exist between these
endogenously expressed proteins. However, co-localization has a
resolution limit of 200 nm and therefore positive results may not
necessarily be indicative of an association, but may simply dem-
onstrate that proteins share similar cellular locations. This would
be expected as Ab has been reported to insert into the lipid raft region
of the plasma membrane, the region to which LRP/LR is localized31.
Therefore, in order to probe the potential of such an interaction
existing under normal cellular conditions, Fo¨rsters resonance energy
transfer (FRET) was employed. FRET is based on the principle that a
donor fluorochrome (phycoerythrin (PE) in this study), within 1–
10 nm of the acceptor fluorochrome (allophycocyanin (APC)), will
non-radiatively transfer energy to the acceptor and this, depending
on the FRET couple chosen, may result either in the enhanced fluor-
escence emission of the acceptor32 or acceptor bleaching. The former
is detected upon using the PE/APC FRET couple employed in this
study. The PE/APC FRET pair was selected as the fluorochromes
exhibit very high molar extinction coefficients (1 200 000 M21cm21
and 5000 M21cm21, respectively) and quantum yields and this
makes them exceptionally sensitive when coupled to antibodies28
and may achieve 90% FRET efficiencies28. Furthermore, although
microscopy is classically employed to assess FRET, the tedious nature
and inability to analyse large cell numbers, led researchers to apply
flow cytometric detection methods instead. The efficacy and accu-
racy of this technique was assessed by investigating whether FRET
was observed between LRP/LR and known ligands to which it either
binds with high affinity (PrPc) or has been shown not to bind (CAT).
APC, a fluorochrome not excited by the 488 nm laser, either alone or
employed to label a protein of interest, did not exhibit fluorescence
emission in the FL3 channel (which employs 488 nm for excitation
and a 660 filter set for emission detection) as the fluorescence intens-
ity was superimposed on that obtained from unlabelled cells
(Fig. 1a,c,e). This therefore demonstrates that the fluorescence
detected within the FL3 channel for unstained, APC only as well as
APC labelling of proteins of interest (PrPc, CAT andAb42) was owing
to the native fluorescence of the cells. However, upon co-labelling of
PrPc -APC and LRP/LR-PE, the fluorescence intensity of APC was
notably augmented (Fig. 1b) whilst co-labelling of CAT-APC and
LRP/LR had no such effect (Fig. 1d). This therefore correctly implies
that LRP/LR and PrPc interact and this in turn allowed FRET to
transpire. Since CAT and LRP/LR do not interact26, the absence of
FRET was expected. The occurrence of FRET between LRP/LR and
Figure 4 | Cell rescuing effects of anti-LRP/LR antibody IgG1-iS18. Cell death of HEK293 cells, assessed by Annexin-V-7AAD assay, post exogenous
treatment with 200 nM and 500 nM synthetic Ab42 and upon co-incubation with anti-LRP/LR IgG1-iS18 or anti-CAT (negative control). Cell death was
assessed 72 h post treatment. No antibody control was set to 100%. Data shown are representative (mean 6 s.d.) of three biological replicates, each
performed in triplicate. *p , 0.05, **p , 0.01, ***P , 0.001; Student’s t-test.
www.nature.com/scientificreports
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Ab (Fig. 1f) therefore suggests that these proteins are within 10 nm if
each other on the cell surface and the most probable consequence
thereof is that these proteins interact. Flow cytometric analysis of
FRET, employing the PE/APC fluorochrome couple, has been suc-
cessfully employed to identify other biologically relevant molecular
interactions28,33.
To confirm that a stable physiological association does indeed
exist between LRP/LR and Ab pull down assays were performed.
Although a similar experiment has been previously performed26,
high quantities (2 mg) of synthetic Ab42 were utilized and thus the
presence of this interaction under normal physiological conditions
warranted investigation. A significantly higher proportional of shed
Ab was present in the eluate of samples containing recombinantly
expressed LRP:FLAG when compared to samples containing NT cell
lysate and conditioned media alone (Fig. 2c) thereby suggesting that
endogenously expressed and shed Ab was successfully immobilized
by LRP/LR and that a physiologically relevant association exists
between these proteins. In addition, inadequate washing and disrup-
tion of non-specific associations between Ab and the LRP:FLAG
containing column can be discounted as contributors to the high
levels of immobilized Ab as the proportion of Ab present in the wash
step 3 fraction was significantly lower than that in the eluate (Fig. 2b).
Moreover, the degree of immobilized Ab in the eluates of the control
samples were not significantly different from the proportion present
in the wash step 3 fraction (Fig.S3a & S3b) nor significantly different
from each other (Fig. 2c), and can therefore be attributable to a low
degree of non-specific binding of Ab to the column as the results
suggest that no proteins present in the NT lysate were able tomediate
Ab-column binding.
The interaction of Ab with cell surface receptors has been repeat-
edly shown to lead to pathological events, including aberrant cell
signalling pathways and the induction of cell death. Although apop-
tosis is the more common cell death modality observed, necrosis has
also been suggested to underlie Ab neurotoxicity34 owing to the
deregulation of intracellular Ca21 levels which are a consequence
of Ab insertions into the plasma membrane35 and adverse effects
on cellular endoplasmic reticula and mitochondria. Therefore, the
form of cell death induced upon Ab treatment was assessed by
Annexin-V-7AAD assay and the induction of apoptosis (which
accounted for.85% of the cell death) was demonstrated to be both
time and concentration dependent (Fig. 3a). Antibody blockade of
LRP/LR, as achieved by co-incubation of the cells with IgG1-iS18
(anti-LRP/LR specific antibody) and 500 nMAb42, significantly low-
ered the degree of apoptosis induced by the neurotoxic peptide in
comparison to untreated and isotype antibody (anti-CAT) treated
controls (Fig. 4). From these results it may be proposed that upon
binding to Ab, LRP/LR may stimulate/promote pro-apoptotic
processes.
Figure 5 | Ab42 Internalization. The degree of cell surface Ab served as a measure of the degree of receptor-mediated internalization. The cell surface
levels of Ab in the no internalization control (1 h, 4uC) was set to 100% (a). Ab42 internalization was confirmed by assessing the degree of
intracellular Ab42 in HEK293 cells. Cells were transfected with pCFP-mem, resulting in plasma membrane labelling (depicted in blue). Intracellular Ab
was labelled with Anti-b-amyloid-APC (depicted in red) (b). Data shown are representative (mean 6 s.d.) of three biological replicates, each performed
in triplicate. *p , 0.05, **p , 0.001; Student’s t-test.
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This may be achieved through aberrant cell signalling. The cellular
survival and proliferative role’s of LRP/LR are reportedly realized
through the Mitogen activated protein (MAP) kinase signal trans-
duction pathway36. LRP/LR has been suggested to transduce cell
survival and proliferative signals through theMAPK signalling path-
way36 upon binding to laminin-137. LRP/LR regulates the expression
of MAPK phosphatases (MKP1 and PAC1) and may thereby influ-
ence the activities of JNK, ERK1/2 and p3836. Marked MAPK dereg-
ulation ensues in AD38. The possibility that Ab binding to LRP/LR
may foil the receptor binding to physiologically relevant ligands such
as laminin-1 and thereby perturb its normal physiological functions-
which may contribute to deregulation, cannot be excluded. This
would not be an unique occurrence, as epigallocatechin 3-O- gallate
(EGCG)mediates its apoptotic activity through binding to LRP/LR39.
Thus, despite its role in maintaining cell survival under physiological
conditions, LRP/LRmay gain pathological functions upon binding to
certain ligands.
In addition, a multitude of research has demonstrated that Ab
binding to PrPc leads to the induction of apoptosis through an upre-
gulation of pro-apoptotic proteins such as Bax40, enhanced Ca21
release into the cytosol41 and the activation of caspases- particularly
caspase 841. However, these pro-apoptotic signals may not be directly
Figure 6 | Effects of antibody blockage and shRNA downregulation of LRP/LR on Ab42 internalization. HEK293 cells were subjected to antibody
treatment: 50 mg/ml IgG1-iS18 (anti-LRP/LR specific antibody) or anti-CAT(negative control) (a) or transfected with shRNA 7.6 (against LRP/LR) (b).
The degree of cell surface Ab served as a measure of the degree of receptor-mediated internalization. The cell surface levels of Ab in the no internalization
control (1 h, 4uC) was set to 100% in both data sets. Successful downregulation of cell surface LRP/LR levels post shRNA downregulation was confirmed
by flow cytometry (c). Cell surface PrPc levels were unaffected by shRNAmediated downregulation of LRP/LR (d). Data shown are representative (mean
6 s.e.m.) of three biological replicates, each performed in triplicate. *p , 0.05, **p , 0.01, ***p , 0.001; One way ANOVA.
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transduced by PrPc as it is not a transmembrane protein and there-
fore must be transduced through receptors to which PrPc binds. We
have recently demonstrated that LRP/LR does indeed contribute to
PrPc-Ab42 mediated cell death [Unpublished data, Pinto, M.G.,
Jovanovic, K., Da Costa Dias, B., Knackmuss, S., Reusch, U.,
Little, M. & Weiss, S.F.T. The 37kDa/67kDa LRP/LR plays a central
role in Ab-PrPc mediated cytotoxicity in Alzheimer’s disease, (2014).].
Therefore, these data suggest that LRP/LR may, either directly or
indirectly, mediate Ab42 induced apoptosis.
It is important to note that this finding is physiologically relevant
as the Ab42 concentrations within AD brains have been reported to
be within the 200–4500 nM Ab42 range42.
Furthermore, it must be noted that at nM concentrations, such as
those employed in this study, Ab42 exists largely as low molecular
weight oligomers43. Moreover, it has been demonstrated that even
upon incubation in cell culture media, low nM concentrations of
synthetic Ab42 (0–500 nM) do not aggregate to form higher order,
less toxic fibrils44. Based on these findings, it may be safely proposed
that the biological effects observed herein may largely be attributable
to oligomeric Ab42, the neurotoxic species in AD.
However, as previously noted, the toxicity of Ab is largely con-
sidered to be caused by its intracellular accumulation and aggrega-
tion- the levels of intracellular soluble Ab are approximately 70 fold
greater in AD brains compared to healthy age-matched controls45.
Moreover it may be the ability of Ab to incite misfolding and
aggregation amongst cellular proteins which consequently leads to
the deregulation of cellular processes. Therefore, it was imperative to
examine whether the exogenously administered Ab42 was interna-
lized into the cells. Internalization was evident from the earliest time
point (5 min) and most pronounced after 15 min. However, evid-
ence for Ab intracellular trafficking and recycling to the cell surface
(possibly along its exocytosis pathway) was apparent as the cell sur-
face Ab levels increased after 1 h (Fig. 5a).
LRP/LR was shown to be a central receptor in mediating the inter-
nalization of Ab42 as antibody blockade of the receptor significantly
augmented cell surface-associated Ab42 and this thereby demon-
strated that the amount of Ab42 internalized was lessened, especially
at the time points 15 min, 30 min and 1 h (Fig. 6a). These results
were further corroborated by shRNA mediated downregulation of
LRP/LR (Fig. 6b) and thereby demonstrated that the effects observed
were not due to a lack of antibody specificity. The increase in cell
surface Ab levels observed at 4uC in cells in which LRP/LR was
downregulated compared to control samples (Fig.6b) may be attrib-
utable to reduced rates of PrPc internalization, thereby allowing for
enhanced Ab binding.
This may be readily justified by the fact that PrPc, a ligand to
which LRP/LR binds with high affinity, has been firmly established
as a protein required for Ab internalization13. However as PrPc lacks
a transmembrane domain, its ability to mediate this internalization
is dependent on its association with transmembrane receptors. LRP/
LR serves a vital role in mediating PrPc internalization into endo-
somes and cellular trafficking, results which have been confirmed in
various neuronal cell types46,47. LRP/LR accounts for 25–50% of PrPc
internalization15. The fact that blockade of the receptor did not
completely abrogate Ab42 internalization (Fig. 6a) may be due to
the fact that only approximately 50% of Ab42 bound to the neuronal
surface is internalized via PrPc-dependent mechanisms48. It is note-
worthy to add that heparan sulphate proteoglycans (HSPGs), to
which LRP/LR similarly binds, have also been reported to mediate
Ab internalization6.
Furthermore LRP/LR is not the sole PrPc-binding protein impli-
cated in its internalization, other such receptors include N-methyl-
D-aspartate (NMDA) receptors49, metabotropic glutamate receptor
5 (mGluR5)50 and low-density lipoprotein receptor related protein
(LRP1)13, and these may therefore account for the internalization of
Ab42 evident during antibody treatment.
It was due to this essential role of PrPc, that possible downregula-
tion of PrPc as a consequence of LRP/LR downregulation needed to
be negated (Fig. 6d). As cell surface PrPc remained unaltered in cells
exhibiting reduced LRP/LR (Fig. 6c and 6d), results which are com-
parable to those observed when RNAimethodologies were employed
to downregulate LRP/LR in vitro51, the central role of LRP/LR in Ab
internalization was validated.
Further studies are currently underway to examine whether LRP/
LRmediates the internalization of Ab directly, in the absence of PrPc,
or whether LRP/LR serves as the scaffold protein required for the
internalization of the PrPc-Ab42 complex.
In conclusion, it has been demonstrated that LRP/LR serves as a
biologically relevant receptor of Ab. This ubiquitously expressed
receptor occupies a central role in mediating Ab42 internalization
and may thereby contribute to the intracellular accumulation of the
neurotoxic peptide and the consequent induction of apoptosis.
Furthermore, specific antibodies and shRNAs directed against the
37 kDa/67 kDa laminin receptor may show promise as possible pro-
phylactic and/or therapeutic tools for the treatment of Alzheimer’s
disease.
Methods
Cell Culture. HEK293 cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) (Hyclone) supplemented with 10% (v/v) Fetal Calf Serum (FCS) and 1%
Penicillin/Streptomycin (P/S) solution andmaintained in a humidified incubator (5%
CO2, 37uC).
Transient Transfection. Upon reaching 70% confluency HEK293 cells were
transfected, by calcium phosphate methodology, with pCIneo-moLRP::FLAG (Vana
andWeiss, 2006) or pCDNA/3CAT (Invitrogen) plasmids and were lysed 72 h post-
transfection.
Pull down Assay. Samples were composed of 200 ml of LRP::FLAG containing whole
cell lysates and 200 ml of either conditioned tissue culturemedia (containing shedAb)
or lysates expressing Chloramphenicol Acetyl Transferase (CAT). Conditioned tissue
culture media was similarly co-incubated with non-transfected (NT) whole cell
lysates (lacking LRP::FLAG) as well as subjected alone to immunoprecipitation to
account for non-specific binding to the anti-FLAGHM2 beads. FLAGH
Immunopercipitation Kit (Sigma-Aldrich) assays were performed as per
manufacturer’s instructions. Samples were subsequently subjected to both
electrophoretic and western blot analysis as well as Amyloid beta Enzyme-linked
Immunosorbent Assays (ELISA). Three independent experiments were performed,
each in triplicate.
Immunoblotting. FLAGH Immunoprecipitation assay eluate samples were detected
using murine anti-FLAG antibody (154000) (Sigma-Aldrich) or anti-
Chloramphenicol Acetyl Transferase (rabbit IgG fraction) (156000) (Sigma-Aldrich).
The secondary antibodies employed were goat anti-mouse HRP (1510 000) (Sigma-
Aldrich) and anti-rabbit-HRP (1510000) (Sigma-Aldrich), respectively. The loading
control, b-actin, was detected employing the rabbit anti-b-actin-HRP antibody
(1510000) (Sigma-Aldrich). Experiments were performed in triplicate, three times.
Amyloid beta Enzyme-linked Immunosorbent Assay (ELISA). Post FLAGH
immunoprecipitation, the Ab concentration in each fraction was assessed by Human
Amyloid b (1-x) Assay kit (Immuno-Biological Laboratories Co.,Ltd) – a solid phase
ELISA, performed as per manufacturer instructions. Three independent experiments
were performed, each in triplicate.
Flow cytometric analysis of Fo¨rsters Resonance Energy Transfer (FRET).To assess
FRET between LRP/LR and CAT, HEK cells were transfected to express recombinant
CAT as described above. For the rest of the samples non-transfected HEK293 cells
were employed. Cells were incubated in serum-free media for 3–4 h prior to
assessment. Cells were detached (5 Mm EDTA-PBS), harvested in serum free media,
centrifuged at 1200 rpm (4uC, 10 min), washed thrice in ice-cold D-PBS and fixed
with ice-cold 2% PFA (20 min, 4uC). These non-permeabilized cells were again
washed (1x PBS) and blocked in 0.5%PBS-BSA for 10 min. The primary antibody
solutions (20 mg/ml) (diluted in 0.05% PBS-BSA) employed were: human IgG1-iS18
(Affimed Therapeutics); murine anti-PrPc (Sigma-Aldrich); rabbit anti-CAT (Sigma-
Aldrich) and rabbit anti-b-amyloid (22–35) (Sigma-Aldrich). The secondary
antibody solutions (20 mg/ml) (diluted in 0.05%PBS-BSA) employedwere: goat-anti-
human-PE (Abcam) IgG1-iS18, goat-anti-mouse-APC (Abcam) and goat-anti-
rabbit-APC (Abcam). The following samples were prepared: 1) unstained cells, 2)
cells stained with goat-anti-human PE only; 3) cells labelled with goat-anti-mouse-
APC only; 4) cells labelled with goat-anti-rabbit-APC only; 5) cells labelled with
IgG1-iS18-PE (LRP/LR detection); 6) cells labelled with anti-PrPc-APC (PrPc
detection), 7) cells labelled with anti-CAT-APC (CAT detection); cells labelled with
anti-Ab42-APC (Ab42 detection), 8) cells labelled with IgG1-iS18-PE & anti-PrPc-
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APC; 9) cells labelled with IgG1-iS18-PE & anti-CAT-APC and 10) cells labelled with
IgG1-iS18-PE & anti-Ab42-APC. Cells were incubated in primary antibody solutions
for 2 h, washed twice in 1xPBS and once in 0.5% PBS-BSA and incubated in
secondary antibody solutions for 2 h. The cells were washed thrice prior to analysis.
Three biological replicates, each performed in triplicate, were conducted. In each
sample, 10 000 cells were analysed.
Antibody Treatment. Varying concentrations (200 nM & 500 nM) synthetic
Amyloid beta peptide 42 (Ab42) (Sigma-Aldrich) was administered to cells in the
presence or absence of 50 mg/ml IgG1-iS18 (anti-LRP/LR specific antibody) (Affimed
Therapeutics) or 50 mg/ml anti-Chloramphenicol Acetyl Transferase (CAT) (rabbit
IgG fraction) (Sigma-Aldrich).
Annexin-V-7AminoactinomycinDAssay.HEK293 cells were subjected toAb42 and
antibody treatment as detailed above. The degree of cell death attributable to
apoptosis was assessed at 24 h, 48 h and 72 h post treatment using Annexin-V-FITC/
7-AAD kit (Beckman Coulter) as per the manufacturer’s instructions. The effects of
antibody treatment on cell death was assessed after 72 h. Three biological replicates,
each performed in triplicate, were conducted. In each sample, 10 000 cells were
analysed.
Nuclear staining- Assessing Nuclear Morphology. HEK293 cells were seeded onto
coverslips and were subjected to 500 nM Ab42 or 8 mM PCA (apoptosis inducing
agent served as the positive control) treatment for 72 h. Cells were subsequently fixed
(4% PFA, 15 min, 4uC), rinsed thrice (1xPBS) and blocked (0.5%PBS-BSA,10 min).
Hoechst 33342 (15100 dilution of 2 mg/ml stock solution) (Sigma-Aldrich) was
administered for 5 min (RT) to cells which were subsequently rinsed and mounted
onto microscope slides using 50 ml of Fluoromount (Sigma-Aldrich). Images were
acquired using Zeiss LSM780 confocal microscope and Zen 2010 imaging software.
shRNAmediated downregulation of LRP.The TransITH–LT1 Transfection reagent
(Mirus) was employed, as per manufacturer’s instructions, to transfect HEK293 cells
with shRNA 1.1, shRNA 7.6 and shRNA scr (scrambled shRNA, negative control).
The production of the shRNA targeting LRP/LR mRNA has been described
previously26,29.
Flow cytometric analysis of cell surface levels of LRP and PrPc. Post LRP
downregulation by shRNA methodology (72 h post transfection) cell surface LRP
and PrPc levels were assessed by flow cytometry. Cells were fixed in 4%
paraformaldehyde (15 min, 4uC), washed thrice (1xPBS) and blocked (0.5%PBS-
BSA, 10 min). Samples were halved, one half was subjected to both primary and
secondary antibody treatments whilst only secondary antibody was administered to
the other sample. Cells were incubated with primary antibodies (20 mg/ml), namely
human IgG1-iS18 (anti-LRP/LR specific antibody) (Affimed therapeutics) and
murine anti-PrPc 8H4 (Sigma-Aldrich) for 3 h at RT, washed thrice and were treated
with 10 mg/ml goat anti-human PE (Abcam) and goat anti-mouse APC (Abcam)
secondary antibodies for 2 h. The cells washed thrice prior to analysis. Three
biological replicates, each performed in triplicate, were conducted. In each sample, 10
000 cells were analysed.
Internalization Assay. Flow cytometric analysis was employed to assess the degree of
Ab42 on the cell surface during different intervals during internalization. Cells (50%
confluency) were either subjected to antibody treatments (50 mg/ml of IgG1-iS18 or
anti-CAT) for 48 h or transfected with shRNAs and assessed 72 h post transfection.
Cellular confluency of 70% was deemed optimal for internalization analysis. Cells
were incubated in serum-free media for 3–4 h prior to assessment and subsequently
subjected to 500 nM Ab42 treatment for 5 min, 15 min, 30 min and 1 h at 37uC in a
5% CO2 humidified environment to allow for internalization. Cells were
concomitantly incubated on ice at 4uC, for 30 min, after which 500 nM Ab42 was
administered to cells and incubated at 4uC for 1 h. Incubation at 4uC arrests cell
receptor mediated internalization (Li et al., 2008). Post treatment, cells were washed
thrice(ice-cold 1xPBS), detached (5 Mm EDTA-PBS), harvested (ice-cold serum free
media,1200 rpm,4uC, 10 min), washed again and fixed (ice-cold 4% PFA,20 min,
4uC). These non-permeabilized cells were again washed (1x PBS) and blocked
(0.5%PBS-BSA, 10 min). Samples were halved, one half subjected to both antibody
treatments whilst only secondary antibody was administered to the other sample.
100 ml of primary antibody solution containing 15100 anti-b-amyloid (22–35)
(rabbit) (Sigma-Aldrich) was administered to the cells and incubated for 2 h. Cells
were washed and were treated with 10 mg/ml goat anti-rabbit APC (Abcam)
secondary antibody for 2 h. Cells washed thrice prior to analysis. Three biological
replicates, each performed in triplicate, were conducted. In each sample, 10 000 cells
were analysed.
Immunofluorescence Microscopy. Cells (70% confluent) were transfected with
pECFP-mem (Clonetech), a plasmid encoding N-terminal 20 amino acid fragment of
neuromodulin which is fused to cyan-fluorescent protein (CFP)) thereby allowing for
plasma membrane visualization. Post transfection, 48 h, cells were incubated in
serum-free media for 3–4 h and subsequently subjected to 500 nM Ab42 for 5 min,
15 min and 30 min (37uC, 5%CO2 humidified) to allow for internalization. Post
treatment, the cells were placed on ice, washed thrice (ice-cold 1xPBS), fixed (4%PFA,
20 min, 4uC), rinsed thrice (ice-cold 1xPBS) and blocked (ice-cold 0.5%PBS-BSA
containing 0.25% Triton X-100,10 min). Coverslips were again washed and
incubated with the primary antibody solution - 15100 anti-b-amyloid (22–35)
(rabbit) (Sigma-Aldrich). Post overnight incubation (4uC) coverslips were again
washed thrice in 0.5% PBS-BSA and incubated with the secondary antibody- 15300
goat anti-rabbit APC (Abcam) for 1 h. Coverslips were washed twice in 0.5% PBS-
BSA and once in 1xPBS and mounted onto clean microscope slides using 50 ml
Fluoromount (Sigma-Aldrich). Images were acquired using Zeiss LSM780 confocal
microscope and Zen 2010 imaging software.
Statistical Evaluation: Student’s t-tests and ANOVAs were used to analyse the data
and obtain p values. All statistical evaluations were performed using GraphPad Prism
(version 5.03) software.
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Brief Overview of Article: 
This original research article demonstrated that the 37kDa/67kDa LRP/LR is indeed 
implicated in mediating PrP
c
-Aβ toxicity. Our previous studies employed antibody blockade 
to demonstrated that LRP/LR is involved in Aβ42-induced neuronal cytotoxicity. However, 
antibody steric effects may have additionally obstructed Aβ42-PrP
c
 associations and thus the 
true significance of the receptor within this context necessitated investigation. Here we 
showed that overexpression of PrP
c
 on the cell surface (as confirmed by flow cytometry) 
augmented the cytotoxic effects of Aβ42 treatment – a finding that in consistent with results 
obtained by others. In addition it was revealed that antibody blockade of the receptor, 
employing an anti-LRP/LR specific antibody IgG1-iS18, was able to significantly enhance 
the cell viability of cells overexpressing PrP
c
 when subjected to toxic Aβ42 treatments. The 
degree of cell survival would not have been as greatly augmented by antibody treatment if the 
toxicity of the PrP
c
-Aβ42 association was independent of LRP/LR. The cell rescuing effects of 
the antibody in PrP
c
-overexpressing and non-transfected cells were not significantly different, 
thereby suggesting that the toxic effects of the Aβ42-PrP
c
 complex are primarily mediated 
through the 37kDa/67kDa LRP/LR. These results illustrated that LRP/LR is indeed 
implicated in Aβ42-PrP
c
 mediated cytotoxicity and thereby validated the central role of 
LRP/LR in Aβ42-induced pathogenesis. Thus, the promise that anti-LRP/LR specific 
antibodies may hold as potential therapeutic tools for Alzheimer’s Disease was again 
validated. 
 
Contribution:  I  assisted in the planning of the experiments and the analysis of data as well as 
contributed significantly to the writing and editing of this original research article. 
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Abstract 
The neuronal perturbations in Alzheimer’s disease are attributed to the formation of 
extracellular amyloid-beta (Aβ), neuritic plaques, composed predominantly of the neurotoxic 
Aβ42 isoform. Although the plaques have demonstrated a role in synaptic dysfunction, 
neuronal cytotoxicity has been attributed to soluble Aβ42 oligomers. The 37kDa/67kDa 
laminin receptor has been implicated in Aβ42 shedding and Aβ42 induced neuronal 
cytotoxicity. As the cellular prion protein binds to both LRP/LR and Aβ42, the mechanism 
underlying this cytotoxicity may be indirectly due to the PrP
c
-Aβ42 interaction with LRP/LR. 
The effects of this interaction was investigated by 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl 
tetrazolium bromide assays.  PrP
c
 overexpression significantly enhanced Aβ42 cytotoxicity in 
vitro. Anti-LRP/LR specific antibody IgG1-iS18 significantly enhanced cell viability in both 
pSFV-hu PrP
c 
1-253 transfected and non-transfected cells treated with Aβ42. These results 
suggest that LRP/LR is implicated in Aβ42-PrP
c
 mediated cytotoxicity and that anti-LRP/LR 
specific antibodies may serve as a potential therapeutic tool for Alzheimer’s disease. 
 
Keywords 
Alzheimer’s Disease (AD), Amyloid-β (Aβ), Cellular prion protein (PrPc), 37kDa/67kDa 
laminin receptor (LRP/LR)  
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Introduction 
Alzheimer’s disease (AD) is a progressive and devastating neurodegenerative disorder 
characterised symptomatically by behavioural and cognitive dysfunction [1]. As the most 
prevalent neurodegenerative disorder affecting the aging population, with over 38 million 
people being afflicted worldwide and economic costs estimated to run into millions of 
dollars, scientific interest remains prioritised on the development of novel therapeutic 
strategies [2].  
The neuronal perturbations in AD are attributed to the formation of extracellular amyloid-
beta (Aβ) neuritic plaques, composed predominantly of the neurotoxic Aβ42 isoform and 
intracellular neurofibrillary tangles, which are aggregations of hyperphosphorylated tau 
protein, a microtubule associated protein[3]. Aβ (40-42) generation occurs via the proteolytic 
cleavage of the amyloid precursor protein (APP) by β-secretase, also termed BACE1 (β-site 
APP cleaving enzyme-1) and the presenilin-containing γ-secretase complex thereby leading 
to release of the sAPPβ fragment and Aβ peptide[4]. Although this amyloidogenic pathway 
has a normal physiological function, it has been suggested that it is the misappropriate 
favouring of this pathway or the decline in Aβ42 clearance or degradation that leads to the 
accumulation of Aβ42 peptides and thus the development of AD [5].  
Although the Aβ plaques and neurofibrillary tangles have been reported to play a role in 
synaptic dysfunction, the neuronal loss characteristic of AD has been largely attributed to the 
formation of soluble Aβ42 oligomers [6].  A common thread seen in Aβ induced cell 
cytotoxicity is the requirement for an interaction between these toxic oligomers and cellular 
components[7]. Owing to their hydrophobic nature these soluble Aβ42 oligomers are 
incorporated into the plasma membrane resulting in membrane distortion and ion channel 
formation[8] 
 
which is of particular concern with regards to the influx of Ca
2+
 ions which may 
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induce cytotoxicity [9]. Several factors associated with the progression of AD are believed to 
be attributed to the association of Aβ42 oligomers with cell surface receptors which may lead 
to an increase in protein-receptor internalisation and the accumulation of intracellular Aβ42 
oligomers [10],[11],[7]. It is in turn these intracellular Aβ42 oligomers and aggregates that 
lead to cellular dysfunction, aberrant cell signalling and the cellular damage which precedes 
cell death [7]. One such receptor to which Aβ42 binds resulting in adverse effects is the 
cellular prion protein[12]. 
The cellular prion protein (PrP
c
) is a glycosylphosphatidylinisotol (GPI) anchored cell surface 
receptor expressed by most tissues and in particular, at high concentrations in neuronal cells 
in which its physiological functions include protection against oxidative stress, synaptic 
transmission and copper homeostasis
 [13]
. Little is clearly defined regarding the role of PrP
c
 in 
AD as a two-fold functionality has been demonstrated. In 2007, Parkin et al, demonstrated 
that a negative feedback loop exists between PrP
c
 and β-secretase [13]. PrPc binding was 
shown to inhibit β-secretase cleavage of APP thus reducing Aβ production and shedding[13]. 
However, Aβ42 oligomers bind with high affinity to PrP
c
, the consequence of which may be 
the internalization of the Aβ42-PrP
c
 complex. This may in turn results in lower cell surface 
PrP
c
 levels, thereby lessening the degree of β-secretase inhibition resulting in enhanced Aβ 
shedding.  A receptor of noted physiological importance that binds to PrP
c 
is the 
37kDa/67kDa laminin receptor (LRP/LR) [14]. The receptor is a multifunctional protein 
involved in cell survival, proliferation, cell adhesion, invasion and the internalization and 
intracellular recycling of PrP
c
[15]. LRP/LR is a high affinity receptor for laminin-1 and 
owing to this, LRP/LR has been shown to play a central role in metastatic cancer. Anti-
LRP/LR specific antibodies reduced cell adhesion and invasion as well as the induction of 
angiogenesis in numerous cancer cell types[16], [17], [18], [19]. An interaction between 
laminin-1 and Aβ42 oligomers has been demonstrated in previous studies.
 
As LRP/LR and 
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Aβ42 share aforementioned mutual binding partners, is has been proposed that LRP/LR may 
be implicated in the pathogenesis of AD[20], [21]
 
. 
Recent studies have implicated LRP/LR as a key player in Aβ42 shedding [20] and Aβ42 
induced cytotoxicity [21] 
 
but owing to the binding of PrP
c
 to both LRP/LR and Aβ, the 
mechanism by which Aβ induces neuronal cytotoxicity may be indirectly due to the PrPc-Aβ 
interaction with LRP/LR. The aim of this study was to examine the effect of PrP
c
 in Aβ42 
induced cell cytotoxicity and to determine the role of the PrP
c
-LRP/LR interaction in Aβ 
mediated cytotoxicity. The determination of the role played by PrP
c
 and more importantly the 
PrP
c
-LRP/LR interaction in Aβ42 induced cytotoxicity may have potentially important 
implications for understanding the pathogenic mechanism of AD and may thus contribute to 
the development of effective therapeutic strategies.  
Methods and Materials 
Tissue culture. HEK293 cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% Fetal Calf Serum (FCS) and 1% Penicillin/Streptomycin 
(P/S) solution. Cells were incubated at 37°C in a humidified 5% CO2 atmosphere. 
Protein-tagged Confocal microscopy. HEK293 cells were seeded onto microscopic 
coverslips as to attain 50% confluency within 24h and incubated in 5% CO2 humidified 
atmosphere at 37°C. Post incubation cells were transfected with the GFP-LRP and Ds-Red-
PrP
c
 plasmids using the TransIT©-LT1 Transfection Reagent [Mirus] and incubated in a 5% 
CO2 humidified atmosphere at 37°C for 24h. The cells were fixed (4% Paraformaldehyde, 10 
min, 4°C), rinsed thrice with 1xPBS and blocked with 0.5%PBS-BSA (5-10min,RT). 
Coverslips were then mounted using a 50μl volume of Fluoromount [Sigma Aldrich]. Slides 
were viewed using the Zeiss LSM 780 confocal microscope and capture using the AxioCam 
MRm camera. Images were subsequently analysed using Zen 2010 imaging software. The 
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Ds-Red and GFP-LRP/LR control and Ds-Red-PrP
c
 and GFP control were performed using 
the above protocol. 
Immunofluorescence Confocal microscopy. HEK293 cells were seeded onto microscopic 
coverslips to a confluency of 50-70% was obtained. The cells were fixed (4% 
Paraformaldehyde , 10 min, 4°C), rinsed thrice with 1xPBS and blocked with 0.5%PBS-BSA 
(5-10mins, RT). Coverslips were additionally washed with 1xPBS and placed such that the 
cell free side of the coverslip lay flush with the slide. 100μl volume of primary antibody 
solution (diluted in 0.5%PBS-BSA) containing a 1:150 anti-PrP
c
 8H4 (mouse) [Sigma 
Aldrich] or 1:100 anti-β-amyloid (22-35) (rabbit) [Sigma Aldrich] was administered to the 
cells. Post an overnight incubation at 4°C in moist containers coverslips were again washed 
thrice in 0.5%PBS-BSA and placed on clean slides. A 100μl volume of secondary antibody 
solution containing 1:300 goat anti-mouse APC [Abcam] or 1:300 goat anti-rabbit FITC [Cell 
Lab] were administered to cells and incubated for 1h in the dark. Coverslips were washed 
thrice with 0.5%PBS-BSA and once in PBS. Coverslips were then mounted using a 50μl 
volume of Fluoromount [Sigma Aldrich]. Slides were viewed using the Zeiss LSM 780 
confocal microscope and capture using the AxioCam MRm camera. Images were 
subsequently analysed using Zen 2010 imaging software. Secondary antibody controls of 
goat anti-mouse APC and goat anti-rabbit FITC were performed using the above protocol. 
HEK293 Tranfection methodology. HEK293 cells were seeded to attain 50% confluency 
within 24h and incubated in 5% CO2 humidified atmosphere at 37°C. Post incubation cells 
were transfected with the pSFV1-huPrP1-253 plasmid using the TransIT©-LT1 Transfection 
Reagent [Mirus] and incubated in a 5% CO2 humidified atmosphere at 37°C for 48h. 
Flow cytometry. pSFV1-huPrP1-253 plasmid [14] transfected and non-transfected cells were 
subjected to flow cytometric analysis following treatment with anti-LRP/LR antibody IgG1-
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iS18 and anti-PrP
c
 antibody 8H4. Cells were fixed  (4% Paraformaldehyde,10 min, 4°C) 
centrifuged at 1500 g for 10 min and resuspended in 1ml 1xPBS. Half of each cell sample 
was treated with 30μg/ml of either anti-LRP/LR antibody IgG1-iS18 or anti-PrPc antibody 
8H4 [Sigma Aldrich], while the other half of the cell sample was incubated in 1xPBS. Cells 
were then incubated for 24h at 4°C. Post incubation the cells were washed three times in 
1xPBS at 1700g at RT. All cells were treated with 20μg/ml of the corresponding goat anti-
human FITC coupled secondary antibody [Cell Lab] or the corresponding goat anti-mouse 
APC coupled secondary antibody [Abcam] and incubated for 1h at RT. The cells were 
washed a further three times as above. The samples were analysed using the BD Accuri C6 
whereby 10000 events were recorded. 
3-(4,5-dimethylthiazol-2-Yl-2,)5-diphenyltetrazolium bromide (MTT) cell viability 
assay. HEK293 cells were seeded in a 96 well plate as to attain 50% confluency within 24h 
and incubated in 5% CO2 humidified atmosphere at 37°C. Post incubation cells were 
transfected with or without the pSFV1-huPrP1-253 plasmid using the TransIT©-LT1 
Transfection Reagent [Mirus] and incubated at 5% CO2 humidified atmosphere at 37°C for 
24h. Post incubation, synthetic Amyloid beta (Aβ42) peptide [Sigma Aldrich] was 
administered to the cells in varying concentrations (100nM, 200nM and 500nM) to determine 
the effect thereof on cell viability. In addition untreated controls (cells incubated in DMEM) 
as well as positive controls (cells incubated with 8mM protocatechuic acid (PCA)- an 
apoptosis inducing agent) were included. Furthermore transfected and non-transfected cells 
were additionally co-incubated with Aβ42 (at 200nM and 500nM) and 50μg/ml IgG1-iS18 
antibody or 50μg/ml anti- chloramphenicol acetyltransferase (CAT) antibody [Sigma 
Aldrich]. Treated cells were incubated for 48 hours (37°C, 5% CO2), following which 20μl of 
1mg/ml MTT was added to each well and the cells subsequently incubated (37°C, 5% CO2) 
for 2h. After incubation, culture media was aspirated and 180μl of DMSO was added to each 
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well to lyse the cells and dissolve the formazan crystals formed within the cells. The 
absorbance was recorded at 570nm using an ELISA microtiter plate reader and the 
percentage of cell survival, relative to the untreated controls, calculated. Each experiment 
was performed in triplicate, three times. 
Statistical evaluation. Student’s t-tests were used to analyse the data and obtain p values. All 
statistical evaluations were performed using GraphPad Prism (version 5.03) software. 
Results 
LRP/LR and Aβ42 co-localise with PrP
c
 on the cell surface. Co-localisation is regularly 
employed to provide evidence of potential protein-protein interactions in a cell. A close 
proximity between LRP/LR and Aβ42 with PrP
c
 would thereby indicate a possible association 
between these proteins. Co-localization of fluorescent protein tagged LRP/LR and PrP
c
 was 
observed on the cell surface of non-permeabilized HEK293 cells (Fig. 1A-C). The 2D 
cytofluorogram represents both the green and red fluorescence and the resultant yellow 
diagonal (Fig. 1D) reveals that the fluorescence from both LRP/LR and PrP
c
 displays spatial 
overlap on the cell surface as seen in the yellow merged image (Fig 1C). This data is 
supported by the highly positive Pearson’s correlation coefficient of 0.872 (Table 1) LRP/LR 
does not non-specifically interact with the fluorescent protein Ds-red nor does PrP
c
 non-
specifically interact with GFP, this is evident by the lack of the yellow merge and diagonal 
2D-cytofluorograms (Fig. 1G,H & Fig. 1 K,L). PrP
c 
does not bind non-specifically to other 
laminin binding receptors as is evidenced by a lack of binding between the Very Late 
Antigen 6 (VLA6), a laminin binding integrin [14].  Co-localisation of immunolabelled PrP
c
 
and Aβ42 was observed on the cell surface of non-permeabilized HEK293 cells (Fig. 1M-O). 
The 2D cytofluorogram represent both the magenta and blue fluorescence and the resultant 
diagonal (Fig. 1P) reveals that the fluorescence from PrP
c
 and Aβ42 overlap on the cell 
82
9 
 
surface. Controls lacking primary antibodies were employed to account for possible 
secondary antibody non-specificity (Fig. 1 Q-T). Again, this data is supported by the highly 
positive Pearson’s correlation coefficient of 0.784 (Table 2) which verifies that PrPc and Aβ42 
co-localise on the surface of HEK293 cells.  
Overexpression of PrP
c
 shows no effect on cell viability. PrP
c
 overexpression, achieved 
through the transfection of HEK293 cells with the pSFV1-hu PrP
c
 1-253 plasmid, was 
confirmed using Flow cytometry. When compared to the mock transfected control, 
transfected cells displayed a greater fluorescent intensity (Fig. 2), thereby demonstrating that 
these cells displayed increased levels of PrPc on their surface (cells were non-permeabilised 
to allow solely for cell surface protein detection). The MTT cell viability assay was employed 
to assess the effects of PrP
c
 overexpression on the viability of HEK293 cells.  The lipofection 
transfection methodology significantly reduced cell viability when compared to the 
untransfected control cells (Fig. 3A). However PrP
c
 overexpression did not affect cell 
viability when compared to the mock transfected control.   
Overexpression of PrP
c
 significantly enhances the cytotoxicity effect of exogenous Aβ42 
treatment. The MTT viability assay was employed to assess the cytotoxic effect of synthetic 
Aβ42 at various concentrations on HEK293cells (Fig. 3B). Exogenous treatment of 100nM, 
200nM and 500nM of synthetic Aβ42 significantly reduced cell viability in HEK293 cells, 
which confirms previous data
24
. pSFV1-hu PrP
c
 1-253 transfected and mock transfected cells 
were subsequently treated with 100nM, 200nM and 500nM of exogenous Aβ42. PrP
c
 
overexpression significantly enhanced cell death induced by the Aβ42 treatments when 
compared to similarly treated mock transfected cells (Fig 3C). 8mM Protocatechuic acid 
(PCA) solution, an apoptosis inducing agent, was employed as a positive control. 
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Anti-LRP/LR specific antibody IgG1-iS18 rescues cells from Aβ42 - PrP
c
 mediated 
cytotoxicity. The MTT viability assay was employed to determine the effect of the anti-
LRP/LR specific antibody IgG1-iS18 on cell viability of pSFV1-hu PrP
c
 1-253 transfected 
and mock transfected HEK293 cells when treated with 200nM and 500nM of exogenous 
Aβ42. Treatment with IgG1-iS18 at 200nM Aβ42 in both the pSFV1-hu PrP
c
 1-253 transfected 
and mock transfected HEK293 cells showed a significant increase in cell viability (Fig. 4A). 
Similar results were obtained for the 500nM Aβ42 treatment (Fig. 4B).  Antibody treatment 
alone, in the absence of Aβ42 administration, did not have an effect  on cell viability (Fig. 
4C). 8mM Protocatechuic acid (PCA) solution, an apoptosis inducing agent, was employed as 
a positive control 
Discussion 
The co-localisation observed between LRP/LR and Aβ with PrPc on the cell surface of 
HEK293 cells, as assessed by confocal microscopy, indicates that a spatial overlap occurs 
between the proteins (Fig 1). Although the close proximity of the proteins on the cell surface 
is not explicitly indicative of an interaction, however, it does imply an association between 
LRP/LR and Aβ with PrPc. This data confirms interactions between LRP/LR and PrPc as well 
as between PrP
c 
and Aβ which has been previously published [15], [21], [22]. As LRP/LR 
and Aβ42 share the aforementioned mutual binding partner, PrP
c
, it has been proposed that 
LRP/LR may be implicated in the pathogenesis of AD [20, 21]. Recent studies have 
implicated LRP/LR as a key player in Aβ42 shedding [20] and Aβ42 induced neuronal 
cytotoxicity [21]
 
yet little is known regarding the exact mechanism played by PrP
c
 and the 
PrP
c
-LRP/LR interaction in Alzheimer’s disease. 
The precise role of the prion protein in AD has recently been a topic of much debate and 
controversy as a two-fold functionality has been  ascribed to PrP
c
 namely: a  neuroprotective 
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role, demonstrated by Parkin et al, [13] and a cytotoxic enhancement effect
 
demonstrated by 
Rushworth et al. [22] owing to the Aβ42- PrP
c
 interaction. However, prior to assessing the 
role of PrP
c, it was necessary to confirm that the Aβ42 concentrations employed were 
cytotoxic. MTT cell viability assays confirmed the cytotoxic effect of exogenous Aβ42 on 
HEK293 cells at varying concentrations (Fig. 3B) of which the results suggest a direct 
correlation between Aβ42 concentration and cell cytotoxicity once a threshold concentration 
has been achieved. Although the threshold of synthetic Aβ42 has been previously documented 
to be a 100-200nM concentration [23], disruption of long term potentiation (LTP)[23] and 
significant decrease in cell viability are largely observed at 500nM Aβ concentrations [24]. 
The results presented here mirror those previously described, as 500nM Aβ42 exogenous 
treatment resulted in greatest cell death. It is of vital importance to note that the 500nM 
concentration employed is below the critical concentration required for fibril formation in 
vitro [25] and it may thereby be suggested that the Aβ formed  oligomers and these in turn 
exerted the cytotoxic effects observed.  The fact that the cytotoxic effect was proportional to 
Aβ42 concentration validates the notion that it is the gradual accumulation of soluble Aβ (and 
consequent increase in the toxic peptide’s concentration), which may be initiated by the 
favouring of amyloidogenic process or deficits in Aβ clearance and degradation, that leads to 
the neuronal loss observed in AD.   
Recent investigations have demonstrated that PrP
c 
serves as a high affinity binding partner for 
Aβ42 oligomers, however, the implications of this association, be it pathological or 
neuroprotective, is a topic of much debate. In this study, MTT cell viability assays exploited 
the overexpression of PrP
c
 as a tool to determine the role of the Aβ42-PrP
c
 interaction in Aβ42 
induced cell cytotoxicity. Cells overexpressing PrP
c
 displayed significantly lower cell 
viability upon Aβ42 treatment when compared to similarly treated mock transfected controls 
(Fig. 3C). This suggests that the Aβ42 induced cell cytotoxicity observed here is mediated 
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through the Aβ42-PrP
c 
interaction. These results correlate with those of previous studies [22]. 
Cell viability was not compared to untreated controls owing to the detectable toxicity of the 
transfection methodology (Fig. 3A). 
Rushworth et al. have recently demonstrated the requirement of Aβ42-PrP
c 
mediated 
cytotoxicity, for cellular components associated with the lipid raft region of the cell 
membrane [22]. It is largely believed that an additional protein mediator is required to 
mediate the cytotoxic effect of this PrP
c
-Aβ complex. Such cell surface receptors include: 
metabotropic glutamate receptor 5 (mGluR5)[26] and N-methyl-D-aspartate (NMDA) 
receptors [27] which mediate the aberrant effects on cellular signalling pathways  and low 
density lipoprotein receptor-related protein-1 (LRP1), which induces internalization of this 
complex and thereby facilitates intracellular Aβ accumulation, aggregation and the resultant 
cellular dysfunction[22] characteristic of AD. Interestingly, the role of a key PrP
c
 receptor, 
37kDa/67kDa LRP/LR, had until recently not been researched with regards to Aβ 
cytotoxicity.  
Our novel findings revealed that blockade of LRP/LR rescued cells from Aβ cell death [21] 
.However, antibody blockade of LRP/LR may have secondarily blocked PrP
c
 binding to Aβ 
through steric effects. Therefore, it was imperative that we ascertained whether LRP/LR is 
indeed a key factor in Aβ pathogenesis.  To accomplish, this cells overexpressing PrPc were 
co-treated with anti-LRP/LR antibody IgG1-iS18 (or anti-CAT, as a negative control) in the 
presence of exogenously administered Aβ42. Our results demonstrate that through the use of 
the anti-LRP/LR specific antibody IgG1-iS18, cells were rescued from Aβ42-PrP
c 
mediated 
cytotoxicity (Fig. 4A & Fig. 4B) as a significant increase in cell viability was observed in 
both the mock transfected and pSFV-hu PrP
c
 1-253 transfected samples at all three 
concentrations of Aβ42 (Fig 4A & Fig 4B). The possibility that the antibodies were able to 
affect cellular viability in the absence of Aβ42 treatment, in both mock and transfected cells, 
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was refuted as is demonstrated in (Fig. 4C).   If the antibody blockade of LRP/LR indirectly 
enhanced cellular viability through sterical hinderance of PrP
c
-Aβ and LRP/LR itself was 
irrelevant, antibody treatment in cells overexpressing PrP
c
 would not have had the significant 
enhanced cell survival effects demonstrated here as the PrP
c
-Aβ complex would have been 
able to induce cell death independently of LRP/LR. The fact that the anti-LRP/LR specific 
antibody significantly enhanced cellular viability despite PrP
c
 overexpression reveals that the 
37kDa/67kDa LRP/LR indeed does play a central role in Aβ42, and more importantly PrP
c
-
Aβ42 mediated, pathogenesis.  
It may be proposed that the 37kDa/67kDa LRP/LR may indeed serve as an internalization 
mediator of the PrP
c
-Aβ42 complex, as the receptor is involved in physiological PrP
c
 
recycling which includes PrP
c
 internalization through clathrin-coated pits – the mechanism 
largely considered the preferred endocytic pathway for PrP
c
- Aβ complexes. It may  therefore 
be suggested that the PrP
c
-LRP/LR interaction may play a central role in the Aβ42-PrP
c 
mediated cytotoxicity observed in AD.  
Further research employing siRNAs targeting LRP/LR mRNA for LRP/LR down regulation 
and the design of a PrP
c
-LRP/LR interaction inhibitors is currently in progress and will 
further elucidate the role of the PrP
c
-LRP/LR interaction in Aβ42- PrP
c 
mediated cytotoxicity. 
LRP/LR is a useful target for AD treatment, as antibody blockade of this receptor has been 
shown to have no adverse effects in animal trials [28], [29]. 
These findings are of considerable value to the AD research community as they provide 
evidence that LRP/LR is indeed a central player in Aβ mediated pathogenesis, thereby 
allowing researchers to move a step closer towards understanding the complex networks and 
mechanisms underlying neuronal loss.  Moreover it may be suggested that the 37kDa/67kDa 
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LRP/LR may serve as a safe alternative target for the development of effective AD 
therapeutics .   
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Figure legends 
Figure 1. Co-localisation of LRP/LR and Aβ42 with PrP
c
 on the cell surface of HEK293 
cells. Human embryonic kidney (HEK293) cells were seeded onto coverslips and allowed to 
proliferate until a confluency of 70% was reached. Cells were subsequently transfected with 
plasmids encoding the following fluorescent proteins or fluorescent  protein coupled proteins, 
namely  (A) GFP-LRP/LR; (B) Ds-Red PrP
c
; (E) GFP-LRP; (F) Ds-Red; (I) GFP; (J) Ds-
Red PrP
c
; and post 48h were fixed (4% paraformaldehyde, 10min, 4°C) and mounted onto 
coverslips. The merged images between (A&B), (E&F), (I&J) are shown in (C, G, K) 
respectively and the corresponding 2D-cytofluorograms have been included to confirm the 
degree of co-localisation (D, H, L). Similarly, to assess the cellular distribution of PrP
c
 in 
relation to Aβ42, non-permeabilised HEK293 cells were fixed and indirectly labelled with:  
(M) anti-Aβ42 & anti-Rabbit-FITC; (N) anti-PrP
c
 & anti-mouse-APC; (Q) anti-Rabbit-FITC 
only and (R) anti-mouse-APC only antibodies. The merged images between (M&N) and 
(Q&R) are shown in (O&S) respectively and the corresponding 2D-cytofluorograms have 
been included to confirm the degree of co-localisation (P&T). Detection of the cell surface 
proteins were performed using the Zeiss LSM 780 confocal microscope and captured using 
the AxioCam MR camera. Images were subsequently analysed using Zen 2010 imaging 
software.  
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Figure 2. Confirmation of the expression of pSFV1-hu PrP
c
 1-253 plasmid in HEK293 
cells. Flow cytometry was employed to confirm PrP
c
 overexpression on the cell surface. Non-
permeabilised HEK cells (either non transfected or transfected with a PrP
c
 expressing 
plasmid) were fixed (4% paraformaldehyde, 10min, 4°C), indirectly labelled with anti-PrP
c
 
and anti-mouse-APC antibodies. The rightward shift in fluorescence intensity of the 
transfected sample in comparison to the non-transfected sample, confirms an increase in PrP
c
 
expression on the cell surface and thus the successful expression of the pSFV1-hu PrP
c
 1-253 
plasmid. Three technical and biological repeats were performed and ten thousand events were 
enumerated per analysis.   
Figure 3. The effects of exogenous Aβ42 and PrP
c
 overexpression on cell viability.  
(A) HEK293 cells were either transfected (mock or in the presence of pSFV1-hu PrP
c
 1-253 
plasmid), employing the Mirus transfection reagent, or treated upon reaching 70% confluence 
and 72h thereafter the cellular viability of the cells was determined by MTT (1mg/ml) assay. 
8mM protocatehuic acid (PCA), an apoptosis inducing agent serves as the positive control. 
(B) HEK293 cells were treated with exogenous  synthetic Aβ42 at varying concentrations 
(100nM, 200nM and 500nM) and the effects thereof on cell viability was assessed after 48h. 
(C) The effects of Aβ42 treatment on mock transfected and pSFV1-hu PrP
c
 1-253 transfected 
HEK293 cells was assessed 72h post transfection and 48h post exogenous Aβ42 
administration. pSFV-hu PrP
c
 1-253 represented as pSFV-PrP in figure legend. 
Data shown (Mean ± s.e.m) representative of three independent experiments (performed in 
triplicate). *** p < 0.001; Students t-test 
 
Figure 4. The cell rescuing effects of anti-LRP/LR specific antibody IgG1-iS18 on cell 
viability. (A) The cellular viability of in both the mock transfected and pSFV-PrP
c
 
transfected cells HEK293 cells was determined by MTT (1mg/ml) assay, post 200nM Aβ42 
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treatment in the absence of antibody as well as in the presence of 50µg/ml anti-LRP/LR 
specific antibody IgG1-iS18 and anti-CAT antibody.  (B) Similarly the effects of 500nM 
Aβ42 treatment on non-transfected and PrPc overexpressing cells, the absence and presence of 
IgG1-iS18 and anti-CAT was investigated. (C) MTT assays were employed to assess the 
influence of the IgG1-iS18 and anti- CAT antibodies on cell viability in the absence of 
exogenous synthetic Aβ42 treatment.  pSFV-hu PrP
c
 1-253 represented as pSFV-PrP in figure 
legend. Data shown (Mean ± s.e.m) representative of three independent experiments 
(performed in triplicate). *** p < 0.001; Students t-test 
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Tables 
Table 1: Pearson’s correlation co-efficient for the co-localisation between LRP/LR and PrPc 
 
Proteins of interest Pearson’s correlation co-efficient 
GFP-LRP/LR  + DsRed-PrP
c
 0.872 
GFP + DsRed-PrP
c
 0.044 
GFP-LRP/LR  + DsRed 0.018 
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Table 2: Pearson’s correlation co-efficient for the co-localisation between PrPc and Aβ42 
 
Proteins of interest Pearson’s correlation co-efficient 
PrPc-APC  + Aβ42 -FITC 0.789 
APC  + FITC 0.021 
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Brief Overview of Article: 
This original research article suggested for the first time that the 37kDa/67kDa LRP/LR may 
occupy a role in the amyloidogenic processing of APP. It was revealed by confocal 
microscopy that LRP/LR co-localizes with APP as well as β- and ɣ-secretases both at the cell 
surface and intracellularly - thereby suggesting a potential association between the receptor 
and these AD proteins. Pull down assays further  suggested that an interaction, be it direct or 
indirect, exists between LRP/LR and β-secretase. Antibody blockade (employing an anti-
LRP/LR specific antibody, IgG1-iS18) as well shRNA-mediated downregulation of the 
receptor did not significantly alter cell surface levels of APP, β- and ɣ-secretase but did 
significantly lower the shedding of both Aβ and sAPPβ fragments. It was therefore proposed 
that LRP/LR may be involved in APP processing, particularly through a possible association 
with β-secretase. It was also suggested that targeting this receptor by means of antibodies or 
RNAi methodology may hamper Aβ shedding and may thereby serve as a promising 
alternative approach for the treatment of Alzheimer’s Disease.  
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Anti-LRP/LR specific antibodies and
shRNAs impede amyloid beta shedding
in Alzheimer’s disease
Katarina Jovanovic1, Danielle Gonsalves1, Bianca Da Costa Dias1, Kiashanee Moodley1, Uwe Reusch2,
Stefan Knackmuss2, Clement Penny3, Marc S. Weinberg4, Melvyn Little2 & Stefan F. T. Weiss1
1School of Molecular and Cell Biology, University of the Witwatersrand, Private Bag 3, Wits 2050, Johannesburg, Republic of South
Africa, 2Affimed Therapeutics AG, Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany, 3Department of
Internal Medicine, University of the Witwatersrand, 7 York Rd, Johannesburg, 2193 Parktown, Republic of South Africa, 4Antiviral
Gene Therapy Research Unit (AGTRU), Department of Molecular Medicine & Haematology, School of Pathology, University of the
Witwatersrand, Private Bag 3, Wits 2050, Johannesburg, Republic of South Africa.
Alzheimer’s disease (AD) is the most prevalent form of dementia. The amyloid beta (Ab) peptide is the
predominant candidate aetiological agent and is generated through the sequential proteolytic cleavage of the
Amyloid Precursor Protein (APP) by beta (b) and gamma (c) secretases. Since the cellular prion protein
(PrPc) has been shown to regulate Ab shedding, we investigated whether the cellular receptor for PrPc,
namely the 37 kDa/67 kDa Laminin Receptor (LRP/LR) played a role in Ab shedding. Here we show that
LRP/LR co-localises with the AD relevant proteins APP, b- and c-secretase, respectively. Antibody blockage
and shRNA knock-down of LRP/LR reduces Ab shedding, due to impediment of b-secretase activity, rather
than alteration of APP, b- and c-secretase levels. These findings indicate that LRP/LR contributes to Ab
shedding and recommend anti-LRP/LR specific antibodies and shRNAs as novel therapeutic tools for AD
treatment.
A
lzheimer’s disease (AD) is the most prevalent form of dementia afflicting in excess of 37 million people
globally1 and is associated with amultitude of genetic, environmental, epigenetic, dietary and lifestyle risk
factors2,3. The neuropathological hallmarks of AD include intracellular neurofibrillary tangle formation
(aggregates of hyper-phosphorylated microtubule associated protein, tau)4 and extracellular Ab plaque depos-
ition5. The Ab peptide and more specifically the 42 amino acid isoform (Ab42), is largely considered the primary
disease causing agent in Alzheimer’s disease (as Ab accumulation is a pre-requisite for tau hyperphosporylation,
the other AD-associated feature)6,7. Ab is generated through the proteolytic cleavage of the amyloid precursor
protein (APP) by b-secretase (BACE1 - b site APP cleavage enzyme)8 and c-secretase (composed of 4 subunits of
which the catalytic domain is composed of Presenilin (PS)9). The mechanisms underlying Ab induction of
neuronal loss (one of the key pathophysiological features of AD) are yet to be firmly established. However, it
is proposed that Abmay do so by eliciting alterations in signal transduction pathways through direct binding to
cell surface receptors, such as N-Methyl-d-Aspartate (NMDA) receptors, insulin receptors or a-7 nicotinic
receptors10,11. Alternatively, Ab may alter signal transduction pathways indirectly via incorporation into lipid
membranes of the plasma membrane and to a lesser extent cellular organelles11,12. This is thought to induce
structural and functional alterations in lipid bound receptors and consequently results in aberrant signal trans-
duction pathways12.
In 2007, Parkin et al. demonstrated a link between cellular prion proteins (PrPc) and the amyloidogenic
processing of APP13. It was shown that PrPcmediates a decrease inAb shedding by regulating b-secretase cleavage
of APP. In addition, PrPc was suggested to be a high affinity receptor for Ab oligomers and vital in mediating the
neurotoxic effects of Ab14. PrPc has also been reported to play an important role in synaptic and neuronal loss15 as
well as mediating toxic signalling induced by Ab16,17.
The extracellular matrix glycoprotein, laminin, similarly exhibits an Ab binding site, namely the IKAV peptide
sequence located on the alpha (a) chain of the tri-peptide18. However, the association between laminin and Ab is
reported to inhibit fibrillogenesis18 and thereby thwart Ab pathogenesis.
The 37 kDa/67 kDa laminin receptor (LRP/LR) (also known as LAMR, RPSA and p40) is a multifunctional
protein located within the cholesterol-rich lipid raft domains of the plasmamembrane, in the cytoplasm as well as
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in the nucleus19. Associations between the receptor and a multitude
of extracellular (laminin and elastin) and intracellular (cytoskeletal
proteins, histones, heparan sulfate proteoglycans (HSPGs)) compo-
nents have been described and are of physiological significance both
in healthy and cancerous cells20–24. Moreover, it has been established
that LRP/LR is a high affinity receptor for laminin and both the
cellular and infectious prion protein isoforms (PrPc and PrPSc,
respectively)25–28 and plays an important role in the binding, receptor
mediated endocytosis and propagation of these proteins29,30. As LRP/
LR and Ab share the aforementioned mutual binding partners, we
proposed that LRP/LR is implicated in AD pathogenesis. However, a
relationship between these proteins has as yet not been investigated.
Results
LRP/LR co-localises with APP, b- and c-secretase on the cell surface.
To assess whether LRP/LR and AD relevant proteins APP, b- and
c-secretase share a similar cell surface localisation, indirect immuno-
fluorescence microscopy was employed. LRP/LR was shown to co-
localise with APP (Fig. 1 and Fig. S1, a–d), b-secretase (Fig. 1 and
Fig. S1, e–h), c-secretase (Fig. 1 and Fig. S1, i–l) on the surface of non-
permeabilised HEK293 (Fig. 1) and N2a cells (Fig. S1), as depicted by
the yellow merged images. 2D-cytofluorograms (Fig. 1 and Fig. S1, d,
h, l) reveal a yellow diagonal confirming co-localisation between the
corresponding cell surface proteins. Pearson’s Correlation co-efficient
was employed to further confirm the observed results (Table 1). A
Pearson’s Correlation co-efficient of 1 is indicative of perfectly
correlated proteins31. The obtained Pearson’s correlation co-efficient
between LRP/LR and the AD relevant proteins are all approximately
within the 0.9 range (Table 1). An alternative laminin binding
receptor, Very Late Antigen 6 (VLA6), employed as a negative
control failed to co-localise with LRP/LR (Fig. 1 and Fig. S1, m–p,
Table 1). The proximity of these proteins on the cell surface thereby
suggests that an association/interaction between the receptor and AD
relevant proteins is feasible.
LRP/LR co-localises with APP, b- and c-secretase within the cell.
To further investigate whether LRP/LR co-localises with APP, b- and
Figure 1 | Co-localisation of LRP/LR with the AD relevant proteins APP, b- and c-secretase on the cell surace. Cell surface proteins on HEK293 cells
were indirectly immunolabelled to allow for detection using the Olympus IX71 Immunofluorescence Microscope and Analysis Get It Research Software.
(a) APP, (e) b-secretase, (i) c-secretase and (m)VLA6were all indirectly labelledwith Alexafluor 633, while an anti-human FITC conjugated antibodywas
used to label IgG1-iS18 bound to LRP/LR (b, f, j, n). The merged images between LRP/LR and relevant proteins are shown (c, g, k, o) and the
corresponding 2D-cytofluorograms have been included to confirm the degree of co-localisation (d, h, l, p).
Table 1 | Pearson’s Correlation Co-efficient for Co-localisation
between LRP/LR and AD relevant proteins
AD relevant proteins IF Confocal
LRP/LR 1 APP 0.862 0.20
LRP/LR 1 b-secretase 0.915 0.53
LRP/LR 1 c-secretase 0.938 0.57
LRP/LR 1 VLA6 0.583 -
LRP/LR 1 GFP - 20.51
The Pearson’s Correlation co-efficient was employed to determine the degree of co-localisation
between proteins of interest, where 1 indicates complete co-localisation and 21 is indicative of no
co-localisation. The co-efficient was calculated for LRP/LR and AD relevant proteins APP, b- and c-
secretase respectively employing both Immunofluorescent Microscopy and Confocal Microscopy
(employing fluorescently tagged proteins of interest).
www.nature.com/scientificreports
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c-secretase in subcellular locations other than the cell surface,
HEK293 cells were transfected with plasmids encoding fluorescently
tagged proteins and examined using confocal microscopy. APP-GFP,
BACE1-GFP (b-secretase) and PS1-GFP (Presenilin 1 – the catalytic
subunit of the c-secretase) were respectively co-expressed with LRP-
dsRed post transfection. The results obtained suggest that LRP/LR
does not only co-localise with the AD relevant proteins on the cell
surface but also intracellularly in the cytoplasm. From Fig. 2c, a
greater degree of co-localisation is observed between APP (APP-
GFP) and LRP/LR (LRP-dsRed) in the cytoplasm, and to a lesser
extent in the nucleus of the HEK293 cells as shown by the intensity
of the yellow stain. Fig. 2g highlights that the co-localisation between
b-secretase (BACE1-GFP) and LRP/LR (LRP-dsRed) is confined to
areas of the cytoplasm, but completely lacking in the nucleus. The co-
localisation between c-secretase (PS1-GFP) and LRP/LR (LRP-dsRed)
reveals a similar relationship in the cytoplasm, however, there also
appears to be a high degree of co-localisation on the cell membrane as
emphasized by staining seen in Fig. 2k. The presence of any co-
localisation between LRP/LR and c-secretase is completely lacking
in the nucleus of the cells. GFP was used as a negative control and
shows very little co-localisation with LRP/LR as is evidenced by the
weak yellow signal obtained in Fig. 2o. The 2D cytofluorograms
(Fig. 2d, h, l) further confirm that co-localisation does occur
between LRP/LR and the AD relevant proteins APP, b- and c-
secretase, as a distinct diagonal passing through quadrant 3 is seen.
The 2D cytofluorogram between GFP and LRP/LR (Fig. 2P) shows a
complete lack of a diagonal and does not pass through quadrant 3,
therefore no co-localisation between LRP/LR and GFP is likely to exist
other than by random chance (as is seen by the weak yellow signals in
Fig. 2o). From Table 1, it is evident that a positive correlation exists
between LRP/LR and APP, b- and c-secretase, as the Pearson’s co-
efficient values are all above 0. The value seen for GFP and LRP
(20.51) is negative and indicates that there is a low level of
correlation between the cellular localisation of these 2 proteins.
Figure 2 | Co-localisation of LRP-dsRed with APP-GFP, BACE1-GFP and PS1-GFP inside HEK293 cells. Fluorescently tagged (a) APP-GFP,
(e) BACE1-GFP, (i) PS1-GFP and (m) GFP were co-expressed with LRP-dsRed (b, f, j, n) in HEK293 cells. Images were captured using the Zeiss LSM 780
confocal microscope and analysed using Zen 2010 software. The resulting merges between LRP-dsRed and APP-GFP (c), BACE1-GFP (g), PS1-GFP (k)
and GFP (o) are shown and the corresponding 2D cytofluorograms for each merge have also been included (d, h, l, p) as a measure of the degree of co-
localisation.
www.nature.com/scientificreports
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IgG1-iS18 and shRNA treatment targeting LRP/LR significantly
reduces Ab shedding. To investigate whether LRP/LR is involved
in the amyloidogenic pathway and more specifically Ab shedding
into the extracellular space, cells were treated with the anti-LRP/
LR specific antibody IgG1-iS1832 and anti-cluster of differentia-
tion (CD19) antibody IgG1-HD3732 (negative control). Cellular
incubation with IgG1-iS18 resulted in a significant reduction in
Ab concentration when compared to the no antibody control
(Fig. 3a). Ab levels were lowered by 47.6% in HEK293 cells
(P 5 0.0008) and 28.5% in SH-SY5Y cells (P 5 0.0064)
(Fig. 3a) after IgG1-iS18 treatment. To further assess the effects
of IgG1-iS18 on Ab shedding, a dose dependency assay was
conducted using SH-SY5Y cells. Ab shedding was significantly
hampered by between 24% (for 25 mg/ml) and 43% (for 100 mg/
ml) denoting that IgG1-iS18 impedes Ab shedding in a dose-
dependent fashion (Fig. 3b).
Figure 3 | Effects of IgG1-iS18. (a) Ab levels in HEK293 and SH-SY5Y cells after treatment with IgG1-iS18 and IgG1-HD37 as detected by an Ab ELISA
after 18 hours of antibody incubation. Data shown (mean6 s.e.m) representative of three independent experiments (performed in triplicate) per cell line.
*p, 0.05, **p, 0.01, ***p, 0.001, NS not significant; Student’s t-test. (b) Ab concentrations after SH-SY5Y cells were treated with varying doses of
IgG1-iS18 for 18 hours, as determined by anAb ELISA.Data shown (Mean6 s.d.) comparing Ab levels of untreated cells (0 mg/ml) and IgG1-iS18 treated
cells (25–100 mg/ml), ***p, 0.0001; n 5 3; one way ANOVA. (c) Flow cytometric analysis of APP, b-secretase and c-secretase levels on the surface of
HEK293 cells post treatment with IgG1-iS18 (mean6 s.d., NS not significant, n5 3, Student’s t-test). (d) (i)Western blot showing sAPPb levels from cell
culture medium after SH-SY5Y cells were treated with varying concentrations (0–100 mg/ml) of IgG1-iS18 for 18 hours. Western blot band intensities
from three independent experiments were quantified using Quantity One 4.6 software. Gels have been cropped for clarity and conciseness purposes and
have been run under the same experimental conditions. (d) (ii) Obtained band intensities were subsequently used to determine the percentage
downregulation of sAPPb. Data shown (mean 6 s.d); ***p , 0.0001; One way ANOVA.
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Owing to the ability of IgG1-iS18 to decrease Ab shedding, it may
be proposed that LRP/LR mediates this process. To further confirm
this role in the amyloidogenic pathway, RNA interference techno-
logy, specifically short hairpin RNA (shRNA), was employed to
downregulate LRP/LR expression. shRNA1 and shRNA7 resulted
in a significant 42.85% and 16.42% decrease in LRP/LR expression
levels, respectively, compared to the scrambled control (shRNAscr)
(Fig. 4a). This downregulation correlated to a significant 16.88% and
11.95% decrease in Ab shedding in HEK293 cells (for shRNA1 and
shRNA7 respectively) (Fig. 4b). No significant difference was
observed between mock-transfected and shRNAscr control trans-
fected HEK293 cells (Fig. S3).
IgG1-iS18 and LRP/LR shRNA treatments do not alter cell surface
expression of APP, b- and c-secretase. To investigate whether LRP/
LR influences the amyloidogenic pathway through altering cell
surface protein expression levels of the aforementioned AD
relevant proteins, flow cytometric analysis of the cell surface levels
of APP, b-secretase and c-secretase was performed post-antibody
(IgG1-iS18 and IgG1-HD37) treatment in HEK293 cells (Fig. 3C
and Fig. S4a). Both antibody treatment and downregulation of
LRP/LR by shRNA1 and 7 (Fig. 4c, Fig. S4 b) did not significantly
alter HEK293 cell surface expression levels of the APP, b- and c-
secretase in comparison to controls.
sAPPb levels are affected by LRP blockade and downregulation. In
an attempt to elucidate the mechanism whereby LRP/LR influences
the amyloidogenic pathway, sAPPb levels were assessed post-
antibody (Fig. 3d(i)) and shRNA treatment (Fig. 4d (i)). Upon a
dose dependent administration of IgG1-iS18 to SH-SY5Y cells, a
Figure 4 | Effects of LRP/LR downregulation by shRNA. (a) HEK293 cells were transfected with LRP/LR-specific shRNA1 and shRNA7 (as well as a
scrambled control, shRNAscr). 72 hours post-transfection, cells were lysed and LRP/LR levels assessed byWestern blotting. b-actin was used as a loading
control. Western blot band intensities from three independent experiments were quantified using Quantity One 4.6 Software. (b) The Ab concentration
of the cell culture medium of shRNA-transfected HEK293 cells was analysed using an Ab ELISA. Data shown (Mean 6 s.d.) comparing Ab levels of
shRNA1 and shRNA7 to shRNAscr, *p , 0.05, **p , 0.01; n 5 3; Student’s t-test. (c) Flow cytometric analysis of APP, b-secretase and c-secretase
levels on the surface of shRNA-transfected HEK293 cells. Data shown (Mean 6 s.d.); n 5 3; Student’s t-test. (d)(i) sAPPb levels in shRNA-transfected
HEK293 cells were analysed by Western blotting. Gels have been cropped for clarity and conciseness purposes and have been run under the same
experimental conditions. (d)(ii) Band intensities were extracted as mentioned previously (Fig. 3 d) and used to calculate the percentage of
downregulation of sAPPb levels.
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significant reduction in sAPPb levels was observed across all antibody
concentrations (Fig. 3d(ii)). Similar results were obtained for shRNA1
mediated LRP/LR downregulated HEK293 cells (Fig. 4d).
LRP/LR interacts with b-secretase.A FLAGH Immunoprecipitation
assay was conducted using a FLAG-tagged variant of LRP
(LRP::FLAG) which had the ability to bind to anti-FLAG M2
beads. Any protein interacting with LRP::FLAG would thus remain
immobilised during subsequent washing steps and would be present
in the eluate of the immunoprecipitation assay. A FLAGH Immuno-
precipitation assay was thus performed to detect whether LRP/LR
shows any interaction with b-secretase in order to further validate
the co-localisation results observed between LRP/LR and b-secretase,
as well as effects seen on sAPPb shedding upon IgG1-iS18
incubation. From Fig. 5, it is evident that a distinct band is present
in the eluate of the FLAGH Immunoprecipitation assay (Fig. 5, lane 4)
corresponding in size to the band detected in the BACE1-GFP
expressing cell lysate control lane (Fig. 5, lane 3). This suggests
that an interaction does exist between LRP/LR and b-secretase, as
only proteins that interact with LRP would be present in the eluate.
CAT (chloramphenicol acetyl transferase) transfected cell lysates
were used as a negative control. CAT was not present in the
immunoprecipitation assay eluate, thus showing no interaction
with LRP (Fig. S5).
Discussion
The co-localisation observed between LRP/LR and the relevant AD
proteins (APP, b and c-secretase) on both HEK293 and N2a cells, as
assessed by immunofluorescence microscopy, indicates that a spatial
overlap occurs between the fluorescently immunolabeled proteins
(Fig. 1 and Fig. S1). Although the close cellular proximity of the
proteins on the cell surface is not explicitly indicative of an inter-
action, it does imply that an association between these proteins and
LRP/LR is possible.
Confocal microscopy was further utilized to examine whether
LRP/LR co-localised with APP, b- and c-secretase in sub-cellular
locations other than the cell surface. From Fig. 2, it is evident that
LRP/LR also shows a high degree of co-localisation with the AD
relevant proteins within the cytoplasm. LRP/LR is known to be pre-
sent in the cytoplasm33 and lipid raft regions34 of the cell membrane
from where it was reported to co-localise with PrPc in the early
endosomes upon LRP/LR-dependent PrPc endocytosis29. With
regard to APP, it is proposed that this protein is internalized from
the lipid raft region of the plasma membrane into early endosomes
via either clathrin35 or raft-mediated endocytosis36. b-secretase is also
located in the lipid raft regions where it too is endocytosed into early
endosomes37 via the GTPase Arf638. All 4 subunits of the c-secretase
have been found to be present in lipid raft regions of not only the
plasma membrane39, but of the Golgi and endosomal membranes40
too. The presence of APP, b- and c-secretase in the endosomes led to
the finding that APP is preferentially cleaved by b-secretase at this
site due to the lower pH within endosomes8. However, the three AD
related proteins are also found in other subcellular locations, such as
the Endopasmic reticulum, Golgi and trans-Golgi network; and
recent studies have shown that APP cleavage can also occur at these
sites41,42. This suggests a widespread distribution of APP and its
cleavage proteins within various cellular structures and various inter-
nalization routes for each of the proteins involved. From our results,
the intracellular distribution of APP, b- and c-secretase is seen to be
fairly widespread through the cytoplasm (Fig. 2a, e and i respectively)
– due to the aforementioned cellular organelles in which they are
found. From the literature it is evident that LRP/LR and the AD
relevant proteins exist in similar cellular locations, and from the
results obtained in Fig. 2 (b, f and j), LRP/LR is indeed found to be
present in very similar intracellular regions (Fig. 2 c, g and k) as these
proteins. This suggests that LRP/LR could be interacting with APP,
b- and c-secretase within the cellular structures in which they are
found, or alternatively, could potentially be involved in the regu-
lation of APP processing.
LRP/LR blockage by IgG1-iS18 was seen to effectively impede Ab
shedding. This was further affirmed by shRNAmediated downregu-
lation of the receptor. These results taken together suggest that LRP/
LR plays a pivotal role in the amyloidogenic processing of APP.
Interestingly, LRP blockage did not result in modulation of cell
surface levels of AD relevant proteins, thereby inferring that the
influence of LRP/LRmay rather be as a result of protein interactions.
sAPPb is the initial cleavage product of APP by b-secretase and is
released into the extracellular space. The administration of IgG1-iS18
at increasing concentrations resulted in a dose dependent decrease in
sAPPb levels, suggesting that blocking LRP/LR impedes b-secretase
activity. Similar results were seen when LRP/LR was downregulated,
thus further corroborating the possibility of an interaction between
these two proteins. These results implicate LRP/LR in the amyloido-
genic process, specifically via promoting b-secretase activity. Since
LRP/LR and b-secretase co-localize and sAPPb shedding is signifi-
cantly impeded by IgG1-iS18 and shRNA treatment, we proposed
that an interaction between b-secretase and LRP/LR exists. This was
verified upon performing a FLAGH Immunoprecipitation assay util-
izing cell lysates of cells expressing LRP::FLAG and BACE1-GFP
(Fig. 5). BACE1-GFP was detected in the eluate of the immunopre-
cipitation, and since only proteins binding to the LRP::FLAG protein
would be present in this fraction, this strongly suggests that an inter-
action between LRP/LR and b-secretase does exist. However, as
crude cell lysates expressing LRP::FLAG and BACE1-GFP were uti-
lised for the assay, it is also possible that any interaction that exists
between these two proteins may be an indirect one, mediated by
another protein present in the cell lysate.
Efforts to develop effective therapies for AD have to take into
consideration that targeting the secretases may cause off target
effects, such as a disruption of BACE1 processing of CHL1 which
is required for axonal guidance43. Here we imply that the role of b-
secretase in the amyloidogenic pathway is augmented by LRP/LR, as
the blockage of LRP/LR reduces the shedding of both sAPPb and Ab,
and LRP/LR is seen to interact with b-secretase. The effects of hin-
dering the interaction between b-secretase and LRP/LR would thus
have to be examined in detail in future studies, to test for the effects it
may have on the other physiological roles in which b-secretase is
involved. Cell viability assays, however, have been performed using
IgG1-iS18 on HEK293 cells, and no significant reduction in cell
viability was observed44, thus suggesting whatever interaction the
antibody may be blocking between b-secretase and LRP/LR is not
detrimental to the cells.
The result of the FLAGH Immunoprecipitation assay further con-
firmed the initial findings suggested by the co-localisation (Fig. 1)
and confocal data (Fig. 2) that an interaction is likely to occur
between LRP/LR and b-secretase both due to their proximity on
Figure 5 | LRP::FLAG Immunoprecipitation Assay Analysis. HEK293
cell lysates containing LRP::FLAG and either BACE1-GFP or CAT (Fig. S5)
were subjected to Pull Down Assay analysis using Anti-FLAG M2 beads.
After subsequent wash steps, eluted fractions were analysed using
Immunoblotting. Lane 1 contained non-transfected (NT) cell lysate, lane 2
contained GFP transfected cell lysate, lane 3 contained BACE1-GFP
transfected cell lysate and lane 4 contained the eluate from the FLAGH
Immunoprecipitation assay between BACE1-GFP and LRP::FLAG. Gels
have been cropped for clarity and conciseness purposes and have been run
under the same experimental conditions.
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the cell surface and within the cell. Thus it further corroborates the
possibility that interactions may also occur between LRP/LR and
APP and/or c-secretase.
In conclusion, we have identified a novel role for LRP/LR in AD
and more specifically in enhancing b-secretase cleavage of APP.
Blockage and downregulation of LRP/LR resulted in a significant
reduction in Ab levels suggesting that anti-LRP/LR specific antibod-
ies and shRNAs could be used as possible alternative therapeutic
tools for AD treatment.
Methods
Tissue culture. HEK293 cells were grown in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% Fetal Calf Serum (FCS) and 1% Penicillin/
Streptomycin (P/S) solution.N2a cells were grown inOptimemwith 10%FCS and 1%
P/S. SH-SY5Y cells were cultured in 151 EMEM:F12 media supplemented with 15%
FCS, 1% Non-Essential Amino Acids, 1% L-Glutamine and 1% P/S. Cells were
incubated at 37uC in a humidified 5% CO2 atmosphere.
Immunofluorescence microscopy. HEK239 and N2a cells were seeded onto sterile
microscope coverslips and incubated for 24 hours (37uC, 5% CO2) allowing the cells
to reach 50–70% confluency. The cells were fixed with 4% Paraformaldehyde (10
minutes, room temperature). The coverslips were rinsed 3 times in PBS and blocked
in 0.5%PBS-BSA solution for 5–10minutes. Following an additional wash in PBS, the
coverslips were placed with the cells facing upwards on a microscope slide. 100 ml of
primary antibody solution (diluted in 0.5%PBS-BSA) containing 15150 IgG1-iS18
and either anti-APP (rabbit polyclonal IgG) (Abcam), anti-BACE (M-83) (rabbit
polyclonal IgG) (Santa Cruz Biotechnology), anti-PEN-2 (FL-101) (rabbit polyclonal
IgG) (Santa Cruz Biotechnology) or anti-very late antigen-6 (VLA6) CD49-f (rabbit
monoclonal IgG) (Immunotech) was added to the cells. These slides were then
incubated overnight at 4uC in moist containers. Cover slips were then rinsed 3 times
in 0.5% PBS-BSA and placed on clean slides. The cells were treated with 100 ml of a
secondary antibody solution containing goat anti-human FITC (Cell Lab) (15350–
15400) (specific for IgG1-iS18) and Alexa FluorH 633 goat anti-rabbit IgG
(Invitrogen) (specific for the anti-APP, anti-BACE, anti PEN-2 or anti-VLA6
primary antibodies). After an hour’s incubation in the dark, the coverslips were
washed twice in 0.5% PBS-BSA and once in PBS and were subsequently mounted
onto clean microscope slides using 75 ml Fluoromount (Sigma Aldrich). These slides
were incubated at room temperature in the dark for 1–2 hours to allow the mounting
medium to set.
Images were acquired at room temperature with 603 magnification using the
Olympus IX71 Immunofluorescence Microscope and Olympus XM10 greyscale
camera. analySIS Research Image Processing Software was used to capture the images
and they were subsequently analysed (and 2D cytofluorograms were constructed)
using CellSens Dimension Software.
Confocal microscopy. HEK 293 cells were transfected with plasmids encoding for
LRP-dsRed and APP-GFP, BACE1-GFP or PS1-GFP respectively. 24 hours post
transfection, coverslips were washed with PBS 3 times and then fixed with 4%
Paraformaldehyde for 15 minutes. Coverslips were subsequently washed in PBS and
mounted cell side down onto clean microscope slides using 75 ml Fluoromount
(Sigma Aldrich). These slides were incubated at room temperature for 1–2 hours in
the dark to allow the mounting medium to set.
Slides were viewed using the Zeiss LSM 780 confocal microscope and captured
using the AxioCam MRm camera. Images were subsequently analysed using Zen
2010 imaging software.
Antibody treatment. HEK293 cells were grown to 50–70% confluency. The tissue
culture medium was aspirated and replaced with media containing 50 mg/ml IgG1-
iS1832, 50 mg/ml IgG1-HD3732, or no antibody. Each of the respective treatments were
performed in triplicate. The cells were subsequently incubated at 37uC, 5%CO2 for 18
hours.
LRP/LR target sequences and structure of shRNA1 and shRNA7. The complete
shRNA expression cassettes were designed with the guide strand on the 39arm, a poly
T termination signal, and to include a full H1 RNA polymerase III promoter
sequence. To prepare the shRNA cassettes, the H1 RNA Pol III promoter was used as
a template in a nested PCR, whereby the sequences corresponding to the shRNAs
were incorporated into two reverse primers (one for the primary PCR and one for the
secondary PCR). The same forward primer, which is complementary to the start of
the H1 promoter, was used in both. The PCR products coding for the shRNA
expression constructs were sub-cloned into the pTZ57R/T vector (Fermentas). A
scrambled shRNA (shRNAscr) that does not target any gene product was used as a
negative control. See figure S2 for LRP/LR target sequence and shRNA 1 and shRNA7
structure.
Cell transfection. The construction of pCIneo-moLRP::FLAG45 and pLRP-dsRed46
have been described previously, while pEGFPN1-APP77037 and pEGFPN1-BACE147
were generous gifts fromDr. Bradley THyman. pEGFP-PS148 was a kind gift fromDr.
Oskana Berezovska. pEGFP-N1 (Clonetech) and pCDNA3/CAT (Invitrogen) were
used as control plasmids. For confocal microscopy, HEK 293 cells were seeded onto
coverslips in 6well plates and incubated overnight. The following day, when cells were
30–50% confluent, calcium phosphate transfection was carried out using 86 ml of 13
HBS, 5.1 mg of total plasmid DNA (i.e. 2.55 mg of each plasmid was used in co-
transfections) and 5.1 ml of 2.5 M CaCl2. Cells were incubated for 24 hours and then
used for confocal microscopy. HEK293 cells were transfected with LRP/LR shRNA 1
and 7 according to the manufacturer’s instructions, using TransITH-LT1
Transfection Reagent (Mirus). Transfected cells were incubated for 72 hours prior to
analysis. For FLAGH Immunoprecipitation assays, HEK293 cells were seeded into
60 mm tissue culture plates and grown to 30–50% confluency overnight. Calcium
phosphate transfection was carried out using 186 ml 13HBS, 11 mg of either pCIneo-
moLRP::FLAG, pEGFPN1-BACE1 or pCDNA3/CAT and 11 ml 2.5 M CaCl2. Cells
were incubated for 72 hours prior to analysis.
Amyloid beta enzyme-linked immunosorbent assay (ELISA). The amyloid beta
(Ab) assay was performed using the Human Amyloid b (1 2 x) Assay kit (Immuno-
Biological Laboratories Co.,Ltd) – a solid phase ELISA. This assay was performed as
per manufacturer’s instructions using the tissue culture media after antibody and
shRNA treatment (see above).
Flow cytometry. Cell lines were subjected to flow cytometric analysis following
treatment with IgG1-iS18 or shRNA1 and 7. Cells were fixed using 4%
paraformaldehyde (10 minutes,4uC), centrifuged at 1500 g (10 minutes, 4uC) and
resuspended in 1 ml IsoFlowTM EPICSTM Sheath Fluid (Beckman Coulter). Half of the
volume of each sample was treated with 30 ug/ml of either anti-APP (rabbit
polyclonal IgG) (Abcam), anti-BACE (M-83) (rabbit polyclonal IgG) (Santa Cruz
Biotechnology) or anti-PEN-2 (FL-101) (rabbit polyclonal IgG) (Santa Cruz
Biotechnology) while remaining sample volumewas incubated in IsoFlowTMEPICSTM
Sheath Fluid (Beckman Coulter). Samples were incubated for 1 hour at room
temperature and subsequently washed three times in IsoFlowTM EPICSTM Sheath
Fluid (Beckman Coulter) (1700 g, 4uC). All samples were treated with 20 ug/ml of the
corresponding goat anti-rabbit FITC coupled secondary antibody (Cell Lab) and
incubated for 1 hour at room temperature. The samples were washed a further three
times (as above) and the cell suspensions were transferred to flow cytometry tubes.
The samples were analysed using Coulter EPICSH XL-MCL (for antibody treated
samples) or the BDAccuri C6 (for shRNA treated samples) and 10 000–50 000 events
recorded.
Western blotting. LRP/LR levels were determined by immunoblotting using IgG1-
iS18 (1510 000) and goat anti-human horseradish peroxidise (HRP) (1510 000) (Cell
Lab). sAPPb levels were assessed by immunoblotting using sAPPb-Wild type Rabbit
IgG (151000) (Immuno-Biological Laboratories Co., Ltd) and goat anti-rabbit HRP
(1510 000) (Cell Lab). FLAGH Immunoprecipitation assay eluate samples were
analysed using either anti-FLAGH (mouse monoclonal IgG) (155000) (Sigma-
Aldrich), anti-BACE1 (rabbit polyclonal IgG fraction) (153000) (Abcam) or anti-
Chloramphenicol Acetyl Transferase (rabbit IgG fraction) (155000)(Sigma-Aldrich).
Anti-mouse HRP (155000) (Sigma-Aldrich) or anti-rabbit HRP (155000) (Sigma-
Aldrich) were used as secondary antibodies. Immunodetection was carried out using
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) and X-ray
film.
FLAGH immunoprecipitation assay. HEK293 cells were lysed 72 hours post-
transfection with pCIneo-moLRP::FLAG, pEGFPN1-BACE1 or pCDNA3/CAT. Cell
lysates expressing LRP::FLAG were then mixed with those containing either BACE1-
GFP orCAT. These cell lysates were then subjected to a FLAGH Immunoprecipitation
Kit (Sigma-Aldrich) analysis according to the manufacturer’s instructions. Eluted
samples were analysed via Immunoblotting.
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Abstract
Alzheimer’s disease (AD) is the most prevalent form of dementia affecting the elderly. Neurodegeneration is caused by the
amyloid beta (Ab) peptide which is generated from the sequential proteolytic cleavage of the Amyloid Precursor Protein
(APP) by the b– and c- secretases. Previous reports revealed that the 37 kDa/67 kDa laminin receptor (LRP/LR) is involved in
APP processing, however, the exact mechanism by which this occurs remains largely unclear. This study sought to assess
whether LRP/LR interacted with APP, b- or c-secretase. Detailed confocal microscopy revealed that LRP/LR showed a strong
co-localisation with APP, b- and c-secretase, respectively, at various sub-cellular locations. Superresolution Structured
Illumination Microscopy (SR-SIM) showed that interactions were unlikely between LRP/LR and APP and b-secretase,
respectively, while there was strong co-localisation between LRP/LR and c-secretase at this 80 nm resolution. FRET was
further employed to assess the possibility of protein-protein interactions and only an interaction between LRP/LR and c-
secretase was found. FLAG co-immunoprecipitation confirmed these findings as LRP/LR co-immunoprecipitated with c-
secretase, but failed to do so with APP. These findings indicate that LRP/LR exerts its influence on Ab shedding via a direct
interaction with the c-secretase and possibly an indirect interaction with the b-secretase.
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Introduction
Alzheimer’s Disease (AD) is the most prevalent neurodegener-
ative disorder affecting the elderly population worldwide. There
are an estimated 37 million people suffering from this disease [1]
and due to the lack of any effective therapies, this number
continues to rise and pose more of an economic and social burden
[2]. Lack of understanding of the disease causing mechanisms have
resulted in great difficulties in the development of effective
therapeutic interventions and as yet, the only treatment strategies
are merely palliative, despite numerous ongoing clinical trials [3].
The two hallmark features of AD are the formation of
extracellular amyloid beta (Ab) plaques and intracellular neuro-
fibrillary tangles composed of hyperphosphorylated tau protein.
Oligomeric Ab is thought to be the candidate etiological agent for
AD since it has been found to mediate neurotoxicity through
interactions with many other proteins [4,5]. One such protein that
has proved to be of significance in AD is the cellular prion protein
(PrPc).
PrPc is thought to have a neuroprotective role with regard to
apoptosis and oxidative stress and also functions in cell signaling as
well as synapse physiology [6]; however, recent reports suggest an
important role for PrPc in mediating the toxicity caused by the Ab
peptide in AD. Lauren et al. showed that PrPc acts as a high affinity
receptor for Ab peptides and thus mediates the impairment of
synaptic plasticity [7]. Recently reports have further verified these
findings by showing that PrPc was required for the neurotoxicity
caused by Ab, through impairment of long term potentiation
(LTP) [8], as well as by regulating the function of the N-methyl-D-
aspartate receptor (NMDAR) – a function which is hindered due
to the Ab - PrPc interaction and leads to excessive activity of the
receptor thereby promoting neuronal damage [9]. PrPc has also
been implicated in neurotoxic signalling upon interaction with Ab
whereby Fyn kinase is activated and leads to dendritic spine loss,
lactate dehydrogenase activation and altered NMDAR expression
on the plasma membrane of neurons [10,11].
The cellular receptor for both PrPc [12] and its infectious
isoform PrPSc [13] is the 37 kDa/67 KDa Laminin Receptor
(LRP/LR). This multifunctional receptor has numerous physio-
logical roles including cell adhesion, migration, survival and
proliferation (for reviews see [14,15]). These roles are exploited by
neoplastic cells whereby the receptor is involved in tumour
metastasis [16,17,18,19], apoptosis [20] and angiogenesis [21].
Due to its role as the receptor for PrPc, we examined whether
LRP/LR may play some role in AD pathways. Blockage of LRP/
PLOS ONE | www.plosone.org 1 June 2014 | Volume 9 | Issue 6 | e100373
111
LR with an anti-LRP/LR antibody (IgG1-iS18) or knock down of
LRP/LR using anti-LRP shRNAs resulted in a significant
reduction both in Ab levels [22] and Ab induced cytotoxicity
[23]. As expression of APP, b- and c-secretase were not affected
upon antibody or shRNA treatment, an interaction between LRP/
LR and one or more of the AD related proteins (APP, b- and c-
secretase) was deemed likely [22]. Since sAPPb shedding was also
impaired upon IgG1-iS18 and shRNA treatment, an interaction
between LRP/LR and b-secretase was examined and co-
immunoprecipitation revealed the existence of a (direct or indirect)
interaction between the 2 proteins [22]. These findings revealed a
novel role for LRP/LR in AD. We thus aimed to further
investigate whether LRP/LR interacts with the proteins which are
central to AD, namely APP, b- and c-secretase using high
resolution imaging.
Materials and Methods
Cell Culture and transient transfection
HEK293 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) (Hyclone) supplemented with 10% fetal calf
serum (FCS) (Hyclone) and 1% Penicillin/Streptomycin. IMR-32
human neuroblastoma cells were cultivated in MEM (Hyclone)
supplemented with 10% FCS, 1% Penicillin/Streptomycin, 1%
Non-Essential Amino Acids and 2 mM L-glutamine. Cells were
incubated at 37uC with 5% CO2. The HEK293 cell line was
obtained from American Tissue Culture Collection (ATCC) while
IMR-32 cells were obtained from the Fox Chase Cancer Centre.
For transfections, cells were seeded onto sterile coverslips within
the wells of a 6 well tissue culture dish (Corning) for all
microscopy. For co-immunoprecipitation, HEK293 cells were
seeded into 60 mm tissue culture dishes (Corning). Once the cells
were 30–50% confluent, calcium phosphate transfection was
performed as described previously [22] for HEK293 cells while
TransITH-LT1 transfection reagent (Mirus) was used for the
transfection of the IMR-32 cells (in accordance with the
manufacturer’s instructions). The procedure for the generation
of the plasmids encoding LRP-dsRed (pLRP-dsRed) [24] and
LRP::FLAG (pCIneo-moLRP::FLAG) [25] has been described
previously. Plasmids for APP-GFP (pEGFPN1-APP770) and
BACE1-GFP (pEGFPN1-BACE1) [26] were a generous gift from
Dr. Bradley T Hyman, while pEGFP-PS1 (coding for PS1-GFP)
[27] was a kind gift from Dr. Oskana Berezovska. For confocal
microscopy, pLRP-dsRed was co-transfected with pEGFPN1-
APP770, pEGFPN1-BACE1 and pEGFP-PS1 respectively in a 1:1
ratio. pEGFP-N1 (Clonetech) and pDsRed-Express N1 (Clone-
tech) were used as controls. For co-immunoprecipitation, pCIneo-
moLRP::FLAG, pEGFPN1-APP770 and pEGFP-PS1 were indi-
vidually transfected into HEK293 cells in 60 mm tissue culture
dishes and incubated for 72 hours, after which the cells were lysed
for further experiments.
Slide preparation
24 hours post transfection, coverslips containing adherent
transfected cells (LRP-dsRed with APP-GFP, BACE1-GFP or
PS1-GFP) were washed with PBS 3 times and then fixed with 4%
Paraformaldehyde in PBS for 15 minutes. Coverslips were washed
with PBS and mounted onto clean microscope slides using 75 ml
Fluoromount (Sigma Aldrich). Slides were maintained at room
temperature for 1–2 hours in the dark to allow the mounting
medium to set.
Confocal Microscopy
Slides were viewed using the Zeiss LSM 780 confocal
microscope equipped with a GaAsp detector and images were
acquired through Z-stack acquisition, with an increment of
60.4 mm (depending on sample) between image frames. The
AxioCam MRm camera was utilized to capture images. Cells
expressing both LRP-dsRed and either APP-GFP, BACE1-GFP or
PS1-GFP were selected and Z-stack acquisition was performed.
Images were displayed as maximum intensity projections and
subsequently analysed for co-localisation using 2D cytofluoro-
grams and fluorescence intensity line profiles obtained with the use
of Zen 2010 imaging software.
SR-SIM Imaging
Slides were prepared as described and superresolution struc-
tured illumination (SR-SIM) was performed. Thin (0.1 mm) Z-
stacks of high-resolution image frames were collected in 5 rotations
by utilizing an alpha Plan-Apochromat 1006/1.46 oil DIC M27
ELYRA objective, using an ELYRA S.1 (Carl Zeiss Microima-
ging) microscope equipped with a 488 nm laser (100 mW),
561 nm laser (100 mW) and Andor EM-CCD camera (iXon
DU 885). Images were reconstructed using ZEN software (black
edition, 2011, version 7.04.287) based on a structured illumination
algorithm [28]. Analysis was performed on reconstructed super-
resolution images in ZEN.
FRET imaging
Cells were seeded onto coverslips, transfected as described
above and Fluorescence Resonance Energy Transfer (FRET)
acquisition and analysis was performed. Image frames were
collected using confocal microscopy (LSM 780, Carl Zeiss)
equipped with a LSM780 GaAsP detector, using a Plan-
Apochromat 636/1.4 Oil DIC M27 objective. Samples were
excited with a 488 nm and 561 nm laser under utilization of a
MBS 488/561 beam splitter. Emission was collected for the donor-
GFP channel at an emission window of 495 nm–510 nm, the
FRET channel at an emission window of 586 nm–600 nm and the
acceptor-dsRed channel at an emission window of 586 nm–
600 nm, using the lambda setting. Appropriate controls for
background, donor spectral bleed-through (DSB) and Acceptor
spectral bleed-through (ASB) were prepared and GFP only control
images as well as dsRed only control images were acquired.
Sensitized emission FRET analysis was performed utilizing
FRET_plus Version 3 for ZEN 2010. FRET (N-FRET, normal-
ized, Xia) data were generated, correcting for emission/excitation
crosstalk and normalizing for the concentration of donor and
acceptor. N-FRET was calculated using the Zeiss FRET plug-in
for HEK293 cells, while the Image-J FRET plug-in was utilized
for the IMR-32 cells, hence the slight differences in the
appearance of the FRET signals in the images.
FLAG Co-immunoprecipitation
HEK293 cells were utilized for this study as they share many
similarities and features with neuronal cells [29]. Only HEK293
cells were subjected to co-immunoprecipitation due to ease of
transfection. Cells transfected with pCIneo-moLRP::FLAG,
pCDNA3.1APPwt or pEGFP-PS1 were lysed 72 hours post-
transfection. Cell lysates from cells expressing LRP::FLAG were
mixed with those expressing either APP-GFP or PS1-GFP. Lysates
were subjected to a FLAG Co-immunoprecipitation assay (Sigma-
Aldrich) according to the manufacturer’s instructions and results
were analysed via immunoblotting.
Interactions between LRP/LR and AD Proteins
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Immunoblotting
Co-immunoprecipitation assay eluates were assessed using
immunoblotting. LRP::FLAG was detected using anti-FLAG
(mouse monoclonal IgG antibody) (1:5000) (Sigma-Aldrich) and
Anti-mouse HRP antibody (1:5000) (Sigma-Aldrich). APPwt was
detected using a rabbit monoclonal (Y188) antibody to Amyloid
beta Precursor Protein (Abcam) (1:3000) and PS1-GFP was
detected using rabbit monoclonal (EP2000Y) antibody against
Presenillin 1 (Abcam) (1:3000). An anti-rabbit HRP antibody
(1:5000) (Sigma-Aldrich) was employed for the detection of the
rabbit primary antibodies. Immunodetection was performed with
SuperSignal West Pico Chemiluminescent Substrate and X-ray
film (both Thermo Scientific).
Results and Discussion
Interactions between c-secretase and LRP/LR
c-secretase is composed of 4 sub-units namely Presenilin 1 or 2
(PS1 or PS2), nicastrin, anterior pharynx defective 1 and
presenilin enhancer 2 [30]. The presenilin proteins form the
catalytic domain of the c-secretase complex as they contain two
aspartyl residues, within transmembrane domains 6 and 7, which
are responsible for the c-secretase cleavage of APP [31]. The 4
Figure 1. LRP/LR co-localises with PS1 of the c-secretase complex. (A) Co-localisation between PS1-GFP and LRP-dsRed is shown for HEK293
cells in the maximum intensity profile for PS1-GFP and LRP-dsRed. The 2D cytofluorogram confirms co-localisation as a diagonal is observed passing
through quadrant 3. A diagonal is indicative of a high degree of co-localisation. Line profile displaying the fluorescence intensities of the 2 colour
channels along a line of interest and reveals co-localisation occurring specifically within the cytoplasmic regions. Line profile reveals aligned spectra
suggestive of high degree of co-localisation. (B) SR-SIM reveals that PS1-GFP and LRP-dsRed show a high degree of co-localisation in HEK293 cells. A
diagonal passes through quadrant 3 of the 2D cytofluorogram suggesting that there is still a high degree of co-localisation between the 2 proteins at
this resolution (80 nm). Scale bar: 5 mm. (C) SR-SIM reveals that co-localisation between LRP-dsRed and PS1-GFP is maintained in IMR-32 cells,
although the 2D cytofluorogram is skewed by the differences in transfectability with the different plasmids. Scale bars: 5 mm.
doi:10.1371/journal.pone.0100373.g001
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subunit complex is found to function predominantly within
cholesterol- and sphingolipid-rich lipid raft microdomains of
membranes, most notably those of the plasma membrane [32],
trans-Golgi Network (TGN) as well as endosomes [33]. The
cellular localisations of LRP/LR are limited to these same regions
and the presence of this protein has also been noted in the Golgi
apparatus [34]. The co-localisation observed from the maximum
intensity projection between PS1-GFP and LRP-dsRed supports
Figure 2. LRP/LR interacts with PS1 of the c-secretase complex. (A)(i) FRET analysis with PS1-GFP donor and LRP-dsRed acceptor in HEK293
cells. Distinct FRET signal is detected on the normalized FRET scale. Scale bar: 20 mm. (ii) Enlarged view of single cell from (i) showing that energy is
transferred in the cytoplasmic and plasma membrane regions of the cell. (iii) Enlarged view from cell in (i) showing FRET signal occurs in perinuclear
membrane. (B) FRET analysis between PS1-GFP donor and LRP-dsRed acceptor performed on IMR-32 cells. Blue FRET signal is detected in the
normalised FRET panel indicating an interaction is present between the two proteins. Scale bar: 5 mm. (C) FLAG co-immunoprecipitation assay was
performed utilizing lysates of HEK293 cells transfected with LRP::FLAG and PS1-GFP. Immunoblot performed using rabbit monoclonal antibody
(EP2000Y) for Presenillin 1. Lane (1) Non transfected cell lysates, (2) cell lysates expressing GFP alone, (3) cell lysates expressing PS1-GFP, (4) FLAG co-
immunoprecipitation eluate of assay performed using cell lysates expressing LRP::FLAG and PS1-GFP. Detected bands are 36 kDa indicating PS1
dimers and not PS1-GFP.
doi:10.1371/journal.pone.0100373.g002
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the notion that LRP/LR and c-secretase appear to be located in
similar cellular regions and compartments in HEK293 cells
(Figure 1A). The 2D cytofluorogram accompanying the maxi-
mum intensity projection shows a clear diagonal passing through
quadrant 3, indicating a high degree of co-localisation between
the signal in the green and red channels which results in the
observed yellow pattern of co-localisation. The line profile
obtained from the maximum intensity projection of the Z-stack
analysis between PS1-GFP and LRP-dsRed (Figure S1 in File S1)
reveals that the spectra are well aligned and fluorescence intensity
is strongest in the cytoplasm and plasma membrane. Due to the
limited resolving power dictated by the wavelength utilized in
laser scanning confocal microscopy, co-localisation does not
necessitate functional protein – protein interactions. This can in
part be overcome by an SR-SIM approach, which provides a
resolution limit of approximately 80 nm (compared to the
200 nm resolution limit of laser scanning microscopy). Figure 1B
reveals that even when SR-SIM is employed, a high degree of co-
localisation is still maintained between these two proteins,
suggesting that these proteins are indeed in close proximity to
one another in HEK293 cells. The expression of both PS1-GFP
and LRP-dsRed is even more distinctly defined within the
cytoplasm and on the plasma membrane when observed at this
resolution. Figure 1C illustrates that co-localisation between PS1-
GFP and LRPdsRed is also maintained in the IMR-32 cells in
similar subcellular locations as in the HEK293 cells. The lack of a
clear diagonal in the 2D cytofluorogram is as a result of differing
transfectability of the cells depicted in the image. As indicated,
only one of the cells was successfully co-transfected with both
PS1-GFP and LRPdsRed and this is where co-localisation is most
evident. In order to further assess whether this co-localisation is
due to protein-protein interactions, Fo¨rster Resonance Energy
Transfer (FRET) was employed as in this technique, the donor
and acceptor have to be within a proximity of 1–10 nm to induce
FRET. A well defined FRET signal is observed in the normalized
FRET scale panel (Figure 2A (i)), strongly suggesting protein-
protein interaction, and not only co-localisation between c-
secretase and LRP/LR. This interaction appears to take place
primarily in the cytoplasm and membrane region as revealed by
the FRET signal distribution pattern, clearly observed in
Figure 3. b-secretase fails to co-localise with LRP/LR at high resolutions. (A) Maximum intensity profile obtained from Z-stack analysis
reveals strong cytoplasmic co-localisation between BACE1-GFP and LRP-dsRed in HEK293 cells. Diagonal in 2D cytofluorogram indicates high degree
of co-localisation, as is confirmed by the line profile. (B) SR-SIM analysis of HEK293 cell expressing BACE1-GFP and LRP-dsRed. No co-localisation
occurs between these proteins. The 2D cytofluorogram confirms the absence of co-localisation as there is no signal detected in quadrant 3. Scale bar:
5 mm. (C) SR-SIM employing IMR-32 cells reveals a lack of co-localisation between LRPdsRed and BACE1-GFP. Scale bars: 5 mm.
doi:10.1371/journal.pone.0100373.g003
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Figure 2A (ii), which shows a close up of the FRET signal
obtained within an individual cell. LRP/LR and PS1 may be also
interacting in the perinuclear region of the cell, shown in
Figure 1C (iii). Furthermore, FRET was also observed in IMR-32
cells as indicated by the blue FRET signals observed in the
normalised FRET panel of Figure 2B, confirming the likelihood
of an interaction between PS1 and LRP. Based on these results, it
is highly likely that a direct interaction does exist between LRP/
LR and the PS1 subunit of the c-secretase. In order to validate
this, FLAG co-immunoprecipitation was performed using
LRP::FLAG and PS1-GFP (Figure 1D) in HEK293 cells. PS1 is
clearly detected in the FLAG co-immunoprecipitation assay
eluate, denoting that PS1 has bound to LRP::FLAG (Figure 1D,
lane 4). PS1 was detected within all of the control lanes, thus the
protein visualized is certainly cellular PS1 and not PS1-GFP. The
band is seen at 36 kDa which confirms that the proteins detected
are most likely the homo-dimer of PS1 [35,36], as the expected
band size for PS1 is 18 kDa. This co-immunoprecipitation
finding further substantiates the FRET data by confirming the
interaction between LRP/LR and PS1. These findings also
suggest an explanation for the altered APP processing observed
upon the blockage and knockdown of LRP/LR [22], as these
treatments may be interfering in or hampering the interaction
between LRP/LR and c-secretase. Further investigation is
required to determine the binding sites involved in the interaction
between these two proteins, in order to elucidate the role of the
interaction between LRP/LR and PS1 in the context of AD
pathology.
Interactions between b-secretase and LRP/LR
b-secretase (also known as BACE1 - b-site APP cleaving
enzyme) is a transmembrane aspartic protease which is predom-
inantly localised in the Golgi and trans-Golgi network (TGN), as
well as in endosomes, where a slightly acidic pH provides the
optimal environment for APP cleavage [37]. Initial reports
suggested not only co-localisation between LRP/LR and b-
secretase on the cell surface, but also that these two proteins
interacted, as shown by co-immunoprecipitation [22]. The
findings presented in Figures 3 and 4 help to further understand
the nature of the possible interactions between b-secretase and
LRP/LR, where the maximum intensity projection (Figure 3A)
constructed from Z-stack images (Figure S2 in File S1) shows
strong co-localisation between the 2 proteins within the cellular
cytoplasm – this most likely occurring in the endosomes. This is
further corroborated by the line profile in which the lines
representing the intensity of BACE1-GFP and LRP-dsRed are
not only aligned, but also show the highest fluorescence intensities
within the cytoplasm. However, when SR-SIM was employed, co-
localisation was lost between LRP/LR and b-secretase, implying
the proteins are situated approximately 100–200 nm from each
other in both HEK293 (Figure 3B) and IMR-32 cells (Figure 3C).
This diminishes the likelihood of a direct interaction between these
two proteins, due to the spatial separation observed. The FRET
findings further confirm this, as no FRET occurred between the
BACE1-GFP donor and the LRP-dsRed acceptor within both the
HEK293 and IMR-32 cells (Figure 4A and B respectively). These
findings infer that the interaction that was reported between LRP/
Figure 4. b-secretase doesn’t interact with LRP/LR as revealed by FRET analysis. (A) FRET did not occur between the donor BACE1-GFP and
the acceptor LRP-dsRed in HEK293 cells as no signal was detected on the normalized FRET scale. Scale bar: 20 mm. (B) Similarly, a lack of interaction
was detected between LRPdsRed and BACE1-GFP when IMR-32 cells were used. Scale bars:10 mm.
doi:10.1371/journal.pone.0100373.g004
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LR and b-secretase [22] is most likely an indirect interaction
mediated by another cellular protein, as whole cell lysates were
employed for co-immunoprecipitation studies. LRP/LR and b-
secretase share several binding/interaction partners, the most
notable one being PrPc [38,39]. It is possible that since LRP/LR is
the cellular receptor for PrPc and plays an important role in
regulating endocytosis [40] and propagation [41] of PrPc, it may
indirectly influence b-secretase activity. Another factor that may
have led to the co-immunoprecipitation between LRP::FLAG and
b-secretase is heparan sulphate proteoglycan (HSPG). Binding
sites for HSPG have been located on LRP/LR and are implicated
in regulating the interaction between LRP/LR and PrPc [42].
Extensive studies have been performed on heparan sulphate, and
analogues thereof, as therapeutic options for Alzheimer’s Disease.
Most notably this proteoglycan is seen to regulate b-secretase
activity and significantly reduce the shedding of Ab [43,44,45].
Thus, HSPG is another molecule which could be responsible for
the indirect interaction suggested by the co-immunoprecipitation
observed between LRP/LR and b-secretase [22], as it interacts
with both of these proteins. PrPc and HSPG could also be
responsible for the decrease in sAPPb (the cleavage product of b-
secretase) levels upon anti-LRP/LR antibody and shRNA
treatment [22] since they may be directly affected by these
treatments, resulting in an indirect effect on b-secretase activity
which they are seen to regulate.
Interactions between APP and LRP/LR
Initially, an interaction between LRP/LR and APP seemed
highly likely and would provide an explanation for the effects seen
on Ab shedding upon antibody and shRNA treatment of LRP/LR
[22]. Initial findings also suggested that these two proteins co-
localise when detected on non-permeabilised cells (indicating cell
surface co-localisation) and within the cells (indicating intracellular
co-localisation) [22]. Z-stacking was performed to further verify
the sub-cellular localisations of these proposed interactions and to
assess whether they were maintained throughout the cell (Figure
S3 in File S1). Maximum intensity projections were constructed
from the images obtained via Z-stacking and revealed a degree of
overlap between the LRP-dsRed with APP-GFP signal as
indicated by the resulting yellow colour when the images are
Figure 5. Co-localisation occurs between APP and LRP/LR. (A) Maximum intensity profile obtained from Z-stack analysis revealing co-
localisation between APP-GFP and LRP-dsRed in the cytoplasm of HEK293 cells. 2D cytofluorogram reveals the co-distribution of green (APP-GFP) and
red (LRP-dsRed) pixels. (B) SR-SIM analysis reveals that APP-GFP and LRP-dsRed co-localise to a lesser extent in HEK293 cells. Co-localisation is highest
at the cell surface and in limited cytoplasmic locations. Scale bar: 10 mm. (C) Similar co-localisation is observed in IMR-32 cells. Scale bar: 5 mm.
doi:10.1371/journal.pone.0100373.g005
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merged (Figure 5A). The line profile constructed from the
maximum intensity projection of the Z-stack between APP-GFP
and LRP-dsRed, shows the intensity of the red and green
fluorescence along the line passing through the HEK293 cell of
interest. These findings suggest a complete spatial overlap between
the fluorescence observed in both the green and red channels. The
observed intensity of both fluorescent channels is highest in the
cytoplasm which further confirms the initial assumption that
LRP/LR and APP are located in similar cellular locations.
Findings in literature further support these data as it is known that
APP is transported to the plasma membrane, where it is
subsequently endocytosed from lipid raft regions into early
endosomes [46,47]. Moreover, LRP/LR is known to also be
located in the lipid raft [48] as well as in early endosomes [40].
Our SR-SIM data indicates a lower degree of co-localisation
between APP and LRP both in HEK293 (Figure 5B) and IMR-32
cells (Figure 5C), which appears to be confined to the plasma
membrane and certain cytoplasmic regions, presumably the
endosomes in which both APP and LRP/LR are localised. This
suggests the proteins are indeed in close proximity to one another,
resulting in the distinct co-localisation pattern. FRET was
employed to further assess the viability of an interaction between
LRP/LR and APP. This analysis revealed that no FRET occurred
between APP-GFP and LRP-dsRed, since signal detection was
lacking on the normalized FRET scale for both HEK293
(Figure 6A) and IMR-32 cells (Figure 6B). These findings indicate
that no interaction takes place between APP and LRP/LR at this
1–10 nm scale. FLAG Co-immunoprecipitation using a FLAG
Figure 6. APP-GFP and LRP/LR fail to interact. FRET was performed using APP-GFP as donor and LRP-dsRed as acceptor in HEK293 cells. No
FRET signal was observed on the normalized FRET scale indicating that no energy transfer occurred from BACE1-GFP to LRPdsRed. Scale bar: 20 mm.
(B) Similarly, no FRET was observed between APP-GFP and LRPdsRed in IMR-32 cells. Scale bar: 10 mm. (C) FLAG co-immunoprecipitation analysis
using lysates of HEK293 cells expressing LRP::FLAG and APPwt. Anti-APP antibody (Y188) was utilised for detection. Lane (1) cell lysates containing
LRP::FLAG, (2) cell lysate with overexpressed APPwt (APP positive control), (3) FLAG co-immunoprecipitation assay eluate of assay performed using
APPwt overexpressing cell lysates but no LRP::FLAG (i.e. Anti-FLAG M2 bead binding control), (4) BAP fusion protein (positive control for FLAG co-
immunoprecipitation assay), (5) empty lane, (6) FLAG co-immunoprecipitation assay eluate of sample with LRP::FLAG and APPwt, (7–9) Wash fractions
1–3 of APPwt+LRP::FLAG FLAG co-immunoprecipitation assay post overnight binding step.
doi:10.1371/journal.pone.0100373.g006
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tagged LRP/LR variant (LRP::FLAG) further confirmed these
results as APP was not detected in the eluate of the assay
(Figure 6C, lane 6). The results obtained from figure 3 collectively
suggest that although LRP/LR and APP are found in similar
cellular locations in which they co-localise, the proximity between
them is still present when SR-SIM is employed (i.e. 80 nm), but
lost at the nanometer scale required for FRET to take place, thus
indicating that it is highly unlikely for any interaction to occur
between these two proteins.
Interactions between GFP and LRP/LR
GFP was used a negative control for these studies as it failed to
co-localise with LRP/LR. This is evidenced by the maximum
intensity projection (Figure 7A) obtained from Z-stack analysis
(Figure S4 in File S1). The 2D cytofluorogram reveals a complete
absence of a diagonal passing through quadrant 3 confirming the
lack of co-localisation between GFP and LRP-dsRed. The line
profile obtained shows two distinct patterns of fluorescence lacking
any co-alignment of the red and green channels further confirming
the low degree of co-localisation between these proteins. These
findings also validate the co-localisation seen between LRP and
APP, b- and c-secretase, as the observed co-localisation is as a
result of the proximity of LRP/LR to the AD proteins and not
simply due to the GFP labels.
Conclusions
In light of this study, we have found that LRP/LR is seen to co-
localise with APP, b- and c-secretase both on the cell surface and
intracellularly within the cytoplasm. This co-localisation is limited
to 200 nm when observed for BACE1 and LRP/LR, to 80 nm
between APP and LRP/LR and less than 10 nm for LRP/LR and
PS1. These results reveal a novel interaction between LRP/LR
and the PS1 catalytic subunit of the c-secretase complex (as
confirmed by co-immunoprecipitation) and suggest that the
previously observed interaction between LRP/LR and BACE1 is
likely an indirect interaction only. These findings cumulatively
highlight the role of LRP/LR in Alzheimer’s Disease.
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0022-2836/$ - see front matter © 2010 EEnterocytes, a major cell population of the intestinal epithelium, represent
one possible barrier to the entry of prions after oral exposure. We
established a cell culture system employing enterocytes from different
species to study alimentary prion interaction with the 37-kDa/67-kDa
laminin receptor LRP/LR. Human, bovine, porcine, ovine, and cervid
enterocytes were cocultured with brain homogenates from cervid, sheep,
and cattle suffering from chronic wasting disease (CWD), scrapie, and
bovine spongiform encephalopathy (BSE), respectively. PrPCWD, ovine
PrPSc, and PrPBSE all colocalized with LRP/LR on human enterocytes.
PrPCWD failed to colocalize with LRP/LR on bovine, porcine, and ovine
enterocytes. Ovine PrPSc colocalized with the receptor on bovine
enterocytes, but failed to colocalize with LRP/LR on cervid and porcine
enterocytes. PrPBSE failed to colocalize with the receptor on cervid and
ovine enterocytes. These data suggest possible oral transmissibility of CWD
and sheep scrapie to humans and may confirm the oral transmissibility of
BSE to humans, resulting in zoonotic variant Creutzfeldt–Jakob disease.
CWD might not be transmissible to cattle, pigs, and sheep. Sheep scrapie
might have caused BSE, but may not cause transmissible spongiform
encephalopathy in cervids and pigs. BSE may not be transmissible to
cervids. Our data recommend the enterocyte model system for further
investigations of the intestinal pathophysiology of alimentary prion
infections.
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Transmissible spongiform encephalopathies
(TSEs) are a group of fatal neurodegenerative
disorders affecting both humans and animals. In
contrast to other “protein misfolding diseases” such
as morbus Alzheimer's disease or Huntington's
disease, prion diseases may be infectious. According
to the protein-only hypothesis,1,2 scrapie prion PrPSc,
an abnormal form of cellular prion PrPc, is thought to
be the major infectious constituent of these diseases
that accumulates in the central nervous system,
resulting in neuronal loss and spongiform degener-
ation in the brain.
TSEs can be transmitted within a single animal
species (intraspecies) or among different species
(interspecies). The oral transmission of prion disease
has been widely observed; for example, bovine
spongiform encephalopathy (BSE) has been sug-
gested to originate from the consumption, by cattle,
of sheep-scrapie-contaminated food.3 In addition, it
has been widely accepted that ingestion of BSE-
infected meat resulted in the development of human
variant Creutzfeldt–Jakob disease,4 showing the
transmissibility of BSE prions to humans. Extensive
experimental studies have been conducted on the
transmission of prions to other animal species,5–7
and the results demonstrated altered incubation
times and survival or an inability to transmit the
disease.8–11 This phenomenon has been termed the
“species barrier.” In addition to the significance of
the variety of prion strains and differences in the
prion protein (PrP) structure, the route of infection is
also an important factor that must be taken into
consideration. This has been illustrated by the fact
that pigs are intracerebrally and intraperitoneally
infectable with the BSE agent, whereas oral infection
and disease transmission have failed.9 Currently,
BSE and variant Creutzfeldt–Jakob disease repre-
sent orally acquired TSEs, but little is known about
the mechanisms underlying the infection process.
After ingestion of prion-contaminated food, the
TSE-causing agent has to cross the intestinal
epithelial cell barrier, where both M-cells (microfold
cells)12 and enterocytes are proposed to mediate
prion uptake and transport.13,14 Enterocytes consti-
tute the major cell population in the intestine15
expressing PrPc on their surface.16 A protease-
resistant PrP is transcytosed across human
enterocytes independently of endogenous PrPc
expression,17 suggesting an alternative receptor-
mediated prion uptake mechanism. Furthermore,
the 37-kDa/67-kDa laminin receptor LRP/LR is
expressed on the apical brush border of entero-
cytes18 and has been shown to be responsible for the
binding of both PrPc19 and infectious prions.20
Moreover, recent studies on human enterocytes
(Caco-2/TC7) revealed LRP/LR-dependent binding
and internalization of bovine prions (PrPBSE) thathave been impeded by preincubation with the
anti-LRP/LR-specific antibody W3.14 W3 has been
reported to be a therapeutic tool in a murine
scrapie model,21 and single-chain antibodies
directed against the LRP/LR interfered with
scrapie propagation22,23 and may potentially
serve as therapeutic antibodies (for review, see
Refs. 24–27).
The spread of chronic wasting disease (CWD), a
prion disease affecting free-range cervids, represents
a severe risk in some regions of North America and
parts of Canada due to hunting of this game and
consumption of infected meat. Although transmis-
sion experiments with transgenic mice propose a
species barrier to CWD prions in humans,28 oral
transmission of CWD to humans via contaminated
food cannot be excluded.
In the present study, we investigated the in-
testinal pathophysiology of alimentary prion infec-
tions by determining the prion uptake capacity of
enterocytes.Results
Cell surface LRP/LR levels on human and animal
enterocytes
In view of the fact that LRP/LR has been identified
as a receptor for PrPc19 and PrPSc,20 respectively, we
examined whether the cell surface level of the
receptor potentially correlates with the PrP uptake
capacity of enterocytes. Cell surface LRP/LR levels
of five different enterocyte species have been
determined by fluorescence-activated cell scanning
(FACS) analysis (Fig. 1). A high LRP/LR level has
been observed on cervid (66.34%; Fig. 1a), human
(72.01%; Fig. 1b), and bovine (40.78%; Fig. 1d)
enterocytes, respectively, in comparison to relatively
low LRP/LR levels on porcine (16.05%; Fig. 1c) and
ovine (3.69%; Fig. 1e) enterocytes (Table 1).
PrPCWD colocalizes with LRP/LR on human
enterocytes
To investigate whether CWD prions might bind
via LRP/LR, we cultured human enterocytes (Caco-
2/TC7) in the absence or in the presence of CWD-
infected brain homogenates and stained them for
LRP/LR (polyclonal antibody W3) and PrPCWD
(anti-PrP antibody 8G8), respectively. Immunofluo-
rescence microscopy, followed by two-dimensional
(2D) cytofluorogram analysis (Fig. 2, histograms,
bottom), revealed that CWD brain-derived PrP
colocalizes with LRP/LR on the cell surface of
Caco-2/TC7 cells (Fig. 2e–g). PrPCWD colocalized
with LRP/LR on cervid enterocytes (Fig. 2a–c). In
contrast, no colocalization of LRP/LR and PrPCWD
Fig. 1. Detection of cell surface LRP/LR levels on human and animal enterocytes by FACS analysis. (a) Cervid (DWM-R),
(b) human (Caco-2/TC7), (c) porcine (IPEC-J2), (d) bovine (FBJ), and (e) ovine (DOMI-1) enterocytes were analyzed for
LRP/LR surface level. LRP/LR levels were detected using the anti-LRP/LR antibody scFv S18 (blue curve). Anti-C9 scFv
antibody was employed as negative control (green curve). Twenty thousand cells were counted per experiment. One of
five representative graphs is shown for each cell line.
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124(Fig. 2i–k) on porcine enterocytes was observed.
Similarly, both bovine and ovine enterocytes failed
to display surface colocalization of PrPCWD with
LRP/LR (Fig. 2m–o and q–s). In order to exclude the
possibility that the PrP fluorescence signal resulted
from any unspecific antibody recognition, we
stained cells with the 8G8 antibody in the absence
of brain homogenates (Fig. 2d, h, l, p, t; Table 1).
Both ovine PrPSc and PrPBSE colocalize with
LRP/LR on human and bovine enterocytes
Human (Caco-2/TC7), cervid (DWM-R), bovine
(FBJ), porcine (IPEC-J2), and ovine (DOMI-1) enter-
ocytes were cultured in the presence of brain
homogenates from ovine-scrapie-infected animals
(ovine PrPSc). Staining of LRP/LR (by anti-LRP/LR
W3) and ovine PrPSc (by 8G8), respectively, revealed
colocalization of PrPSc with LRP/LR on the cell
surface of Caco-2/TC7 cells (Fig. 3e–g, 2D cyto-
fluorogram analysis, bottom). Furthermore, ovine
PrPSc colocalizes with LRP/LR on bovine entero-Table 1. Colocalization of infectious PrPs of different specie
enterocytes
Cervid (DWM-R) Human (Caco
PrPCWD + +
Ovine PrPSc − +
PrPBSE − +
Cell surface LRP/LR levels (%) 66.34 72.01cytes (Fig. 3m–o). In contrast, ovine PrPSc (Fig. 3a–c)
did not colocalize with LRP/LR on cervid enter-
ocytes. According to 2D cytofluorography, sheep
PrPSc failed to colocalize with LRP/LR on porcine
enterocytes (Fig. 3i–k). Moreover, intraspecies bind-
ing analysis revealed that ovine PrPSc demonstrates
merely an “in-part” colocalization with LRP/LR on
ovine enterocytes (DOMI-1) (Fig. 3q–s; Table 1).
Human, cervid, bovine, ovine, and porcine
enterocytes, respectively, were incubated with
BSE-infected brain homogenate (PrPBSE) and
stained with antibodies W3 and 8G8, respectively,
for LRP/LR and PrPBSE. Immunofluorescence stud-
ies, followed by 2D cytofluorogram analysis,
revealed colocalization of LRP/LR and PrPBSE on
Caco-2/TC7 cells (Fig. 4e–g). PrPBSE colocalized
with the laminin receptor on the cell surface of
bovine enterocytes (Fig. 4m–o). In contrast, accord-
ing to 2D cytofluorogram analysis, no colocalization
of PrPBSE and LRP/LR on cervid and ovine
enterocytes (Fig. 4a–c and q–s, respectively) was
detected. PrPBSE, however, colocalized in part withs with LRP/LR on the cell surface of human and animal
-2/TC7) Porcine (IPEC-J2) Bovine (FBJ) Ovine (DOMI-1)
− − −
− + In part
In part + −
16.05 40.78 3.69
Fig. 2. Binding and colocalization of PrPCWD with LRP/LR on human and cervid enterocytes. The 37-kDa/67-kDa
LRP/LR was detected with the anti-LRP/LR antibody W3 on (a) cervid (DWM-R), (e) human (Caco-2/TC7), (i) porcine
(IPEC-J2), (m) bovine (FBJ), and (q) ovine (DOMI-1) enterocytes. PrPCWD was detected with the anti-PrP antibody 8G8 on
(b) cervid, (f) human, (j) porcine, (n) bovine, and (r) ovine enterocytes. Merging of both stainings is shown on (c) cervid, (g)
human, (k) porcine, (o) bovine, and (s) ovine enterocytes, respectively. Two-dimensional cytofluorograms showing the
joint distribution of green and red and the area of colocalization representing the intersection line are plotted for each
double-stained image (2D cytofluorogram, lower panels). For control (d, h, l, p, t), PrP staining was carried out by
incubating cells with 8G8 in the absence of brain homogenates. All cells were incubated with a total concentration of 50 μg
of protein from corresponding homogenates.
296 Prion–LRP/LR Interactions on Enterocytes
125LRP/LR on porcine enterocytes (Fig. 4i– k; Table 1).
We want to highlight that PrPBSE and ovine PrPSc
colocalize with LRP/LR on human enterocytes to a
similar extent (compare Figs. 3 and 4).Discussion
We established a cell culture model, including
enterocytes from different species with heteroge-
neous morphology, to study the intestinal patho-
physiology of alimentary prion infections by
determining the prion uptake capacity of entero-
cytes. The laminin receptor plays an important role
in prion propagation and presents a target for
therapeutic approaches (for review, see Refs. 24–27
and 29). Brain homogenates originating from ani-
mals suffering from prion diseases were applied to
human and animal enterocytes, respectively, and
LRP/LR-dependent PrP binding was analyzed byimmunofluorescence microscopy. Enterocytes rep-
resent the model of choice, as this cell type has been
demonstrated to bind and internalize BSE prions via
the 37-kDa/67-kDa LRP/LR.14
Colocalization of BSE prions with LRP/LR on
Caco-2/TC7 cells confirmed that endocytosis of
bovine prions by Caco-2/TC7 cells is LRP/LR
dependent,14 providing evidence for the important
role of enterocytes, in conjunction with LRP/LR, in
the oral transmission of BSE to humans. The lack of
colocalization of BSE prions with LRP/LR on cervid
enterocytes possibly suggests that BSE might not be
transmissible to cervids. We could not detect a
colocalization of BSE prions with LRP/LR on ovine
enterocytes, which might suggest that BSE may not
be orally transmitted to sheep. However, some
reports indicate an oral transmission of BSE to
sheep,30-32 which might be dependent on the
genotype of the recipient.33 LRP/LR only exhibited
an “in-part” colocalization with PrPBSE on porcine
Fig. 3. Binding and colocalization of ovine PrPSc with LRP/LR on human and bovine enterocytes. The 37-kDa/67-kDa
LRP/LR was detected on (a) cervid (DWM-R), (e) human (Caco-2/TC7), (i) porcine (IPEC-J2), (m) bovine (FBJ), and (q)
ovine (DOMI-1) enterocytes by the anti-LRP/LR antibodyW3. Ovine PrPSc was detected by the anti-PrP antibody 8G8 on
(b) cervid, (f) human, (j) porcine, (n) bovine, and (r) ovine enterocytes. Merging of corresponding micrographs is shown
for (c) cervid, (g) human, (k) porcine, (o) bovine, and (s) ovine enterocytes. Two-dimensional cytofluorograms showing
joint distribution and colocalization are plotted (lower panels). All cells were incubated with a total concentration of 50 μg
of protein. For control (d, h, l, p, t), cells were stained with 8G8 in the absence of infected brain homogenates.
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126enterocytes, thereby providing a potential explana-
tion for the failure to induce porcine infection with
BSE by the oral route.9
The fact that both PrPCWD and ovine PrPSc
colocalize with LRP/LR on human enterocytes
possibly suggests that PrPCWD and ovine PrPSc
may be orally transmitted to humans, potentially
giving rise to new zoonotic diseases. In contrast,
PrPCWD failed to colocalize with LRP/LR on bovine,
ovine, and porcine enterocytes, suggesting that
PrPCWD may not be transmissible to sheep, cattle,
or pigs via the oral route.
Sheep scrapie prions colocalize with LRP/LR on
bovine enterocytes, supporting the sheep origin
hypothesis stating that BSE originated from the
oral consumption, by vegetarian sheep, of meat and
bone meal from cattle suffering from BSE.3 The
failure of colocalization between ovine PrPSc and
LRP/LR on cervid and porcine enterocytes may
suggest that sheep scrapie might not be orally
transmissible to elk, deer, and pigs. It has been
demonstrated very recently that prions are secretedinto the oral cavity of scrapie-infected sheep.34 This
finding suggests a possible oral intraspecies/inter-
species transmissibility of prions (for comment, see
Da Costa Dias and Weiss35). In light of our findings
(Table 1), we cannot exclude an oral transmission of
ovine PrPSc to humans and cattle; transmission to
the former may possibly result in another zoonotic
disease, whereas transmission to the latter confirms
the sheep origin hypothesis for the development of
BSE.3 It must be emphasized, however, that our
model system investigates colocalization of the
prion receptor LRP/LR with different prion species,
which does not necessarily allow for conclusions on
the oral transmissibility of prion disorders but rather
allows for inferences with regard to the intestinal
pathophysiology of prion diseases.
Observed differences in the colocalization of
prions to LRP/LR on the surface of species-specific
enterocytes might be due to the individual strain of
prion employed.
FACS analyses revealed that 72.01% of human
enterocytes, 66.34% of cervid enterocytes, 40.78% of
Fig. 4. Binding and colocalization of BSE prionswith LRP/LRonhuman andbovine enterocytes. (a–d)Cervid (DWM-R),
(e–h) human (Caco-2/TC7), (i–l) porcine (IPEC-J2), (m–p) bovine (FBJ), and (q–t) ovine (DOMI-1) enterocyteswere incubated
with BSE-infected brain homogenate (total protein concentration, 50 μg). LRP/LR was detected with the anti-LRP/LR-
specific antibodyW3 (a, e, i, m, q), and BSE PrPswere detectedwith the antibody 8G8 (b, f, j, n, r). Merging of corresponding
micrographs is shown for (c) cervid, (g) human, (k) porcine, (o) bovine, and (s) ovine enterocytes. Two-dimensional
cytofluorograms displaying the area of colocalization of the laminin receptor and BSE prions on the cell surface are plotted.
For control (d, h, l, p, t), cells were stained with 8G8 in the absence of infected brain homogenates.
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and 3.69% of ovine enterocytes, respectively, express
LRP/LR on the cell surface (Fig. 1; Table 1). Since no
convincing colocalization of PrPCWD, ovine PrPSc,
and PrPBSE with LRP/LR has been observed on
porcine and ovine enterocytes (revealing low LRP/
LR levels of 16.05% and 3.69%, respectively), we
speculate that a minimum level of LRP/LR on
enterocytes might be required for an efficient prion
infection by the oral route.
We cannot exclude the possibility that prions
might use alternative infection pathways, besides
the LRP/LR-mediated PrP internalization process,
to enter enterocytes such as M-cells,36 which might
also mediate prion uptake, further leading to prion
propagation in gut-associated lymphoid tissues.37
As recently demonstrated, BSE prions bind to and
become internalized by human enterocytes in an
LRP/LR-dependent manner.14 As shown in this
work, CWD and sheep scrapie prions also bind to
human enterocytes via LRP/LR. The importance ofthe laminin receptor as a target for therapeutic
approaches22,23,38,39 has already been demonstrated.
From our colocalization studies and the finding
that the anti-LRP/LR antibody W3 prevented the
binding of BSE prions to enterocytes,14 we
conclude that the laminin receptor LRP/LR may
play a vital role in the oral transmission of prion
diseases.
Our data recommend the enterocyte model system
for further studies investigating the intestinal path-
ophysiology of other alimentary prion infections.Materials and Methods
Isolation of primary ovine enterocytes
A female Leine sheep (N18 months) was euthanized by
intravenous injection of T61® and Narcoren®. A segment
of the duodenum distal to the pylorus was taken and
rinsed with Krebs–Ringer buffer to remove food particles.
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128Duodenal segments were digested in phosphate-buffered
saline (PBS) containing 0.8 U/ml collagenase, 0.8 U/ml
dispase, and 5 mM CaCl2 for 30 min at 37 °C. The mucosa
was scrapped off carefully from the underlying muscula-
ture and digested additionally for 10 min at 37 °C with
0.8 U/ml dispase and 5 mM CaCl2. Mucosal enterocytes
were separated from other cells by sequential filtration
through a 1000-μm sieve and a 300-μm sieve. The filtrate
was centrifuged at 200g for 5 min and washed in PBS with
100 U/ml penicillin/100 μg/ml streptomycin. The pellet
was resuspended in Medium 199 with Earle's salts, 2 mM
L-glutamine, 25 mM Hepes, 15% fetal calf serum (FCS),
and 50 μg/ml gentamicin (Gibco Invitrogen). Cell yield
and viability were determined by 0.4% trypan blue. About
4×105 to 6×105 cells/cm2 were seeded on 6-cm Petri
dishes in Medium 199.Tissue culture of enterocytes
Caco-2/TC7 cells (human enterocytes; provided by M.
Rousset) were grown in Dulbecco's modified Eagle's
medium (DMEM), 4500 mg/l D-glucose, 2 mM Glutamax,
20% FCS, 1% penicillin/streptomycin (P/S), and 1%
nonessential amino acids (NEAA; Gibco Invitrogen). FBJ
cells (bovine enterocytes; provided by R. Riebe) were
maintained in DMEM/minimum essential medium with
Hank's salts (1:1), 1000 mg/l D-glucose, 2 mM Glutamax,
10% FCS, 1% P/S, 1% NEAA (Gibco Invitrogen), and
500 mg/l NaHCO3. DWM-R cells (cervid enterocytes;
provided by R. Riebe) were cultured in Iscove's modified
Dulbecco's medium/F12 Nutrient Mix (1:1), 2 mM Gluta-
max, and 10%FCS (Gibco Invitrogen). IPEC-J2 cells (porcine
enterocytes) were cultured in DMEM/F12 Nutrient Mix
(1:1), 1000mg/l D-glucose, 2mMGlutamax, 5% FCS, 1%P/
S, 1%NEAA, 0.1% insulin–transferrin–selenium, and 5 ng/
ml epidermal growth factor (Gibco Invitrogen). After 2 days
of growth in Medium 199, adult enterocytes were cultured
in Iscove's modified Dulbecco's medium/F12 Nutrient Mix
(1:1), 2 mMGlutamax, and 10% FCS (Gibco Invitrogen). All
cell types were grown at 37 °C with 5% CO2.Brain homogenate preparation
Brains samples from infected cattle (BSE), white-tailed
deer (CWD), and sheep (scrapie) were homogenized to
20% (wt/vol) in PBS at 4 °C.Fluorescence-activated cell scanning
Cultured cells were detached with 1 mM PBS/ethyle-
nediaminetetraacetic acid, centrifuged at 1200 rpm at 4 °C,
and fixed in 4% paraformaldehyde (4 °C). The cell surface
LRP/LR levels of each cell type were stained by the single-
chain anti-LRP/LR antibody scFv S18.22 scFv C9, an
antibody against hepatitis B surface protein, was used as
negative control. Primary antibodies were diluted 1:50 in
FACS buffer (0.01% sodium azide, 20 mM ethylenedia-
minetetraacetic acid, and 2% FCS in 1× PBS) and incubated
for 1 h at 4 °C. After three washing steps, the cells were
incubated with the secondary antibody c-myc FITC (1:50;
Santa Cruz Biotechnology) and resuspended in FACS
buffer for analysis.Immunofluorescence microscopy
Cells were fixed with 4% paraformaldehyde and
permeabilized with 0.3% Triton X-100. The primary
antibody (8G8) and the secondary antibodies [Alexa
Fluor® 488 goat anti-mouse IgG (H+L) and Alexa Fluor®
633 goat anti-rabbit IgG (H+L); Molecular Probes and
Invitrogen] were diluted in PBS/0.3% Triton X-100. Cells
were incubated overnight at 4 °C with primary antibodies
(1:150), followed by incubation with secondary antibodies
(1:300). Immunofluorescence backgrounds were estimated
by the signal obtained in cells incubated with noninfec-
tious brain homogenates or by fluorescence of infected
cells when secondary antibodies were applied alone.
Examination was performed by confocal fluorescence
microscopy (Zeiss LSM 510).Acknowledgements
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Introduction
Angiogenesis, the formation of new blood vessels from pre-
existing capillaries[1], is a physiologically vital process involved in
embryonic development, wound healing; the female menstrual
cycle, tissue growth[1] and vascular remodeling.[2] This process is
highly regulated in healthy individuals. However, the de-regula-
tion of angiogenesis has been implicated in numerous diseases
including rheumatoid arthritis, ischemic heart and limb disease
and retinopathy.[1] Angiogenesis is also a vital event in tumour
growth and metastasis.[3]
The endothelial cells involved in the angiogenic process are
responsive to two sets of cellular signals namely: soluble factors and
cell signaling events transduced through the interactions with the
extracellular matrix.[4,5] Soluble pro-angiogenic factors include:
basic fibroblast growth factor (bFGF), transforming growth factor-
a (TGFa), platelet derived endothelial cell growth factor (PDGF),
insulin-like factors (IGF1 and IGF2) and tumour necrosis factor a
(TNFa)[6] all of which are constituents of MatrigelTM, the
basement reconstituent employed in angiogenesis investigations.
Furthermore, the vascular endothelial growth factor (VEGF), is
the principle angiogenic inducer.[6,7,8] Angiogenesis is a multi-
step process involving endothelial cell activation and subsequent
degradation of the surrounding extracellular matrix or basal
lamina.[1] This results in protease activation and subsequent
release of pro-angiogenic factors/ peptides which in turn stimulate
endothelial cell migration towards the angiogenic signal, prolifer-
ation and differentiation.[1,3]
Tumour angiogenesis involves tumour blood vessels that
support continued tumour growth.[2] Once tumours exceed a
certain maximal diameter, diffusion of oxygen and nutrients
become limited and the resultant hypoxia and nutrient deprivation
results in the secretion of growth factors and ultimately the onset of
angiogenesis and subsequent tumour progression. Thus tumour
cells affect vascular endothelial cells by paracrine mechanisms.[9]
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Owing to the crucial role of angiogenesis in tumour progression
and metastasis, selective inhibition of tumour angiogenesis has
become a promising approach in anti-cancer therapy.[10]
As previously stated, cell-ECM interactions are imperative in
angiogenesis and the basement membrane is of particular
importance in this regard. Laminins are cross-shaped trimeric
glycoproteins critical in the maintenance of basal membrane
structure.[3,11] Of the 15 available laminin isoforms- laminin-1
(a1b1e`E`1) is of particular interest in angiogenesis as it mediates
endothelial cell adhesion and differentiation[1], tube formation
and furthermore modulates the activity of endostatin, an
angiogenic inhibitor that blocks tube formation[12]. This laminin
isoform is the major glycoprotein component of MatrigelTM. [3]
The a1 chain of laminin-1 contains an IKAV (isoleucine, lysine,
alanine and valine) site which promotes collagenase, plasminogen
and metalloprotease activity.[3,13,14] The activation of these
enzymes results in matrix degradation thereby permitting cellular
detachment and migration and the release of matrix-sequestered
pro-angiogenic factors, all of which are central to successful tube
formation.[3]
A central receptor in mediating the cell growth, movement and
differentiation properties of laminin is the non-integrin 37kDa/
67kDa laminin receptor (LRP/LR) which binds to the ECM
component with high affinity.[15,16] LRP/LR possess two
laminin-1 binding sites, a direct binding domain termed a peptide
G sequence (161aa–180aa) and an indirect binding domain
located towards the carboxyl-terminus (205aa–229aa).[15,16] This
type-II transmembrane receptor is overexpressed in numerous
cancers (gastric[17], breast[18], cervical[19], colon[20], colorec-
tal[21], lung[22], ovarian, pancreatic[23] and prostate[24]) ,
correlates with cancer aggressiveness and it has been proposed that
LRP/LR may be indicative of tumour prognosis.[23,24,25] LRP/
LR downregulation has been shown to induce apoptosis and
potentially hamper proliferation in cancer cell lines.[26] LPR/LR
is implicated in numerous tumourigenic processes which are akin
to angiogenesis namely (tumour) cell adhesion, invasion[27,28],
viability, proliferation and migration.[15,16] Within classical
tumour biology these processes are required for the cell invasion
and the formation of metastasis.
Moreover, it is the interaction between LRP/LR and laminin-1
that results in proteolytic activation, a process central to
angiogenesis, as previously discussed. Furthermore, a role for
LRP/LR in tube formation has previously been proposed.[4] This
study aimed to investigate the angiogenic blocking effect of anti-
LRP/LR specific antibodies on the in vitro angiogenesis of the
primary endothelial cell line, human umbilical vein endothelial
(HUVE) cells.
Materials and Methods
Cell culture and conditions
HUVE cells (Invitrogen, Gibco) were cultured in Medium 200
(Invitrogen, Gibco) supplemented with Low Serum Growth
supplement (LSG) (Invitrogen, Gibco) such that the resultant
media consisted of: 2% (v/v) fetal bovine serum; 1 mg/ml
hydrocortisone; 10 ng/ml human epidermal growth factor
(EGF); 3 ng/ml basic fibroblast growth factor (bFGF) and
10 mg/ml heparin.
Reagents and Antibodies
MatrigelTM, employed to induce tube formation is derived from
the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, serving as a
reconstituted basement membrane, was obtained from BD
Biosciences.
Polyclonal anti-LRP/LR antibody W3 was produced as
described previously by Rieger et al., (1997). [29]
IgG1-HD37 was recombinantly produced in a mammalian
expression system as described by Zuber et al., (2008).[27] In brief,
human embryonic kidney cells (HEK293 EBNA) expressing the
EBNA-1 gene were transiently co-transfected, by calcium phos-
phate methodology, with plasmids encoding the heavy (p EU1.2
VH_HD37) and light chains (p EU4.2 VL_HD37) of the anti-
Figure 1. Detection of cell surface 37kDa/ 67kDa LRP/LR and CD31 on HUVE cells by immunofluorescence microscopy. HUVE cells
were seeded on coverslips and allowed to proliferate until 30–40% confluency was reached. Non-permeabilised cells were fixed and were indirectly
labeled with either an anti-human FITC (fluorescein- isothiocyanate) coupled antibody (Cell Lab) for LRP/LR detection (A) or anti-CD31-FITC antibody
(Sigma-Aldrich) (D) . CD31 is an endothelial cell marker and serves as a positive control. Cells were subsequently stained with the Hoechst 33342
nuclear stain (Sigma-Aldrich) (B and E). Merged images (C and F) illustrate cell surface detection of LRP/LR and CD31 in conjunction with nuclear
staining, respectively. Magnification: x63. An Olympus IX71 Immunofluorescence Microscope and Analysis Get It Research Software were employed
for image acquisition.
doi:10.1371/journal.pone.0058888.g001
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Cluster of differentiation 19 (CD19) antibody IgG1-HD37.
Affinity chromatography employing protein A sepharose was
utilized for antibody purification.
Indirect Immunofluorescence microscopy
HUVE cells were seeded on sterilised cover slips and upon
attaining 30–40%, the culture media was aspirated and cells fixed.
Cell surface proteins of interest were detected with the appropriate
primary antibodies, anti-LRP/LR specific antibody IgG1-iS18 or
anti-cluster of differentiation 31 (CD31) coupled to fluorescein
isothiocyanate (FITC) (Sigma Aldrich). These proteins were
detected on separate cellular samples. Antibodies were diluted in
0.5% PBS-BSA. Post overnight incubation at 4uC, secondary
antibody anti-human-FITC (Beckman Coulter) was added to cells
treated with IgG1-iS18 and consequently incubated for 1h (in the
dark at room temperature). As the CD31 antibody is a conjugated
antibody this step was not performed. Thereafter, cells were
subjected to Hoechst 33342 nuclear staining. Fluorescent images
were acquired using the Olympus IX71 Immunofluorescence
Microscope and Analysis Get It Research Software.
Flow cytometric Analysis
Flow cytometry was employed to determine LRP/LR levels on
the surface of non-permeabilised HUVE cells as described by [28].
Control samples were re-suspended in 100 ml of sheath fluid,
whilst the experimental samples were re-suspended in 100 ml anti-
LRP/LR specific antibody (IgG1-iS18) solution (30 mg/ml). Post
an 1h incubation at room temperature samples were subsequently
incubated in the presence of 100 ml anti-human-FITC secondary
antibody (20 mg/ml) for 1h. Samples incubated solely with the
secondary antibody served to control for background emission and
the possible non-specificity of this antibody. Post final incubation,
10 000 cells per sample were analysed employing a Beckman
Coulter EPICSH XL-MCL flow cytometer. Data shown is
representative of three biological replicates.
Angiogenesis Assay
To determine the endothelial tube formation potential of
HUVE cells and establish the optimal vascular endothelial growth
factor (VEGF) concentration required for the induction of HUVE
cell tube formation, an angiogenesis assay employing varying
VEGF concentrations was conducted. A volume of 50 ml of
MatrigelTM (BD Biosciences) was affixed to the wells of a pre-
chilled 96 well plate and incubated at 37uC for 1h to allow for
MatrigelTM to polymerise. Cell suspensions, in which VEGF
(Sigma Aldrich) had been exogenously applied to achieve the
varying concentrations (10 ng/ml, 15 ng/ml, 20 ng/ml, 25 ng/ml
and 30 ng/ml), were prepared (using Medium 200) and 46104
cells were seeded in each well. Post incubation at 37uC for 18h,
tubular morphology was assessed. A Zeiss inverted microscope was
employed to examine tube formation and a Canon Camera V6.0.
for imaging the cultures. Remote Capture version 2.7.3.23 and
AxioVision LE 4.3 software were used for tube length analysis.
To examine the role of LRP/LR in endothelial tube formation
and to evaluate the efficacy of the anti-LRP/LR antibody as an
angiogenic inhibitor, an angiogenesis assay (as described above)
was performed. Post MatrigelTM preparation, cell suspensions
containing 15 ng/ml exogenous VEGF, were employed for cell
seeding and post 18h incubation at 37uC, tube length was
measured. Conditioned media was gently aspirated so as to
minimise tubular disruption, varying antibody concentrations
(5 mg/ml, 50 mg/ml and 100 mg/ml) of polyclonal anti-LRP
antibody, W3 and IgG1-HD37 (negative control) were composed
in Medium 200 and administered to cells. Post 24h incubation at
37uC, cells were again examined and tubular morphology
analysed. Comparisons in measurements prior to and post
antibody treatment of the same cells were conducted.
Statistics
Statistical analyses were performed using a two-tailed Students’
t-test with a 95% confidence interval. p-values , 0.05 were
considered significant
Results
Human umbilical vein endothelial cells express LRP/LR on
their cell surface
As LRP/LR is a key receptor in mediating cellular adhesion,
proliferation and migration, mediating the cellular effects of
laminin-1 and has previously been implicated in angiogenesis, we
examined whether the receptor was expressed on the surface of the
HUVE cell model employed in this study. HUVE cells displayed
LRP/LR on their cell surface as is depicted by the positive staining
Figure 2. Flow cytometric detection of 37kDa/67kDa LRP/LR
levels on the surface of HUVE cells. Cell surface LRP/LR levels on
the surface of non-permeabilised HUVE cells were ascertained primarily
by incubating cells with IgG1-iS18 followed by incubation with anti-
human-FITC coupled secondary antibodies (Sigma-Aldrich). The red
curve represents the no antibody control, whilst the blue curve
represents treatment with both antibodies. The percentage represents
the proportion of cells exhibiting LRP/LR on their cell surface and was
calculated using a linked marker from the point of intersection between
the curves and the end of the blue curve. A Coulter EPICSH XL-MCL flow
cytometer was employed and ten thousand cellular events were
counted.
doi:10.1371/journal.pone.0058888.g002
Table 1. Effect of varying vascular endothelial growth factor
(VEGF) concentrations on in vitro HUVE cell angiogenesis.a
VEGF concentration (ng/ml) Average Tube length (mm)
0 12.13
10 12.17
15 13.68
20 10.98
25 12.31
30 10.34
aCells were seeded on MatrigelTM (BD Biosciences) at a density of 46104 cells/
well and incubated in 5% CO2 humidified atmosphere (37uC) for 18h.
doi:10.1371/journal.pone.0058888.t001
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in Fig.1A. Moreover, flow cytometric analysis revealed that 97%
of HUVE cells (Fig.2) exhibited LRP/LR on their cell surface
further verifying the results obtained by immunofluorescence
microscopy. The cluster of differentiation 31 (CD31), also called
platelet endothelial cell adhesion molecule (PECAM-1), is an
abundantly expressed cell surface marker of endothelial cells
involved in wound healing and angiogenesis[30,31] and served as
the positive control (Fig.1D).
Optimal VEGF concentration for in vitro angiogenesis of
HUVE cells
VEGF, the major pro-angiogenic factor, is up-regulated by
hypoxia and is a key soluble factor secreted by tumour cells to
induce angiogenic processes in endothelial cells (paracrine
signaling). Furthermore, VEGF receptors are expressed on
endothelial cells such as the HUVE cells but are present on few
other cell types. As exogenous VEGF administration is required
for tube formation on MatrigelTM, we evaluated the concentration
of VEGF which would provide maximal angiogenesis, as gauged
Table 2. Percentage reductiona of endothelial tube length in HUVE cells.
W3 IgG1-HD37
Percentage reduction in
tube length (%) p-value
Percentage reduction
in tube length (%) p-value
Antibody concentration
(mg/ml)
5 –21.62b 0.2980 1.85 0.9674
50 64.72 0.0082 50.87 0.243
100 100 0.0024 40.10 0.0544
aReductions are calculated based on comparisons between the tube lengths of antibody treatments and no antibody treatments. Average tube length of the ‘‘No
antibody’’ treatment was set to 100%.
bThe negative value is indicative that the average tube length was 21.62% greater than that on the ‘‘ No antibody’’ treatment (therefore 121.62%) and therefore rather
than a tube reduction an increase was observed.
doi:10.1371/journal.pone.0058888.t002
Figure 3. The anti-angiogenic effects of W3 on HUVE cell tube formation. HUVE cell suspensions were prepared with 15 ng/ml exogenously
administered VEGF and plated on MatrigelTM (BD Biosciences) at a density of 46104 cells/ well. Post 18h incubation, tubular structures were
microscopically analysed and enumerated by Canon Camera V.6., Remote Capture Version 2.7.3.23 and Axio Vision LE 4.3 software, respectively. Post
assessment conditioned media was gently aspirated to ensure minimal disruption of formed tubes, and fresh media with varying concentrations
(5 mg/ml, 50 mg/ml and 100 mg/ml) of W3 (B, F, J) or IgG1-HD37 (negative control) (D, H, L) were administered the respective samples. Tubular
morphology was assessed (as previously described) 24h post antibody treatment. Magnification: x40
doi:10.1371/journal.pone.0058888.g003
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according to tube length. Statistical evaluation of these results
revealed no significant difference between the VEGF treatments
(data not shown). However, the 15 ng/ml VEGF treatment
displayed the highest average tube length (Table 1) and as such
was the concentration employed for subsequent experimentation.
Anti-LRP/LR specific antibody reverses HUVE cell
angiogenesis
The role of LRP/LR in the induction of angiogenesis has been
proposed owing to its close association with tumourigenic
processes, its interaction with laminin-1 and its role in the
activation of matrix-remodeling enzymes. Thus we investigated
whether impedance of the receptor by anti-LRP/LR specific
antibody W3 would influence tubular morphology. Treatment of
tubular structures with 50 mg/ml of W3 resulted in a significant
reduction in tube length of 64.72%, whereas treatment with
100 mg/ml of W3 resulted in a significant 100% reduction in tube
length (Fig.3 and Table 2). Treatment of tubular structures with
IgG1 HD37 directed against CD19 did not significantly reduce
tube length (Fig.3 and Table 2).
Discussion
Angiogenesis has received considerable attention over the past
few decades as a possible target for pathological diseases which
require vascularisation, most notably cancer.[9] Through selective
inhibition of tumour angiogenesis, tumour growth and progression
and the success of metastatic tumourigenic cells at distal sites,
owing to oxygen and nutrient deprivation, will be halted. Thus
therapeutics aimed at decreasing vascularisation are promising
anti-cancer tools which may be effective against numerous
cancers.
The rate-limiting step in the angiogenic process is the
degradation of the basement membrane which is promptly
followed by endothelial cell detachment, proliferation and re-
organisation into tubular structures. A key receptor in cellular
adhesion to the basal membrane is the 37kDa/67kDa LRP/
LR.[28] Through interactions with the laminin-1, the major
glycoprotein component of the basal lamina and MatrigelTM basal
membrane reconstituent employed here, LRP/LR mediates
cellular attachment and induces proteolytic activation of type IV
collagenase and other matrix metalloproteases.[32,33] These in
turn degrade the basal membrane, release matrix-sequestered pro-
angiogenic factors and allow for cellular migration towards the
angiogenic stimulus. Thus, since angiogenesis requires basal
membrane degradation and LRP/LR plays a fundamental role
in this process, immunofluorescence microscopy and flow cytom-
etry analyses were performed to detect and determine the
proportion of HUVE cells which expressed LPR/LR on their
cell surface. Once LRP/LR was confirmed to be located on the
cell surface of HUVE cells (Fig.1A), flow cytometric analysis
revealed that 97% of the examined cells displayed LRP/LR on
their cell surface (Fig.2). It has been reported that neoplastic cell
lines express very high levels of LRP/LR on their cellular surface
when compared to non-tumorigenic controls[27,28] and that these
elevated levels correlate with an increased invasive poten-
tial.[27,28] Although HUVE cells are non-tumorigenic, the high
LRP/LR levels correlates to the invasive role of these cells as they
Figure 4. The effects of antibody treatment on the average tube length of HUVE cells. HUVE cell suspensions containing 15 ng/ml VEGF
were prepared and plated on MatrigelTM as previously described. Post treatment with varying concentrations of (5 mg/ml, 50 mg/ml and 100 mg/ml)
W3 or IgG1-HD37, tube length was enumerated. The bar graph depicts the average tube length post treatment. Error bars represent sd. *p,0.05;
Student’s t-test.
doi:10.1371/journal.pone.0058888.g004
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are required to degrade the basal membrane and migrate towards
stimuli for the formation of 3D tubular structures.
Thus far, the most influential inducer of angiogenic activity is
the stimulation of the VEGF molecular signaling pathway.[34] It
has been reported that successful angiogenesis may be induced
upon administration of VEGF within the 10 ng/ml – 30 ng/ml
range.[35,36,37] However, the exogenous administration of
VEGF has been shown to possess a biphasic response.[38] In this
study, maximal tube length was observed at a VEGF concentra-
tion of 15 ng/ml (Table 1). Therefore, the application of 15 ng/ml
exogenous VEGF in subsequent experiments was justified.
Previous studies have shown that the adhesive and invasive
potential of numerous cancer types (fibrosarcoma, lung, cervical,
breast, colon and prostate) is significantly reduced upon applica-
tion of anti-LRP/LR specific antibodies, namely IgG1-
iS18.[27,28] Other tools targeting LRP/LR, including RNA
interference (RNAi) technology, the pentosan polysulfate and the
heparan mimetic HM2602[16,27,28] have similarly hampered the
invasion of tumourigenic cells. The mechanism of action whereby
these modalities are suggested to impede invasion is through the
impedance of the LRP/LR – laminin-1 interaction which
subsequently thwarts cellular adhesion, this being a vital process
preceding cellular invasion.
HUVE cell angiogenesis was similarly disrupted (50 mg/ml)
(Fig. 3F) and completely abolished (100 mg/ml) (Fig.3J) upon
administration of the anti-LRP/LR specific antibody. When
compared to the no antibody control, a significant tube length
reduction of 64.72% and 100% was observed upon treatment with
50 mg/ml and 100 mg/ml W3, respectively (Fig.4 and Table 2).
These results therefore demonstrate that anti-LRP/LR specific
antibody W3 significantly blocked tube formation by HUVE cells
– thereby reiterating the fundamental role of LRP/LR in
angiogenesis. This is depicted schematically in Fig.5. This is the
first work to demonstrate that antibodies directed against the non-
integrin laminin receptor (LRP/LR) may inhibit the morphogen-
esis of endothelial cells into tubular structures. It has also been
reported that antibodies directed against laminin-1 under similar
experimental conditions (HUVE cell induced angiogenesis on
MatrigelTM), did not inhibit cellular adhesion to the matrix but did
preclude tube formation.[39] Therefore, it may be suggested that
the anti-LRP/LR antibody W3, blocked the interaction between
LRP/LR and laminin-1, thereby ceasing differentiation of HUVE
cells into tubular structures.
In summary, the strikingly significant abolishment of tubular
structures in the HUVE cell angiogenesis model by W3, suggests
that anti-LRP/LR specific antibodies may prove a potential
therapeutic tool for the treatment of tumour angiogenesis.
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Figure 5. A schematic representation of the effect of anti-LRP/LR specific antibodies on angiogenic tube formation. (A) The
administration of anti-LRP/LR antibody W3, to HUVE cells which had established tubular structures on Matrigel
TM
, inhibited further degradation of the
basement membrane, a requirement for tube formation. This halted the development for additional tubular structures. Moreover, the antibody also
bound to existing tubes and thereby blocked the interaction between LRP/LR and Laminin-1, hence resulting in (B) the reversal of tube formation and
cells were consequently observed as single cells on the Matrigel
TM
.
doi:10.1371/journal.pone.0058888.g005
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Abstract
Two key events, namely adhesion and invasion, are pivotal to the occurrence of metastasis. Importantly, the 37 kDa/67 kDa
laminin receptor (LRP/LR) has been implicated in enhancing these two events thus facilitating cancer progression. In the
current study, the role of LRP/LR in the adhesion and invasion of liver cancer (HUH-7) and leukaemia (K562) cells was
investigated. Flow cytometry revealed that the HUH-7 cells displayed significantly higher cell surface LRP/LR levels
compared to the poorly-invasive breast cancer (MCF-7) control cells, whilst the K562 cells displayed significantly lower cell
surface LRP/LR levels in comparison to the MCF-7 control cells. However, Western blotting and densitometric analysis
revealed that all three tumorigenic cell lines did not differ significantly with regards to total LRP/LR levels. Furthermore,
treatment of liver cancer cells with anti-LRP/LR specific antibody IgG1-iS18 (0.2 mg/ml) significantly reduced the adhesive
potential of cells to laminin-1 and the invasive potential of cells through the ECM-like Matrigel, whilst leukaemia cells
showed no significant differences in both instances. Additionally, Pearson’s correlation coefficients suggested direct
proportionality between cell surface LRP/LR levels and the adhesive and invasive potential of liver cancer and leukaemia
cells. These findings suggest the potential use of anti-LRP/LR specific antibody IgG1-iS18 as an alternative therapeutic tool
for metastatic liver cancer through impediment of the LRP/LR- laminin-1 interaction.
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Introduction
Cancer is a global burden that has been shown to be the leading
cause of death in economically developed countries and the second
leading cause of death in economically developing countries[1].
According to the World Cancer Research Fund (WCRF), an
estimated 14.1 million cases of cancer were diagnosed in the year
2012 and it is predicted that approximately 24 million new cases of
cancer will be diagnosed by the year 2035, globally (http://www.
wcrf.org/cancer_statistics/). Currently, lung cancer has been
identified as the most commonly diagnosed cancer type, with the
two cancer types central to the present study namely liver cancer
and leukaemia, being ranked as sixth and eleventh most diagnosed
cancer types, respectively (GLOBOCAN). It has been reported
that approximately 782000 cases of liver cancer and 352000 cases
of leukaemia were diagnosed in the year 2012 (http://www.wcrf.
org/cancer statistics/world cancer statistics.php), thus indicating
the pressing need to develop effective treatments against cancer.
Cells are largely dependent on the extracellular matrix (ECM),
which is the non-cellular component of all tissues and organs that
provides a physical scaffold to cellular components and also assists
with initiation of essential biochemical processes needed for proper
tissue differentiation, homeostasis and morphogenesis[2]. Cells
adhere to the ECM via the action of ECM receptors[2].
Particularly, the non-integrin 37-kDa/67-kDa laminin receptor
(LRP/LR) is a major component of the extracellular matrix,
assisting in numerous physiological processes[3,4,5]. It is suggested
that 37-kDa LRP is the precursor of the 67-kDa high affinity
laminin receptor LR, however, the exact mechanism by which the
precursor forms the receptor is unknown[6].
LRP/LR is predominantly a transmembrane receptor, howev-
er, it is also evident in the nucleus and the cytosol[7,8]. In the
nucleus, LRP/LR plays a critical role in the maintenance of
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nuclear structures whilst in the cytosol, it assists in translational
processes[8]. As a transmembrane receptor, LRP/LR serves
several functions such as cell migration[9], cell-matrix adhe-
sion[10], cell viability and proliferation[3,4,5].
LRP/LR has been shown to have a high binding affinity for
laminin-1. Laminin-1 is part of a family of laminins, which are
extracellular matrix proteins that constitute several non-collage-
nous glycoproteins that are found in the basement mem-
brane[11,12]. This glycoprotein is believed to play critical roles
in cell attachment[11], assembly of the basement membrane[11],
cell growth and differentiation[13], cell migration[11,14], neurite
outgrowth[11,15] and angiogenesis[16]. Laminin-1 has also been
shown to promote the invasive phenotype of tumorigenic cells[17].
LRP/LR has been found to be over-expressed on the surface of
several tumorigenic cells[18]. The result of this over-expression is
an increased interaction between LRP/LR and laminin-1, and this
interaction has been shown to be crucial in enhancing adhesion
and invasion – two key components of metastasis[19]. Essentially,
laminin-1 in the basement membrane interacts with LRP/LR on
the surface of tumorigenic cells leading to adhesion[19]. This, in
turn, results in the secretion of proteolytic enzymes such as type IV
collagenase in order to hydrolyse type IV collagen in the basement
membrane, thereby allowing tumorigenic cells to invade and
eventually translocate to a secondary site[19].
Since the LRP/LR-laminin-1 interaction has been identified as
the crucial event in adhesion and invasion, blockage of this
interaction could be deemed as an essential mechanism to treat
metastatic cancer. This implicates LRP/LR as a target for the
treatment of metastatic cancer. Furthermore, several studies have
shown that application of anti-LRP/LR specific antibodies
significantly reduces the adhesive and invasive potential of certain
tumorigenic cells, such as HT1080 fibrosarcoma[18], lung[4],
cervical[4], colon[4], prostate[4], breast[20] and oesophageal[20]
cancer cells. Particularly, anti-LRP/LR specific antibody IgG1-
iS18 has been suggested to interrupt the LRP/LR-laminin-1
interaction [4], thus IgG1-iS18 may be deemed as a possible
therapeutic tool in the treatment of metastatic cancer.
In this study, the ability of anti-LRP/LR-specific antibody
IgG1-iS18 to impede the adhesive and invasive potential of
leukaemia and liver cancer cells was investigated. Due to the high
incidence and mortality rates regarding these two cancer types,
alternative therapeutic options become a necessity. It is notewor-
thy that similar studies have been conducted, however, it is
possible that not all metastatic cancer cell types may be responsive
to IgG1-iS18 treatments. It therefore becomes necessary to carry
out these metastatic studies on different cancer types in order to
gain insight into the use of the antibody as an alternative broad
spectrum therapeutic antibody for the treatment of various cancer
types. Thus, this study was conducted with the aim of determining
whether IgG1-iS18 is capable of significantly reducing the
adhesive and invasive potential of leukaemia and liver cancer
cells, therefore providing the possibility for the antibody to be used
as an alternative therapeutic tool in the treatment of these two
cancer types.
Materials and Methods
Cell culture and conditions
Human breast adenocarcinoma (MCF-7), liver carcinoma
(HUH7) and leukaemia (K562) cell lines obtained from ATCC
were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
high glucose (4.5 g/l) supplemented with 10% fetal calf serum and
1% penicillin/streptomycin at 5% CO2 and 37uC.
Reagents and antibodies
Matrigel used for cell invasion assays is derived from the
Engelbreth-Holm-Swarm (EHS) mouse sarcoma and was obtained
from BD Biosciences.
Laminin-1used for cell adhesion assays was obtained from
Sigma-Aldrich.
Chloramphenicol acetyl transferase (CAT) antibody was
obtained from Sigma-Aldrich.
IgG1-iS18 was recombinantly produced in a mammalian
expression system as reported by
Zuber et al., (2008)
Confocal microscopy
In order to visualize the location of LRP/LR on the cell surface,
confocal microscopy was employed. Cells were first seeded on
coverslips and allowed to reach 70% confluency. Cells were fixed
in 4% paraformaldehyde in PBS for approximately 15 minutes
followed by several washes with PBS. Cells were blocked in 0.5%
BSA in PBS for 5-10 minutes. After one PBS wash, excess PBS was
blotted off. Cover slips containing cells were placed on a glass slide
(with cells facing upwards) and this was followed by addition of
primary antibody IgG1-iS18 (1:100) diluted in 0.5% BSA. Post an
overnight incubation at 4uC, coverslips were rinsed thrice in PBS/
BSA. After addition of the FITC-coupled secondary antibody that
had been diluted in 0.5% BSA, incubation in the dark was allowed
for 1 hour. Followed by three washes as before, DAPI diluted in
PBS was then administered for 5–10 minutes to allow for staining
of the nucleus. Cells were finally washed once in PBS alone and
mounted onto a clean slide using GelMount (Sigma-Aldrich). A
period of 45 minutes was allocated to allow for setting to take
place.
Flow cytometry
Quantification of cell surface levels of LRP/LR was conducted
using flow cytometry. EDTA(5 mM) in PBS was used to facilitate
detachment of adherent cells which was followed by centrifugation
at 1200 rpm, 10 min. Cells were subsequently fixed by re-
suspending cells in PFA for 10 min at 4uC. Cells were again
centrifuged in 1X PBS which allowed for the preparation of five
cell suspensions, one to which no antibody was added (thus serving
as the unstained control), one to which anti-CAT antibody was
added (serving as an isotype control) and one to which anti-LRP/
LR specific antibody IgG1-iS18 was added. The remaining two
cell suspensions were incubated only in PBS in order to be used as
negative controls for the IgG1-iS18 and anti-CAT antibody. All
suspensions were incubated at room temperature for 1 hour.
Following three washing steps with 1X PBS, goat anti-human
phycoerythrin (PE)-coupled secondary antibody (Beckman Coul-
ter) was added to the cell suspension containing the IgG1-iS18
primary antibody as well as one of the suspensions that was
incubated in PBS only. The cell suspension that was incubated
with the anti-CAT antibody as well as the remaining cell
suspension that was incubated only in PBS, were both supple-
mented with a goat anti-rabbit allophycocyanin (APC)-coupled
secondary antibody followed by another 1 hour incubation period
of all cell suspensions. Furthermore, three post-incubation washes
were performed and cell suspensions were analysed using the BD
Accuri C6 flow cytometer. Experiments were performed in
triplicate and repeated at least three times.
SDS PAGE and Western blotting
Total LRP/LR levels were determined by the use of sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE).
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To perform the SDS-PAGE, 10 mg of total protein was used.
Proteins that were separated according to size by SDS-PAGE were
then identified by application of specific antibodies in the process
of Western blotting. The proteins resolved on the polyacrylamide
gel were transferred onto a polyvinylidene fluoride (PVDF)
membrane using 1X transfer buffer (20% methanol in 192 mM
glycine and 25 mM Tris) for 45 minutes at 350 mV and a semi-
dry transferring apparatus. Blocking buffer (3% BSA in 1X PBS
Tween) was then used in order to block the blotted membrane for
1 hour. Once blocked, the membrane was probed with anti-LRP/
LR specific primary antibody IgG1-iS18 (1:10000) for 1 hour.
Prior to incubation of the membrane with goat-anti-human-
peroxidase (1:5000) secondary antibody, three washes with 1X
PBS Tween were performed. A further three washes in 1X PBS
Tween were performed after incubation in the secondary
antibody, followed by the detection of HRP by use of an
enhanced chemiluminescent substrate (Thermo scientific). The
resulting fluorescence was developed and fixed onto an X-ray film.
Experiments were executed in triplicate and repeated at least 3
times.
Adhesion assay
In order to assess the adhesive potential of the varying
tumorigenic cell lines to the basement membrane in vitro,
laminin-1 (10 mg/ml)(BD Biosciences) was used to coat 96
microwell plates, leaving uncoated wells to be used as negative
controls. After the coating of the wells for 1 hour and washing with
0.1% BSA in DMEM, other protein binding sites on the microwell
plate were blocked using 100 ml of 0.5% BSA in DMEM for one
hour. Cells were suspended in serum-free culture medium and
added to wells at a density of 46105 cells/ml in order to assess the
adhesion potential. Furthermore, cells that have been pre-
incubated with IgG1-iS18 (0.2 mg/ml) and with anti-CAT (Sigma,
0.2 mg/ml) antibody as the negative control were added to the
relevant wells in order to examine the effects of the antibodies on
the adhesion potential of the cells. The plates were incubated at
37uC for 1 hour and thereafter, non-adherent cells were washed
away with PBS and adherent cells were fixed with 4%
paraformaldehyde for 10 minutes. Adherent cells were stained
with 0.1% crystal violet. The stain was extracted using 1% SDS
and the absorbance of the extracted sample at 550 nm was assayed
as a measure of the adhesive potential. Experiments were
performed in triplicate and repeated at least three times.
Invasion assay
In vitro analysis of the ability of the tumorigenic cell lines to
invade the basement membrane was carried out using the ECM-
like Matrigel. Serum-free cold culture medium (DMEM) was used
in order to dilute the Matrigel and this diluted gel was dispensed
onto the upper chamber of a 24 transwell plate (BD falcon, 8 mm
pore size). This gel was then allowed to solidify for approximately
5 hours at 37uC. After being harvested, cells were resuspended in
serum-free culture media at a density of 16106 cells/ml. Antibody
treatments required cells to be incubated with IgG1-iS18 (0.2 mg/
ml) or the negative control anti-CAT (Sigma, 0.2 mg/ml) antibody.
Cells were subsequently loaded onto the upper Matrigel-covered
chamber and incubated for 18 hours. The lower chamber was
filled with 500 ml of culture media containing 10% FCS (for the
test) and no FCS (for the control), and incubated at 37uC for
18 hours. This was followed by aspiration of the media in the
lower and upper chamber. Non-invasive cells were then removed
by use of a cotton swab. The remaining invasive cells were then
washed with 300 ml of PBS and fixed using 300 ml of 4%
paraformaldehyde, 10 min. Cells were stained using 0.5%
toluidine blue dye and after extraction of the dye using 1%
SDS, absorbance was then measured at 620 nm using an ELISA
reader. Experiments were carried out in triplicate and repeated at
least three times.
Statistical evaluations
The two-tailed Student’s t-test with a confidence interval of
95% was used in order to analyse the data, with p-values of less
than 0.05 being considered significant. The extent or degree of
association between LRP/LR levels on the cell surface and
invasive/adhesive potential was measured using the Pearson’s
correlation coefficient. The Pearson’s correlation coefficient
was also used to measure the correlation between the adhesive
and invasive potential of the cell lines. A positive coefficient
was an indication of direct proportionality between the two
variables, whereas a negative coefficient implied inverse
proportionality.
Results
Liver cancer and leukaemia cells reveal LRP/LR on the cell
surface
Pivotal to the occurrence of metastasis is the interaction
between laminin-1 and LRP/LR on the cell surface. Hence, it
was necessary to visualize cell surface LRP/LR as a means of
confirmation that cells indeed do display LRP/LR on their
surface. Both tumorigenic cell lines, as well as the poorly-
invasive breast cancer control, revealed LRP/LR on the cell
surface as depicted in Fig.1 a). The green fluorescence in the
images below is indicative of cell surface LRP/LR as cells were
non-permeabilized and the secondary antibody was shown to
not bind non-specifically, as confirmed by the controls
depicted in Fig.1 b) and Fig.1 c) below. Anti-CAT antibody
was used as a negative control due to its ability to bind
specifically to chloramphenicol acetyltransferase (CAT) which
is a bacterial protein and is therefore absent in mammalian
cells.
High percentages of tumorigenic cells display LRP/LR on
the cell surface
Although confocal microscopy confirmed that the cell lines do
indeed display LRP/LR on their cell surface, further quantifica-
tion of the cell surface levels of LRP/LR was required. Flow
cytometry was employed for this quantification.
As shown in Fig.2 A, C and E, all three tumorigenic cell lines
revealed high percentages of cells within a specific population
that display LRP/LR on the cell surface, with the shift between
the two peaks in each graph being indicative of a change in
fluorescence intensity due to the cell-surface staining of the cells
with anti-LRP/LR specific antibody IgG1-iS18 and the fluoro-
chrome-coupled secondary antibody. HUH-7 liver cancer cells
displayed a higher percentage of cells exhibiting LRP/LR on the
cell surface in comparison to K562 leukaemia cells as well as the
poorly-invasive breast cancer (MCF-7) control cell line. Fig. 2 B,
D and F additionally include the unstained control and this
control served to show that the PE secondary antibody does not
bind non-specifically. The shifts in fluorescence intensity of
unstained, APC only and anti-CAT-APC labelled cells (the
negative controls) are represented in the Fig S1. It is also
noteworthy to add that cell debris and cell aggregates were
excluded from analysis as they were outside the defined gate (Fig.
S3).
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Liver cancer cells display significantly higher and
leukaemia cells display significantly lower cell surface
LRP/LR levels compared to poorly-invasive breast cancer
cells
In addition to the percentage of cells exhibiting LRP/LR on
their cell surface, the actual cell surface LRP/LR levels within a
specific cell population was analyzed using flow cytometry. The
same number of cells (20000 cells) within specific populations of
the three tumorigenic cell lines were labelled with the same
concentration (30 mg/ml) of previously-mentioned primary and
secondary antibodies over the same time period. Thus, the more
LRP/LR that is present on the surface of the tumorigenic cells, the
more primary antibody IgG1-iS18 would bind to LRP/LR and
subsequently, the more IgG-specifc fluorochrome-coupled second-
ary antibody would bind to the primary antibody. Thus, the
median fluorescence intensities (MFI) would differ between the
three cell lines (Table 1) and therefore can be used as an indicator
of cell surface LRP/LR levels. It was observed that, in comparison
to the poorly-invasive MCF-7 breast cancer control cell line, liver
cancer cells (HUH-7) displayed higher levels of LRP/LR on their
cell surface (Fig.3). Additionally, K562 leukaemia cells revealed
lower cell surface LRP/LR levels in comparison to the MCF-7
cells (Fig.3).
The median fluorescence intensities obtained post anti-CAT
labelling and detection demonstrate that there is no significant
difference in the degree of cell-surface CAT staining across all
three cell lines (Fig. S2)
Total LRP/LR levels do not differ significantly between
the tumorigenic cell lines
As previously mentioned, LRP/LR does not exclusively occur
on the cell surface but is additionally seen in the nucleus and
cytosol, hence Western blot analysis was performed in order to
assess total LRP/LR levels. Experiments were performed in
triplicate and repeated three times. A representative blot is
depicted in Fig.4. It is noteworthy to state that only the 37 kDa
laminin receptor precursor could be detected by use of anti-LRP/
LR specific antibody IgG1-iS18.
Following detection of LRP, quantification of total LRP levels
was required and densitometry was employed to achieve this. Fig.5
depicts the densitometric analysis, which revealed that statistically,
there was no significant difference observed in total LRP levels
between the three tumorigenic cell lines.
IgG1-iS18 significantly impedes the adhesive potential of
liver cancer cells
Pivotal to the initiation of invasion is the adhesion of a
tumorigenic cell to the basement membrane through the LRP/
LR-laminin-1 interaction as it allows for other interactions to
occur that facilitate degradation of the basement membrane. Cells
were incubated with IgG1-iS18 and anti-CAT antibodies (0.2 mg/
ml) and after an hour, absorbance readings of the resultant
solution were indicative of the degree of cell attachment to the
laminin-1-coated plates.
As depicted in Fig.6, the no antibody control allowed for the
determination of the adhesive potential of the cell lines and it
was observed that both liver cancer (HUH-7) as well as
leukaemia cells (K562) were more adherent than the poorly-
invasive breast cancer (MCF-7) control cells. However, IgG1-
iS18 was only effective at impeding the adhesive potential of
liver cancer cells and no significant reduction in adhesion was
observed for leukaemia cells treated with the anti-LRP/LR
specific antibody IgG1-iS18. As expected, the anti-CAT
Figure 1. Visualisation of LRP/LR on the surface of liver cancer (HUH-7) and leukaemia (K562) cells. Cells were non-permeabilized in
order to allow for visualisation of the cell surface. a) Cells were labelled with primary antibody IgG1-iS18 and a FITC-coupled secondary antibody. b)
Cells were labelled with anti-chloramphenicol acteyltranferase (CAT) antibody as the negative control. c) Cells were labelled only with the FITC-
coupled secondary antibody to confirm that the secondary antibody does not bind non-specifically.
doi:10.1371/journal.pone.0096268.g001
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control antibody did not have a significant effect on the
adhesive potential of the tumorigenic cell lines.
Invasion of the Matrigel by liver cancer cells (HUH-7) is
significantly impeded by anti-LRP/LR specific antibody
IgG1-iS18
Invasion of the basement membrane is considered as a pre-
requisite for the progression of a metastatic cancer, hence invasion
assays using a Matrigel, which mimics the components of the
basement membrane, were performed to determine the invasive
potential of the tumorigenic cell lines. Similarly to the adhesion
assays, the no antibody control allowed for the determination of
the invasive potential of the cell lines. Furthermore, cells were
treated with anti-LRP/LR specific antibody IgG1-iS18 and anti-
CAT antibody (0.2 mg/ml).
As shown in Fig.7, liver cancer (HUH-7) cells are significantly
more invasive in comparison to the poorly-invasive breast cancer
(MCF-7) control cell line, whilst leukaemia (K562) cells showed a
significantly lower invasive potential compared to the control.
Moreover, IgG1-iS18 successfully hampered the invasive potential
of liver cancer (HUH-7) cells whilst no significant result was
observed for the leukaemia cells. As expected, the anti-CAT
antibody control did not significantly affect the invasive potential
of the tumorigenic cell lines.
Discussion
Several studies have revealed that, on the cell surface, various
tumorigenic cell lines exhibit an overexpression of the 37 kDa/
67 kDa LRP/LR, therefore suggesting that the LRP/LR-laminin-
1 interaction may be pivotal for cancer cells to undergo
metastasis[21]. It may therefore be useful to inhibit this interaction
as a means of hampering adhesion and invasion – two events
found to be crucial to the occurrence of the process of metastasis.
A study conducted by Zuber et al has demonstrated that the IgG1-
iS18 antibody is highly specific for LRP/LR[18]. Furthermore,
recent research has shown that anti-LRP/LR specific antibody
IgG1-iS18 significantly impedes the adhesive and invasive
potential of cervical[4], lung[4], prostate[4], colon[4], breast[20]
and oesophageal[20] cancer cells. The present study investigated
the role of LRP/LR in the adhesion and invasion of liver cancer
(HUH-7) as well as leukaemia (K562) cells, and aimed to establish
whether application of anti-LRP/LR specific antibody IgG1-iS18
significantly reduces the adhesive and invasive potential of these
two tumorigenic cell lines.
Initially, confocal microscopy revealed that all three tumori-
genic cell lines indeed display LRP/LR on their cell surface
(Fig. 1a). However, this technique is limited by the fact that it is not
quantitative and further analysis was required in order to establish
Figure 2. Quantification of liver cancer (HUH-7) and leukaemia (K562) cells within a population which exhibit LRP/LR on their cell
surface. The first peak in graphs A, C and E is representative of non-labelled cells i.e. cells labelled with goat anti-human PE-coupled secondary
antibody only, whereas the second peak is indicative of cells labelled with both anti-LRP/LR specific antibody IgG1-iS18 and the secondary antibody,
both at a concentration of 30 mg/ml. Graphs B, D and F depict the inclusion of an unstained control to show no non-specific secondary antibody
binding. Experiments were carried out in triplicate and repeated at least three times with 20 000 cells being counted per sample.
doi:10.1371/journal.pone.0096268.g002
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the levels at which LRP/LR is displayed on the cell surface of
these tumorigenic cell lines.
Significantly high percentages (.87%) of all three tumorigenic
cell lines, namely HUH-7, K562, and MCF-7 (poorly-invasive
breast cancer control) cells displayed LRP/LR on their cell surface
(Fig.2). Furthermore, it was observed by analysis of differences in
median fluorescence intensities that, in comparison to the MCF-7
control cell line, liver cancer cells (HUH-7) revealed significantly
higher and leukaemia cells (K562) revealed significantly lower cell
surface LRP/LR levels (Fig.3). As previously stated, LRP/LR
plays essential roles in adhesion, invasion, proliferation and
migration of cells[9]. Seeing that the HUH-7 cell line is known
to be invasive and the K562 is understood to be a suspension cell
line (ATCC), the cell surface levels of LRP/LR that have been
observed may be correlating with the invasive potential of these
cell lines.
Additionally, total LRP/LR levels were analysed by Western
blotting in order to account for LRP/LR in the nucleus and
cytosol of the tumorigenic cell lines. Western blot analysis (Fig.4)
confirmed that all three tumorigenic cell lines express the 37 kDa
LRP, however densitometry analysis of these blots (Fig.5) revealed
that both the invasive and poorly-invasive cell lines show similar
levels of total LRP and no significant differences were observed. It
is noteworthy to state that in the nucleus and cytosol, LRP/LR
serves particularly to maintain nuclear structures and facilitate
translational processes, respectively[8]. Hence, even though total
LRP levels do not differ significantly between the invasive and
poorly-invasive tumorigenic cell lines, the cell surface LRP/LR
levels are of importance to the occurrence of adhesion and
invasion in the invasive and poorly-invasive tumorigenic cell lines.
The current study revealed differences in only cell surface levels of
LRP/LR between the three tumorigenic cell lines, and this is in
agreement with results obtained in previously published research
[4]. However, another study contradicted these results by showing
that tumorigenic cell lines differed only in total LRP/LR
levels[20]. These discrepancies in the latter-mentioned study
could be owing to the fact that those cancerous cells may require
enhanced protein synthesis in order to carry out metastatic
processes, hence increased total LRP/LR levels were observed
rather than increased cell surface LRP/LR levels.
The results obtained in the present study suggests that anti-
LRP/LR specific antibody IgG1-iS18 caused a significant
reduction in the adhesive potential of metastatic liver cancer cells
on laminin-1 and additionally hampered the invasive potential of
Figure 3. Quantification of cell surface LRP/LR levels on liver cancer (HUH-7) and leukaemia (K562) cells by flow cytometry. Cells
were labelled with primary antibody IgG1-iS18 (1:25) and anti-human phycoerythrin (PE) secondary antibody. 20000 cells were analyzed across all
three cell lines, and the median fluorescence intensities (MFI) were used as an indicator of cell surface LRP/LR levels. The MFI values indicated in the
last column of Table 1 were used in order to construct this figure and it is noteworthy that the MFI value corresponding to the MCF-7 cell line was set
to 100%. Experiments were performed in triplicate and repeated at least three times. **p = 0.0025, ***p,0.0001.
doi:10.1371/journal.pone.0096268.g003
Table 1.Median fluorescence intensity (MFI) values as an indicator of differential expression of LRP/LR between MCF-7, HUH-7 and
K562 cell lines.
Cell lines MFI of unstained cells
MFI of cells labelled with
IgG1-iS18 and PE
(MFI of cells labelled with IgG1-iS18
and PE) – (MFI of unstained cells)
MCF-7 1623.666667 38753.16667 37129.5
HUH-7 2678.166667 49556 46877.83333
K562 13823.75 35392 21568.25
*All values are representative of an average of results obtained from experiments that were performed in triplicate and repeated three times.
doi:10.1371/journal.pone.0096268.t001
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this cancer type on the Matrigel. Figures 6 and 7 depict these
significant decreases in the adhesive and invasive potential of
metastatic liver cancer (HUH-7) cells upon administration of
IgG1-iS18, respectively. It is noteworthy to state that leukaemia
(K562) cells showed no significant reduction in the adhesive and
invasive potential upon administration of IgG1-iS18. It may be
suggested that variations in the adhesive and invasive potential of
both HUH-7 and K562 cell lines may be attributed to variations in
cell surface LRP/LR levels. Hence, lower cell surface LRP/LR
levels observed for leukaemia cells (Fig.3) could be held
accountable for the lower adhesive and invasive capacity observed
in this cell line, and vice versa for HUH-7 cells which exhibited
high cell surface LRP/LR levels (Fig.3) and resulted in the
increased adhesive and invasive capacity of this cell line. The
significant reduction in the invasive potential of metastatic liver
cancer cells after administration of anti-LRP/LR specific antibody
IgG1-iS18 may be attributed to the inhibition of adhesion (Fig.6)
by the IgG1-iS18 antibody, as adhesion is understood to be a pre-
requisite for the occurrence of invasion during the induction of
metastasis[20].
On the contrary, the K562 leukaemia cells were observed to be
more adherent (Fig.6) but less invasive (Fig.7) than the poorly-
invasive MCF-7 control cell line. This observation could be due to
K562 cells expressing tissue inhibitors of metalloproteinases
(TIMPs) and these TIMPs could be resulting in the inhibition of
type IV collagenase activity[22], thereby preventing degradation
of type IV collagen in the Matrigel and preventing K562 cells from
undergoing invasion in vitro.
Analysis of the correlation between cell surface levels of LRP/
LR with the adhesive and invasive potential of liver cancer (HUH-
7) and leukaemia (K562) cells, resulted in considerably high
correlation coefficients (Table 2). This signifies a positive and
directly proportional relationship between the two parameters.
Hence, this confirms that adhesion is a pre-requisite for invasion to
occur, as seen by the high correlation coefficients obtained for
adhesive to invasive potential for both experimental cell lines.
Furthermore, the high correlation coefficients obtained for cell
surface LRP/LR levels to the adhesive and invasive potential of
the cell lines suggests that the aggressiveness of these two cancer
types is enhanced by high levels of cell surface LRP/LR, which is
consistent with results obtained by previous studies [4,20]. It is
important to note that only cell surface levels of LRP/LR were
considered in the calculations of Pearson’s correlation coefficients
since no significant difference was observed in total LRP/LR levels
between the three tumorigenic cell lines (Fig.5).
In Table 2, the high Pearson’s correlation coefficients observed
between the adhesive and invasive potential for both cell lines
ascertains that adhesion is indeed a mandatory step for the
occurrence of invasion, where lower adhesive potential in
leukaemia cells subsequently resulted in a lower invasive potential
as well. This finding is in line with that of previously published
literature which shows that the LRP/LR-laminin-1 interaction is
pivotal for adhesion as well as secretion of enzymes that degrade
Figure 4. Detection of the relative expression of total 37 kDa
LRP levels using lysates of liver cancer (HUH-7) and leukaemia
(K562) cell lines. Anti-LRP/LR specific antibody IgG1-iS18 was used as
the primary antibody in conjunction with a secondary HRP-coupled
antibody. b-actin was employed as a loading control.
doi:10.1371/journal.pone.0096268.g004
Figure 5. Total LRP levels of liver cancer (HUH-7) and leukaemia (K562) cell lines detected by Western blot analysis using primary
anti-LRP/LR specific antibody IgG1-iS18 and goat anti-human HRP secondary antibody. Quantification was conducted using
densitometry and data are representative of experiments carried out in triplicate and repeated three times. Non-significant (NS): p.0.05.
doi:10.1371/journal.pone.0096268.g005
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Figure 6. Effect of anti-LRP/LR specific antibody IgG1-iS18 on the adhesion of liver cancer (HUH-7) and leukaemia (K562) cells to
laminin-1 determined through adhesion assays. p-values shown in red (*p = 0.0238; ***p= 0.0002) are indicative of the increase in adhesive
potential of liver cancer (HUH-7) and leukaemia (K562) cells in comparison to the breast cancer (MCF-7) control cell line. p-values shown in black
(**p = 0.0031; ***p = 0.0005) represent the reduction in adhesive potential after treatment of cells with appropriate antibodies. A reduction of 63.35%
in the adhesive potential was observed upon administration of IgG1-iS18 to the HUH-7 liver cancer cells. Data represents experiments performed in
triplicate and repeated at least three times.
doi:10.1371/journal.pone.0096268.g006
Figure 7. Effect of anti-LRP/LR specific antibody IgG1-iS18 on the invasion through the ECM-like MatrigelTM by liver cancer (HUH-7)
and leukaemia (K562) cells. p-values indicated in red (*p= 0.0485; **p = 0.0053) represent the changes in invasive potential of cell lines in
comparison to the MCF-7 control, whilst p-values shown in black (*p = 0.0214; **p = 0.0091) are indicative of the effect of appropriate antibodies on
the invasive potential of the cell lines. Upon administration of IgG1-iS18 to the HUH-7 liver cancer cells, a reduction of approximately 39.75% was
observed regarding the invasive potential of the cells. Data is representative of experiments carried out in triplicate and repeated at least three times.
doi:10.1371/journal.pone.0096268.g007
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the basement membrane and therefore promote invasion through
the basement membrane[23].
Several studies have suggested that anti-LRP/LR tools such as
pentosan sulphates and monoclonal antibodies directed towards
the laminin receptor have shown the potential to significantly
impede the adhesive and invasive potential of selected cancers
such as laryngeal carcinoma cells as well as human fibrosarcoma
cells through the interruption of the LRP/LR-laminin-1 interac-
tion [18,24].
Overall, it is strongly suggested that proteolytic cleavage of the
basal lamina and subsequently the process of invasion is
significantly enhanced through the LRP/LR-laminin-1 interac-
tion[23]. Furthermore, anti-LRP/LR specific antibody IgG1-iS18
has been shown in the present study to significantly impact on the
behaviour of metastatic liver cancer cells at the critical stages of
adhesion and invasion in vitro, thereby suggesting the use of the
antibody as an alternative therapeutic tool in the treatment of
metastatic liver cancer.
Due to different cancer types exhibiting different behavioural
characteristics, it cannot be assumed that anti-LRP/LR specific
antibody IgG1-iS18 will have the same effect on all cancer types.
Hence, the results of the current study will assist in providing the
scientific community with novel aspects regarding the use of the
antibody as a possible therapeutic tool for metastatic liver cancer.
Furthermore, studies concerning appropriate delivery systems for
the IgG1-iS18 antibody need to be conducted since LRP/LR
plays critical roles in several essential physiological processes and
the targeting of LRP/LR specifically in tumorigenic cells may
prove to be difficult. Successful animal trials may indeed deem the
antibody as a potential therapeutic tool for metastatic cancers.
Supporting Information
Figure S1 Quantification of liver cancer (HUH-7) and
leukaemia (K562) cells within a population which
display the CAT protein on their cell surface. The first
peak in graphs A,C and E represents cells labelled with APC-
coupled secondary antibody only, whilst the second peak indicates
cells that are labelled with both anti-CAT antibody as well as the
secondary antibody. The unstained control is included in graphs
B, D and F to confirm that the secondary antibody does not
significantly bind non-specifically. Experiments were performed in
triplicate and repeated at least three times with 20000 cells
counted per sample.
(TIF)
Figure S2 Quantification of cell surface CAT protein
levels on liver cancer (HUH-7) and leukaemia (K562)
cells by flow cytometric analysis. Cells were labelled with
anti-CAT antibody and APC-coupled secondary antibody. An
analysis was performed on 20000 cells per sample across all three
cell lines. The median fluorescence intensities of the samples
labelled with both anti-CAT antibody and the secondary antibody
were used as an indicator of CAT expression on the cell surface
(with the unstained control being taken into account). The MFI
value for the MCF-7 cell line wasset to 100%. Experiments were
carried out in triplicate and repeated at least three times. N.S: p.
0.05.
(TIF)
Figure S3 Flow cytometric gating of MCF-7 (poorly-
invasive breast cancer), HUH-7 (liver cancer) and K562
(leukaemia) cell samples. Cells were gated to exclude debris
and aggregated cells from the analysis. R1 and R3 indicate the
gated cell population.
(TIF)
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Chapter 5 
Discussion 
The following discussion is based on the work published in the following two original 
research articles:  
 
1. Da Costa Dias et al.,(2013). Anti-LRP/LR specific antibody IgG1-iS18 and knock-
down of LRP/LR by shRNAs rescue cells from Aβ42 induced cytotoxicity. Scientific 
Reports, 3, 2702; DOI:10.1038/srep02702. 
 
2. Da Costa Dias et al.,(2014). The 37kDa/67kDa Laminin Receptor acts as a receptor 
for Aβ42 internalization. Scientific Reports, 4, 556; DOI:10.1038/srep05556.  
 
It must be noted that a distinction between LRP/LR and LR will be made throughout this 
chapter. LRP/LR will be employed when a discrimination between the 37kDa laminin 
receptor precursor (LRP) and 67kDa laminin receptor (LR) isoforms could not be made- 
particularly with regards to expression of the laminin receptor on the cell surface. However, 
the pCIneoLRP::FLAG mammalian expression construct employed for the recombinant 
expression of the receptor employed for FLAG
®
 co-immunoprecipitation studies exclusively 
encodes the 37kDa LRP isoform, and shall hereafter be denoted as LRP.  
 
Furthermore, prior to the discussion of the results a justification for the use of human 
embryonic kidney (HEK) 293 cells (HEK293) throughout these studies must be provided. 
These cells were originally isolated from kidney tissue and should therefore biochemically 
most closely resemble kidney epithelial cells. However, their transformation with sheared 
fragments of human adenovirus type 5 (Ad5), necessary for the establishment of an 
immortalized cell line, has led them to display properties associated with cells of a neuronal 
lineage
273, 274
. Recent studies have demonstrated that HEK293 cells express four 
neurofilament subunits, namely: NF-L, NF-M, NF-H and α-internexin, which are normally 
expressed only by neurons
273
. Furthermore, 61mRNAs previously considered to be 
exclusively expressed by neuronal cells, have been detected in the HEK293 cells
274
. HEK293 
cells have also been shown to express numerous voltage-activated ion-channels (such as Ca
2+
 
channels), ligand-gated ion-channels, intracellular regulatory proteins and G-coupled 
receptors which are of neuronal origin
274
. Morphologically, HEK293 cells have similar 
proportions to neuronal soma. From this evidence, it is clear that HEK293 cells have 
attributes of neuronal cells. However, in contrast to neuronal cells, HEK293 cells are 
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relatively simple with regards to maintenance, do not have as stringent passage number 
limitations and are easily transfected with inexpensive and accessible methods such as 
calcium phosphate precipitation. It is owing to this that HEK293 cells were employed, in 
addition to the neuronal cell lines, throughout these studies. 
Moreover, the observed trends with regards to the cell biological effects of Aβ42 
administration in the presence and absence of anti-LRP/LR specific antibody IgG1-iS18 
(Figure 3a-c, original article 4.1) were consistent across all three cell lines (HEK293 and 2 
neuronal cell lines - N2a (murine) and SHSY5Y (human)). Owing to this, later experiments 
conducted with the aim of identifying interactions and probing mechanisms – both of which 
required cellular transfection were conducted solely in the HEK293 cells. It may be 
suggested, owing to the biochemical similarities between the HEK293 and neuronal cells, 
that the results obtained in the HEK293 cells would be comparable to those obtained in 
neurons.   
LRP/LR is highly expressed in both non-neuronal (HEK293 in this study and BHK cells
275
) 
and neuronal cells, including: murine Neuro-2a (N2a) and mouse neuroblastoma (MNB)
258
  
cells as well as ovine neuronal cells 
276
. Furthermore, it may be suggested that the LRP/LR-
dependent effects observed in non-neuronal cells may indeed be more pronounced in 
neuronal cells owing to the fact that higher levels of LRP/LR have been reported in neuronal 
tissues when compared to the LRP/LR levels in peripheral tissues
276
.   
 
5.1  Interactions between the 37kDa/67kDa LRP/LR and Aβ 
Co-localization Studies- Co-localization studies were employed as the primary step in 
ascertaining whether LRP/LR and Aβ form an association on the cell surface.   
Co-localization is extensively employed in cell biology to provide details regarding the 
spatial proximity of proteins, as sharing a similar cellular location is a prerequisite for 
interaction. LRP/LR and Aβ were found to co-localize on the surface of HEK293 and N2a 
cells (Figure 1, original research article 4.1) as revealed by the yellow merged image and 
diagonal 2D cytofluorogram (which is indicative of a spatial overlap between the 
fluorochromes employed to indirectly immuno-label each protein of interest). The graphical 
co-localization was substantiated by the highly positive (approaching +1) Pearson’s 
correlation coefficients (Table 1, original research article 4.1). A laminin binding integrin, 
150
Very-Late Antigen 6 (VLA6) (Figure 1, original research article 4.1), was employed as the 
negative control and demonstrated no co-localization with LRP/LR, results which are in 
accordance with that of Jovanovic et al., (2013)
272
. 
It is important to note that although this methodology has been widely employed to 
investigate potential associations between Aβ and other cellular proteins (including post-
synaptic density protein 95 (PSD-95)
277
, cystatin C
278
, mitochondrial protein Dynamin-
related protein (Drp1)
279
 and lysyl oxidase
280
) additional analyses employing co-
immunopreciptation, FRET and more precise biochemical methods such as isothermal 
titration calorimetry (ITC) and  surface plasmon resonance (SPR) are usually undertaken to 
firmly establish the presence of such associations. This is owing to the fact that confocal laser 
scanning microscopy has a resolution limit of 200nm. As a consequence hereof, indirect 
immunofluorescence microscopy may only be employed as a preliminary indicator of 
potential interactions. Thus, these findings suggested that an association between LRP/LR 
and Aβ may exist, but this suggestion needed to be confirmed by more sensitive methods.   
These results are not surprising as LRP/LR has been reported to localize to the lipid raft 
domains of the plasma membrane
281
. Similarly Aβ has been documented to insert specifically 
into the lipid raft regions of the plasma membrane 
141, 282, 283
, forming ion permeable pores 
which result in membrane distortion and may thereby contribute to cytotoxicity
284
. Thus, 
since both proteins are largely located within the lipid raft domains of the plasma membrane, 
their co-localization was anticipated.   
The validity of this finding was further assessed by Fӧrsters resonance energy transfer 
(FRET) and pull down assay methodology complemented with sensitive Aβ detection 
employing an Aβ-specific ELISA.   
Fӧrsters resonance energy transfer (FRET)- Fӧrsters resonance energy transfer (FRET) was 
proposed by Theodor Fӧrster in 1946-1948 and is based on the principle that a donor 
fluorochrome (phycoerythrin (PE), employed in this study), within a distance of 1-10nm of 
the corresponding acceptor fluorochrome (allophycocyanin (APC)), will non-radiatively 
transfer energy to the acceptor. This will only occur if the emission spectrum of the donor 
and the excitation spectrum of the acceptor significantly overlap
285
. The consequence hereof 
depends on the FRET couple chosen, and may either result in the enhanced fluorescence 
emission of the acceptor, as detected in this study (Figure 1, original article 4.2)
286
, or 
acceptor photobleaching.   
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Here a flow cytometry-based FRET assay was employed to investigate whether LRP/LR and 
Aβ interact on the surface of HEK293 cells. The highly sensitive PE/APC FRET pair was 
employed in this study
287
,
285
. APC does not emit fluorescence in the FL3 channel, a 
conclusion reached owing to the superimposition of histograms depicting APC-labelled 
proteins of interest with that of unstained cells (Figure 1 a,c,e, original article 4.2). 
However, in the presence of interacting proteins, FRET indeed occurs between PE and APC, 
resulting in enhanced APC fluorescence emission, observed graphically as a shift towards the 
right (Figure 1 b and f, original article 4.2). The sensitivity and selectivity of this technique 
was validated employing proteins known either to interact (PrP
c
) (Figure 1 a and b, original 
article 4.2) or not associate (chloramphenicol acetyltransferase (CAT)) (Figure 1 c and d, 
original article 4.2) with LRP/LR. Energy transfer was detected between LRP/LR and Aβ at 
the cell surface, thereby indicating that the proteins are within a 10nm radius of each other. 
This provides strong evidence for a cell surface interaction between these proteins.   
It must be noted that a flow cytometric FRET approach was employed in place of the more 
conventional microscopic FRET analysis owing to the high throughput of the technique. 
Flow cytometry-based FRET allows for the fluorescence intensity of thousands of cells to be 
quantified and therefore significantly reduces the susceptibility of the results to investigator 
bias.  
FRET is regularly employed to examine Aβ associations and has been successfully utilized to 
demonstrate that Aβ interacts with integrins and transferin288.Moreover, 
FRET is frequently exploited as a sensitive tool for investigating Aβ oligomerization 
mechanisms
289
 and for differentiating between different Aβ aggregation states (monomers vs 
higher order oligomers)
290
. The frequent utilization of this technique within AD research, and 
specifically with regards to Aβ interaction studies, adds further confidence to the data  
obtained and the deductions drawn during this study.  
 
To investigate whether LRP and Aβ form a truly stable association, pull down assays were 
employed.   
 
FLAG
®
 Pull down Assay- Pull down assays, a form of affinity chromatography, allow for the 
identification or confirmation of stable protein-protein interactions and was employed here 
to investigate the binding potential between LRP and Aβ42. 
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Pull down assays were performed employing LRP::FLAG and 2µg of exogenously 
administered synthetic Aβ42 and the presence of both proteins in the eluate samples (Figure 
2a, original article 4.1) implied that a stable association between these  proteins may exist. 
However, as the concentration of Aβ greatly exceeded that normally present in the brains of 
AD patients, 200-4500nM
291
, the experiments were repeated employing conditioned 
media (media into which Aβ would be endogenously shed as a result of normal APP 
metabolism within the cells). The Aβ levels in each fraction were subsequently assessed and 
again, a significant proportion of Aβ was detected in the eluate (Figure 2b, original 
research article 4.2). To negate the possibility that Aβ immobilization may have 
been influenced by non-specific adhesion of other cellular components to the anti-FLAG
®
 
affinity column, both sets of experiments were conducted employing non-transfected (NT) 
whole cell lysate controls (Figure 2d, original research article 4.1 and Figure 2c, original 
research article 4.2). Furthermore, as consequence of the inherent “sticky” nature of Aβ42, 
the ability of the peptide to bind to the affinity column in a lysate-independent manner also 
required investigation. In both sets of  these control experiments the percentage of Aβ42 
present in eluate fractions  was not significant (Figure 2f,original article 4.1 and Figure 2c, 
original article 4.2).These results therefore demonstrated that a physiologically relevant 
association exists between the 37kDa LRP and Aβ42. 
 
A direct physical association between LRP/LR and Aβ42 is not unlikely. Aβ42 has been 
reported to bind to both heparin and HSPGs, the latter interaction has been reported to 
promote Aβ42 aggregation
292
 and may thereby account for the presence of these cellular 
components within neuritic plaques
293
. The extracellular C-terminus of LRP/LR, the region to 
which shed and cell surface Aβ42 would bind, mimics heparin - due to its predominantly 
negatively charged nature as well as the presence of 5 repeats of the E/D-W-S/T motif 
187, 188
. 
Thus, owing to the structural and charge similarities between LRP/LR and heparin, it is 
probable that Aβ42 may also be able to interact directly with the C-terminus of the receptor.  
 
However, this interaction may be mediated by other Aβ42 binding partners which are 
similarly ligands for LRP/LR such as PrP
c
, laminin and HSPGs. 
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5.2 The cell biological effects of the 37kDa/67kDa LRP/LR – Aβ association 
The exogenous application of 200nM and 500nM synthetic Aβ42 significantly reduced cell 
viability and proliferation across all three cell lines, namely human embryonic kidney 
(HEK293), murine (N2a) and human (SH-SY5Y) neuroblastoma cells (Figure 3, original 
article 4.1). Similarly, treatment of cells with these toxic concentrations of Aβ42 induced both 
time and concentration dependent apoptosis, as quantified by Annexin-V-FITC/7-AAD 
assays and confirmed by nuclear morphological assessment (Figure 3, original article 4.2). 
The results obtained are in accordance with those obtained in other studies with regards to the 
apoptotic inducing potential of Aβ42
294
 as well as with regards to the peptide’s inhibitory 
effects on cellular proliferation
295
.  
The role of LRP/LR in the aforementioned Aβ42 pathogenesis was evaluated through 
antibody blockade and shRNA-mediated downregulation of the receptor. Blockade of the 
receptor, as achieved by co-incubation of the cells with IgG1-iS18 (anti-LRP/LR specific 
antibody) and treatment with varying Aβ42 concentrations, resulted in a significant 
enhancement of cell viability and proliferation (Figure 3, original article 4.1) and 
significantly lowered the degree of  apoptosis induced by the neurotoxic peptide (Figure 4, 
original article 4.2). These results were reproduced when Aβ42 treatments were administered 
to cells in which LRP/LR had been downregulated, thereby demonstrating that the cell 
rescuing effects of the antibody were not as a result of a lack of antibody specificity. 
Furthermore, the downregulation results revealed that the protective antibody effects were not 
owing to indirect antibody steric hindrance of other pathological associations at the cell 
surface.  Therefore, these data suggest that LRP/LR may, either directly or indirectly, mediate 
Aβ42-induced apoptosis and inhibition of proliferation. 
The role of LRP/LR in Aβ42-induced apoptosis is credible as a recent report has demonstrated 
that neuronal apoptosis induced by Aβ42 may occur via the JNK pathway which consequently 
results in the stimultation of FasL expression
296
, which is pro-apoptotic. LRP/LR is 
associated with both of these components (as discussed above in sections 1.11.1.1 and 
1.11.2.1.1) and it is therefore probable that LRP/LR may be implicated in Aβ42-induced 
apoptosis.  
 
It must be emphasized that these findings are of physiological relevance as the concentration 
of Aβ42 within the brains of AD patients is reportedly within the 200-4500nM range
291
. 
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Furthermore, it must be noted that at nM concentrations, such as those employed in this 
study, Aβ42 exists largely as monomers or low molecular weight oligomers
297
. Moreover, it 
has been demonstrated that even upon incubation in cell culture media, low nM 
concentrations of synthetic Aβ42 (0-500nM) do not aggregate to form higher order, less toxic 
fibrils
298
. Based on these findings, it may be safely proposed that the biological effects 
observed herein may largely be attributable to oligomeric Aβ42, the neurotoxic species in AD.  
 
The final aim of this study was to investigate a possible mechanism underlying the role of 
LRP/LR in Aβ42-mediated pathogenesis.  
Since the toxicity of Aβ42 is largely attributable to its intracellular accumulation, 
understanding  Aβ42 internalization processes is of paramount importance. It must be noted 
that Aβ42 internalization in neuronal cells occurs predominantly via receptor-mediated 
mechanisms
298
.  
5.3  37kDa/67kDa LRP/LR mediated Aβ42 internalization  
Our studies demonstrated that receptor-mediated uptake of exogenous Aβ42 occurs rapidly  
(within 5min) and was most pronounced after 15min. The internalization and intraneuronal 
accumulation of exogenously administered Aβ42 has been well documented
299-302
.  
Furthermore, our studies indicated that the cell surface levels of Aβ42 increased after 1h, 
thereby providing evidence that the peptide may be recycled to the cell surface (Figure 5a, 
original article 4.2). This is in accordance with observations reported in previous studies 
which revealed that, at physiologically normal levels, both non-toxic Aβ40 as well as Aβ42 are 
readily cleared from the cell either through proteolytic degradation or efficient exocytosis
299, 
303
. This accounts for the relatively low levels of intraneuronal Aβ42 associated with 
organelles such as the trans-golgi network, Golgi vesicles, endosomes, lysosomes and 
mitochondria under normal physiological, non-disease causing Aβ42 levels
303
. However, 
within the diseased state, Aβ42 accumulation and co-localization with these organelles as well 
as within the cytosol is clearly evident
304
. The central role of exocytosis in maintaining 
homeostasis and the non-diseased state has been revealed as, even at low Aβ42 
concentrations, inhibition of exocytosis significantly augmented intracellular Aβ42 
accumulation
303
. This process of exocytosis would remain functional in diseased cells, 
however, owing to the higher concentration of aggregation prone Aβ42 and its deleterious 
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effects on the endo-lysosomal system (as discussed briefly below) a significant proportion of 
Aβ42 would be released into the cytosol with detrimental cellular effects (as discussed briefly 
below) and would therefore not be effectively exocytosed. 
It is important to note that Aβ42 accumulation, specifically within the endo-lysosomal system, 
is considered central to Aβ42-mediated neurotoxicity (as shall be discussed below). 
Lysosomal accumulation of this neurotoxic peptide has been reported to be mechanistically 
similar to PrP
Sc
 replication
305
, a process in which LRP/LR has been shown to play a central 
role
258, 260
.  
The reliance of the Aβ42 internalization process on cell surface LRP/LR was demonstrated by 
the fact that antibody blockade and shRNA-mediated downregulation of the receptor 
significantly impeded Aβ42 internalization (Figure 6 a and b, original article 4.2).Therefore, 
this data suggests that LRP/LR plays a central role in Aβ42 internalization and this may be the 
mechanism underlying the role of the receptor in Aβ42 pathogenesis.  
This data is contradictory to studies performed by Hu et al.,
298
 who reported that extracellular 
Aβ42 is readily internalized by SH-SY5Y cells and murine neurons but not HEK293 cells. 
However, the degree of uptake during the Hu et al.,
298
 study was only assessed at a single 
time point of 24h, and it is feasible that the majority of internalized Aβ42 may indeed have 
been cycled back to the cell surface by this time. It is probable that, after multiple rounds of 
Aβ42 internalization and recycling, a gradual progressive accumulation of the peptide would 
occur within the endo-lysosomal system and begin to “leak” into the cytosol. It is therefore 
highly plausible that within 24h intracellular Aβ42 may be minimal but after 48h-72h, the 
degree of intracellular Aβ42 accumulation (and the cytosolic immunodetection thereof) may 
be substantially elevated. This would correlate with cell biological data as both our results 
(Figure 3, original article 4.2) as well as those of others
306-308
  have revealed that the 
induction of apoptosis is minimal after 24h but becomes more pronounced with longer 
periods of incubation. Furthermore, the receptors that have been reported to mediate Aβ42 
internalization are largely neuronal specific (as discussed below) and are not expressed by 
HEK293 cells. This may thereby account for the slower rates of internalization, and 
subsequent intracellular Aβ accumulation observed within the HEK293 cells by Hu et al.,298.  
It is noteworthy to add that HSPGs, to which LRP/LR similarly binds, have also been 
reported to mediate Aβ42 internalization and toxicity
309
 and HSPGs are expressed at high 
levels on the surface of HEK293 cells
310
. An important feature, which is universally required, 
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for mediating Aβ42 toxicity, is the anchorage of the protein to the cell surface. This therefore 
justifies the pathological role of HSPGs compared to the neuroprotective effects of soluble 
heparin as heparin competes with cell surface HSPGs for Aβ42 binding and thereby hampers 
Aβ42 uptake
309
. 
Several cell surface receptors have been demonstrated to facilitate Aβ42 internalization, and 
most are reported to do so solely as a consequence of their associations with PrP
c
.  PrP
c
 binds 
to approximately 50% of Aβ42 on the neuronal cell surface and has therefore been reported to 
be central to the internalization of at least 50% of extracellular Aβ42
311
. However, PrP
c
 lacks a 
transmembrane domain, a feature vital to this process, and it is therefore likely that PrP
c
 
recruits its receptors to facilitate this uptake. Such receptors include: N-methyl-D-aspartate 
(NMDA) receptors
312
, metabotropic glutamate receptor 5 (mGluR5)
313
 and low-density 
lipoprotein receptor-related protein 1 (LRP1)
145
.  
It must be noted that although these receptors have  received the most attention with regards 
to Aβ42 internalization they could not have contributed to the uptake observed during this 
study as HEK293 cells express very low levels of LRP1
298
 and do not endogenously express 
glutamate receptors (NMDA and mGluR5)
314
. 
Studies are currently underway to investigate the dependence of LRP/LR-mediated Aβ42 
internalization on the presence of cell surface PrP
c
.    
It is highly plausible that LRP/LR, HSPGs and PrP
c 
may function co-operatively in mediating 
Aβ42 internalization.  
 
5.4  The possible consequences of 37kDa/67kDa LRP/LR acting as a receptor for Aβ 
binding and internalization   
The consequences of LRP/LR forming an association with Aβ42 along its C-terminal domain 
and serving as a receptor for Aβ42 internalization may be vast.   
The most apparent outcome of such an association is that LRP/LR may facilitate intracellular 
Aβ42 accumulation and aggregation. Internalization mediated by LRP/LR results in the 
transfer of its cargo to the endo-lysosomal pathway
257
 and the fate of an Aβ42 load would be 
no different. The low pH within the late endosomes and lysosomes as well as their ability to 
concentrate solutes promotes fibril formation and aggregation
302
. Furthermore, Aβ42 is 
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notoriously resistant to lysosomal enzyme-mediated degradation
302
. Aβ42 accumulation 
within the endo-lysosomal system enhances the permeability of the membranes of these 
organelles, resulting in the leakage of lysosomal contents into the cytosol
315
. The lysosomal 
enzymes released may in turn further contribute to cellular damage through the hydrolysis of 
vital proteins (such cytoskeletal proteins) as well as through the induction of plasma 
membrane blebbing - the distortion (formation of irregular bulbs) of the membrane as a 
consequence of local cytoskeletal decoupling from the plasma membrane 
315
. In addition, the 
release of the internalized Aβ42 allows for amyloid aggregates to accumulate within the cell 
which consequently has adverse effects on cellular processes (such as inhibition of axonal 
transport
316
). Moreover, cytosolic Aβ42 may disrupt mitochondrial functioning and may 
promote oxidative stress, which inhibits proliferation and induces apoptosis (as discussed in 
section 1.9.3 above). Many AD researchers now consider the intraneuronal accumulation of 
Aβ42 as the first step in the fatal cascade leading to AD establishment
305
.  
It has been demonstrated that LRP/LR contributes to the internalization of the neurotoxic 
peptide and may thereby transfer Aβ42 to the endo-lysosomal system and this may thereby 
underlie the role of LRP/LR in mediating Aβ42 pathogenesis.  
In addition, there may be several secondary consequences of this internalization process.  
Since the binding of Aβ42 to LRP/LR induces internalization, an increased Aβ42 concentration 
would increase the rate of internalization ultimately resulting in a reduction of cell surface-
associated LRP/LR. This would therefore result in fewer LRP/LR–laminin-1 interactions and 
thus prevent the pro-survival and pro-proliferation signals transduced as a consequence of 
this association. Thus, the observed inhibition of cellular proliferation caused by the LRP/LR-
Aβ42 association, may be a result of aberrations caused in the pro-survival LRP/LR-mediated 
signalling pathways and not intracellular Aβ42 accumulation alone.  
Furthermore, the LRP/LR-laminin-1 association has been reported to induce the activity of 
MAP Kinase phosphatases such as MKP1 and PAC1
212
 (discussed above in section 1.11.1.1 
above), which consequently dephosphorylate and deactivate ERK, p38 and JNK. However, 
deterring this association (through enhanced LRP/LR internalization) may consequently 
reduce the repression of these MAPK signalling cascades. This is deleterious as activated 
JNK 
268, 269
, p38 
265, 270
 and ERK
265
  have all be implicated in Aβ42- induced apoptosis 
(discussed in detail in section 1.12.2 above). Thus, reduced cell surface LRP/LR levels may 
contribute to altered phosphatase activity which may directly modulate MAPK signalling 
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(ERK, JNK and p38 levels and activities) which plays a central role in Aβ42-mediated 
apoptosis and therefore AD pathogenesis.  
 
As previously discussed (in section 1.11.2.2 above) LRP/LR is expressed at high levels on 
human brain microvascular endothelial cells (BMECs), which constitute the BBB. LRP/LR 
has also been firmly established as a central receptor for mediating BBB crossing of 
pathogens and thereby allows for pathogenic cerebral infiltration
254
. Thus, based on the 
findings reported here, it is probable that LRP/LR associated with the BBB may interact with 
and mediate the uptake of Aβ42 from the periphery. This uptake would contribute to the 
enhanced cerebral and CSF Aβ42 levels and reduced plasma Aβ42 levels which are indicative 
of AD progression (as discussed with regards to biomarkers in section 1.4 above). 
Augmentation of the intracerebral and CSF Aβ42 levels would clearly promote Aβ42 
internalization and the toxic effects thereof. Thus, it is feasible that LRP/LR may play a role 
in AD pathogenesis by aiding the accrual of intracerebral Aβ42.       
All the aforementioned consequences are purely speculative and experimentation to 
investigate whether these processes may indeed contribute to Aβ42 pathogenesis must be 
conducted. 
 
5.5  Conclusion   
In conclusion, the findings obtained during the course of this PhD suggest that the 
37kDa/67kDa LRP/LR forms a physiologically relevant association with Aβ42 on the cell 
surface. In addition, it has been demonstrated that this association is central to the apoptosis 
and inhibition of proliferation induced by Aβ42. Moreover, LRP/LR has been shown to act as 
a receptor for Aβ42 internalization, and may thereby contribute to AD by mediating processes 
leading to intraneuronal Aβ42 accumulation and the deleterious cellular effects thereof. 
Antibody blockade and shRNA-mediated downregulation of LRP/LR impeded Aβ42 
internalization and rescued cells from Aβ42-induced cell death and inhibition of proliferation. 
Thus, LRP/LR represents a novel target in Alzheimer’s Disease. The significant cell 
biological rescuing effects observed during this study suggest that the aforementioned tools 
directed against LRP/LR, namely the anti-LRP/LR specific antibody IgG1-iS18 and shRNAs, 
may show promise as possible prophylactic and/or therapeutic AD tools. Since there are as 
yet no non-palliative AD therapeutics, a feature shared by all other neurodegenerative 
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disorders, these findings are of immense importance as these tools may show potential as 
novel disease-modifying therapeutics for the treatment of Alzheimer’s Disease.   
5.6 Future Work 
Although this study has elucidated a novel role for LRP/LR in Aβ42-mediated pathogenesis 
and a mechanism underlying the role of the receptor in this process has been identified, many 
other contributing factors and mechanisms may be additionally involved and therefore 
require elucidation. Furthermore, whether LRP/LR is dependent on PrP
c
 to mediate the 
functions revealed in this study requires investigation. 
It must be noted that previous administration of single chain Fv antibodies directed against 
the 37kDa/67kDa Laminin receptor
261
 and siRNA downregulation of LRP/LR did not have 
any side effects in vivo and thus it is presumed that IgG1-iS18 (an improved full length 
antibody) would similarly not result in adverse side-effects. The overall pharmacological 
properties of IgG1-iS18 are considered generally appropriate since IgG1-iS18 exhibits high 
specificity for the 37kDa/67kDa LRP/LR and binds exclusively to peptide TEDWSAAPT, 
which spans the region 272-280aa
246
. Furthermore, the half-life of W3, a polyclonal anti-
LRP/LR antibody, in the blood is 14 days
260
 and it is presumed that IgG1-iS18 woud have a 
comparable half-life. However, the large size of full-length IgG antibodies (150kDa) would 
limit the blood-brain barrier permeability of this treatment strategy. 
The blood-brain barrier permeability of IgG1-iS18 as well as the safety, pharmacokinetics 
and pharmacodynamics of the antibody must be investigated prior to the initiation of animal 
trials.  
Thereafter, the efficacy of the antibody will be validated in animal trials. Transgenic AD 
mice harbouring 5 EOAD/FAD mutations (3 mutations in APP and 2 mutations in the PSEN1 
encoding genes) develop pathological features mimicking the human condition within 4 
months, namely: plaque deposition, synaptic and neuronal loss as well as cognitive deficits. 
These transgenic mice will be the most suitable to assess whether IgG1-iS18 is able to 
slow/prevent the neuronal cell loss and consequently prevent or prolong the period prior to 
the cognitive decline associated with AD progression.    
In the event that the animal trials are successful, phase I clinical trials will be initiated to 
assess the efficacy of IgG1-iS18 treatment in human patients.   
160
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Annexure I 
Patent Application 
Patent Title:   Compounds for use in the treatment of Alzheimer’s disease 
 
Inventors:  Stefan Franz Thomas Weiss, Katarina Jovanovic, Danielle Gonsalves, 
Bianca Da Costa Dias, Stefan Knackmuss, Uwe Reusch, Melvyn Little 
 
Applicant:   University of the Witwatersrand 
 
Patent Number:  PCT/IB2012/054918  WO 2013/042053A2 
 
Description: 
The Patent application PCT/IB2012/054918 (Weiss 3), entitled “compounds for use in the 
treatment of Alzheimer’s disease” was published as WO 2013/042053 on 28 March 2013, in 
the name of the University of the Witwatersrand. The claims of this patent application 
involve methods employing tools targeting the laminin receptor (LRP/LR) as a means of 
reducing Alzheimer’s Disease proteins and thereby possibly as treatment strategies for 
Alzheimer’s Disease. National applications have been filed in the US (14/345,770), Europe, 
China and South Africa (2014/02471). 
  
 
 
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
